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GASTROINTESTINAL ANGIODYSPLASIAS
Angiodysplasias are the most common vascular anomalies of the gastrointestinal tract.1 
They consist of ectatic, dilated, thin-walled vessels that are lined by endothelium alone or 
in combination with smooth muscle.1 The prevalence rises with increasing age and they 
are more often symptomatic in patients over 60 years old.2, 3 Predisposing factors are von 
Willebrand disease, end-stage renal disease and aortic stenosis.4, 5 Approximately 40-60% of 
the patients have more than one angiodysplastic lesion  and they are most frequently located in 
the colon.6 Angiodysplasias may become the source of low grade chronic or intermittently massive 
(rectal) bleeding. 
Approximately 90% of the bleeding angiodysplasias spontaneously cease  bleeding, However, 
typically the gastrointestinal bleeding from angiodysplasias is chronic and recurrent.7 The incidence 
of overt rebleeding has been estimated at  35% while  occult rebleeding occurs in  55% of rebleeds.8 
A previous episode of rebleeding is an independent risk factor for further bleeding recurrence.9 
The phenotype of the disease has a wide range , from asymptomatic to a high disease burden with 
need for frequent red blood cell transfusions, hospitalizations and surgery.10 The angiodysplasia-
related mortality is around 2%.11
PATHOGENESIS
The pathophysiological basis of angiodysplasias remains to be identified.  The most accepted 
hypothesis is that chronic low-grade intermittent obstruction of submucosal veins leads to 
congestion of capillaries and failure of the pre-capillary sphincters.12 This results in dilated veins 
which are prone to bleeding. Angiogenesis, defined as  the formation of new blood vessels by 
the extension or elaboration of existing vasculature, is central to the pathology of angiodysplasias. 
Angiogenesis is regulated by angiogenic stimulators and inhibitors. Under pathophysiological 
conditions such as hypoxia, mechanical stress, or inflammation there is a dramatic increase in 
endothelial proliferation driven by angiogenic regulators such as growth factors, proteases and 
protease inhibitors, cytokines and chemokines. 13 Specifically, increased expression of vascular 
endothelial growth factor (VEGF) along with increased serum concentrations  of VEGF, endoglin, 
Angiopoietin-2 and -1, platelet derived growth factor and tumor necrosis factor-α have been 
identified in  angiodysplastic lesions.14, 15 These factors drive  angiogenesis. 
A more recently identified relevant angiogenic regulator  is Von Willebrand factor.16 Before 
the pathogenesis of the Heyde’s syndrome was clarified, dr. Heyde recognized the combination 
of patients with aortic-valve stenosis and gastrointestinal bleeding due to angiodysplasias. 
Aortic  stenosis leads to high shear stress, which unfolds the high-molecular-weight multimers of 
Von Willebrand factor. This exposes the binding site for ADAMTS13 and the multimer is cleaved, 
resulting in a reduced size and less hemostatically competent Von Willebrand factor (see figure 1).17 
Aortic-valve replacement is effective in this specific patient population, and  the clinical corollary is 
that  patients with recurrent bleeding should be screened for aortic-valve stenosis.18
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SYMPTOMS 
In most cases angiodysplasias are non-symptomatic and are discovered as an incidental 
finding. The situation is different if a patient presents with iron deficient anemia who possesses 
gastrointestinal angiodysplasias. In absence of other (gastrointestinal) pathology, the anemia 
is attributed to the presence of angiodysplastic lesions. The presentation of gastrointestinal 
angiodysplasia is completely dependent on the structural integrity of the angiodysplastic lesions. 
The tortuous vessels of an angiodysplastic lesion are fragile and may degenerate and leak blood. 
The risk of bleeding is related to the number and size of the angiodysplastic lesions. The usual 
manifestation is that of painless subacute or recurrent bleeding, that ceases spontaneously in 
most cases. Bleeding may consist of bright red blood, maroon stools or (rarely) melena, or may be 
occult.  Blood loss, if massive, causes symptoms such as  hematemesis, melaena or hematochezia. 
The symptoms of angiodysplasia are related to the recurrent blood loss; i.e anemia. Symptoms 
generally worsen as anemia becomes more severe. Common signs of (severe and protracted) iron-
deficiency anemia include brittle nails; cracks at the sides of the mouth; pale skin and swelling of 
Figure 1. The role of von Willebrand factor in the pathogenesis Heyde’s syndrome. Derived from J. Loscalzo. 
NEJM, 2012.17 
G
eneral Intro
d
uctio
n
1
11
the tongue. Iron-deficient anemia may be associated with a number of symptoms such as angina 
pectoris, heart rhythm irregularities, coldness of hands and feet, difficulty concentrating, dizziness, 
and fatigue. Moreover, anemia is independently associated with a negative impact on the quality 
of life.19 
DIAGNOSIS
Angiodysplasia are composed of ectatic, dilated, thin-walled vessels that are lined by endothelium 
alone or endothelium along with small amounts of smooth muscle. There is a protruding central 
vessel that “fans” out in a mesh like structure. The most prominent feature in angiodysplasia is 
the presence of dilated, tortuous submucosal veins. Small arteriovenous communications are also 
present and are due to incompetence of the precapillary sphincter. The diagnostic method used 
depends on the presentation of bleeding:
1. Endoscopy is the most frequent used tool. The indication to perform an esophagogastro- 
duodenoscopy and colonoscopy are iron-deficiency anemia or overt bleeding in 
a hemodynamic stable patient. When the upper- and lower gastrointestinal endoscopy 
do not give an explanation for the occult or overt bleeding, small bowel visualization can 
be performed with videaocapsule endoscopy. This is only indicated for patients who are 
dependent on iron or red blood cell supplementation.20 When performing videocapsule 
endoscopy for small bowel bleeding, angiodysplasias are the most frequent found cause of 
the bleeding.21 The diagnostic yield is around 60-80%.22 
2. When no diagnosis is made upon videocapsule endoscopy and there is clinical significant 
ongoing bleeding, balloon-assisted enteroscopy is an option. It can be advanced to 240–360 
cm distal to the pylorus orally and 100–140 cm proximal to the ileocecal valve rectally. 
In some patients this gives full visualization of the small bowel. The diagnostic yield of 
double balloon enteroscopy ranges from 60 to 80% in patients with suspected small bowel 
bleeding. The complication rate for diagnostic procedures is around 0.8%, with around 0.3% 
of the patients undergoing oral balloon enteroscopy developing pancreatitis.23 
3. In the hemodynamic unstable, massive gastrointestinal bleeding patient, emergent 
computed tomography angiography should be performed, which can be proceeded by 
angiography and embolization of the vasculature feeding the bleeding site.24 Computed 
tomography angiography has been shown to be able to detect bleeding rates as slow as 
0.3 ml/min.
4. Surgery is the last option and can be considered when there is massive bleeding and 
embolization facilitated by angiography has been unsuccessful. 
TREATMENT
Treatment is only indicated in patients with symptomatic angiodysplastic lesions, in particular 
patients with overt bleeding or symptomatic anemia. There are multiple treatment options for 
angiodysplasias and I will discuss the options briefly. In general, in absence of specific guidelines, 
G
eneral Intro
d
uctio
n
1
12
most physicians will use a step-up approach that leads from conservative measures to invasive 
procedures such as surgery. A treatment algorithm is shown in figure 2 (derived from Sami et al.). 
1. Conservative management consisting of iron supplementation and, when necessary, red 
blood cell transfusion. As a result of ineffective endoscopic therapy, some patients develop 
chronic anemia and become dependent on symptomatic treatment with (parenteral) iron 
supplementation and / or red blood cell transfusions.
2. Endoscopic intervention with argon plasma coagulation (APC). Endoscopic APC is seen as 
the first-line treatment.1 Recurrent bleeding rates in patients treated with APC are high, 
varying between 11-20% in two years.7, 25 With the exception of a re-bleeding rate up to 45% 
in patients with small bowel angiodysplasias, which might be due to the ease of missing 
lesions during a first enteroscopy.26
3. Pharmacological therapies based on anti-angiogenic properties. Angiodysplasia patients 
account for up to 50% of patients with chronic severe gastrointestinal bleeding and 
multiple pharmacological agents have been proposed in this difficult to manage bleeding.27 
Estrogen and progesterone have been proven to be ineffective.8 Thalidomide suppresses 
the expression of VEGF and thereby inhibits neoangiogenesis. It is effective in decreasing 
bleeding episodes by more than 50% in the majority of patients with refractory bleeding 
due to angiodysplasias.28 The downside of thalidomide is the risk of irreversible side-effects, 
such as polyneuropathy.29 The somatostatin analogue octreotide also downregulates 
VEGF, but also decreases splanchnic blood flow and enhances platelet aggregation.30, 31 
Although there are many case-series that make octreotide treatment promising, there is 
no well performed randomized controlled trial that proves the efficacy of octreotide in 
angiodysplasia bleeding.32
4. Radiological intervention with artery coiling and embolization during angiography is only 
indicated when patients present with hemorrhagic shock. 
5. Surgery is the last option. In case all other options have been unsatisfactory and the patient’s 
quality of life is severely compromised.10 
QUESTIONS
In this thesis we strive to answer the following questions, leading to the aims stated below.
1. What is the risk profile of angiodysplasia patients in the different disease stages of 
asymptomatic, symptomatic and recurrent bleeding angiodysplasias? What is the impact of 
angiodysplasia disease on the health-related quality of life?
2. How are current treatment options for patients with symptomatic angiodysplasias used 
in clinical practice? Is there variation between gastroenterologists and which factors are 
important in their decision-making process? 
3. Are there new pharmacological effective treatment options for patients who are treatment 
resistant to current treatment options?
G
eneral Intro
d
uctio
n
1
13
Figure 2. Treatment algorithm for patients with gastrointestinal angiodysplasia(s). Derived from Sami et al. 
AP&T, 2014.1 OGIB = obscure gastrointestinal bleeding; AS = aortic stenosis; AVR = aortic valve replacement; 
APC = argon plasma coagulation; IM = intramusculair; SC = subcutaneously 
G
eneral Intro
d
uctio
n
1
14
AIMS OF THE THESIS
I. To identify the risk profile for different disease stages and to assess the impact on quality 
of life
II. To assess variation and evaluate current treatment strategies given to patients with 
gastrointestinal angiodysplasias
III. To optimize current available therapies, investigate new therapies for the treatment of 
symptomatic angiodysplasias
OUTLINE
I. To identify the risk profile for different disease stages and to assess the 
impact on quality of life
In chapter 2.1 we answered the research question: What are currently know risk factors for 
the different diseases stages of angiodysplasia disease? We hypothesized angiodysplasia disease is 
multifactorial and other factors then the always mentioned aortic stenosis, chronic kidney failure 
and Von Willebrand disease are also of influence.1 To investigate this hypothesis we performed 
a systematic review of current available literature. 
Throughout performing the systematic review of chapter 2.1, we noticed there is no clear 
differentiation of the different disease stages symptomatic angiodysplasia bleeding and incidental 
found angiodysplasias during endoscopy. Therefore, we asked: are there different risk factors for 
incidental and symptomatic angiodysplasias? The case-control study of chapter 2.2 answers this 
research question. We hypothesized that there are different factors associated with incidental 
and symptomatic angiodysplasias, and that incidental angiodysplasias can be seen as a distinct 
disease stage.  
The presence of bleeding angiodysplasia may have a profound impact on the quality of life of 
affected patients. A point estimate and the range of impact of the disease on the patients quality 
of life has not been assessed . We hypothesized that patients with (symptomatic) angiodysplasia 
disease have a decreased health-related quality of life. In chapter 2.3 we investigate this hypothesis 
by means of a cross-sectional cohort study with validated patient reported outcome measures. An 
overarching aim of this study was that in case a decreased quality of life could be measured, we 
advocated to include patient-reported outcomes in clinical trials performed in this research area. 
II. To assess variation and evaluate current treatment strategies given to 
patients with gastrointestinal angiodysplasias
The second aim of this thesis is to assess variation and evaluate current treatment strategies 
given to patients with gastrointestinal angiodysplasias. This aim was driven by the finding  that 
a specific  guideline that deals with the treatment of angiodysplasias is absent. To improve existing 
treatment options, it is important to know which knowledge gaps there are, how current treatment 
options are used in daily practice and whether there is practice  variation. Therefore, we addressed 
the research question (chapter 3.1): Is there variation in treatment strategies for angiodysplasias 
among gastroenterologists? We hypothesized there to be is a high variation in treatment strategies 
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used among gastroenterologists. We conducted a quantitative web-based survey to answer our 
research question. 
Upon designing  our randomized controlled clinical trial (chapter 4.2), one of the main issues 
was to select the primary outcome measure that is relevant to patients and physicians alike and that 
can be influenced by the chosen intervention. We elected the number of red blood cell transfusions 
as  the primary outcome of our clinical trial. The question at large was that we did not know under 
which conditions and when treating physicians would transfuse their patients. We struggled with 
the question: is there an appreciable practice variation among  gastroenterologists with respect 
to blood transfusion as option to treat  chronic anemia as a result of  gastrointestinal bleeding? 
Are there predictors of transfusion preferences? Chapter 3.2, gives answer to these questions with 
the results of our adaptive choice-based conjoint survey. We hypothesized that there are predictors 
of transfusion preferences. 
As mentioned in the general introduction, argon plasma coagulation (APC) is the first-line 
therapy in patients with symptomatic gastrointestinal bleeding. We aimed to evaluate the use of APC 
therapy in clinical practice and the consequences of delay in treatment. Therefore we developed 
the research question: Is there a need for re-endoscopy with APC in angiodysplasia patients that 
were not treated with APC during the  index endoscopy? We hypothesized that re-endoscopies 
with APC are needed to treat patients that were initially not treated during index endoscopy for 
gastrointestinal bleeding. To answer this research question, we performed a retrospective cohort 
study which is published in chapter 3.3.
III. To optimize current available therapies and investigate new therapies for 
the treatment of symptomatic angiodysplasias
In chapter 4.1 we address the research question: are somatostatin analogues effective in patients 
with transfusion dependent angiodysplasia bleeding? We performed an individual patient data 
meta-analysis of all available cohort studies to investigate this question. The hypothesis was that 
somatostatin analogues are effective and safe in the treatment of refractory angiodysplasia bleeding.
As there was no randomized controlled trial that investigated the effectiveness of somatostatin 
analogues for red blood cell transfusion dependent gastrointestinal angiodysplasia bleeding, we 
designed the OCEAN-trial. The study protocol is published in chapter 4.2. The trial is currently in 
the stage of including patients. We hypothesized that octreotide is effective and safe in the treatment 
of refractory angiodysplasia bleeding.
Chapter 4.3, is a case-report that describes a woman with treatment-resistant transfusion 
dependent angiodysplasia bleeding. We asked  ourselves whether  tranexamic acid might be 
a potential new treatment option for treatment resistant angiodysplasia bleeding? We describe our 
experience with  tranexamix acid in a single  case. 
Finally, chapter 5 provides a general discussion and future perspectives of this thesis. This 
chapter summarizes our results and discusses future steps to continue improvement of clinical care 
to patients with gastrointestinal angiodysplasias. 
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Chapter Question Hypothesis Study design
Characterization of gastrointestinal angiodysplasia disease
2.1 What are currently know 
risk factors for the different 
diseases stages?
Angiodysplasia disease is 
multifactorial and other 
factors then the always 
mentioned aortic stenosis, 
chronic kidney failure and 
Von Willebrand disease, are 
also of influence
Systematic review
2.2 What are risk factors for 
incidental and symptomatic 
angiodysplasias?
There are different 
factors associated with 
incidental and symptomatic 
angiodysplasias
Case-control study
2.3 What is the quality of life of 
patients wit angiodysplasias?
Symptomatic angiodysplasia 
patients have a decreased 
quality of life
Cross-sectional cohort
Evaluation of current treatment strategies
3.1 Is there variation in treatment 
strategies for angiodysplasias 
among gastroenterologists? 
There is a high variation in 
treatment strategies for 
angiodysplasias
Quantitative web-based survey
3.2 When do gastroenterologists 
transfuse chronic anemia? 
There are predictors of 
transfusion preferences
Adaptive choice-based conjoint 
survey
3.3 Is there a need for re-
endoscopy with APC in 
angiodysplasia patients that 
were not treated with APC 
during index endoscopy?
Re-endoscopies with APC 
are needed to treat patients 
that were initially not treated 
during index endoscopy
Retrospective cohort study
Investigating new therapies for symptomatic angiodysplasias
4.1 Are somatostatin analogues 
effective in patients with 
transfusion dependent 
angiodysplasia bleeding?
Somatostatin analogues 
are effective in reducing 
the transfusion need in 
angiodysplasia bleeding
Individual patient data meta-
analysis
4.2 What is the best study design 
to investigate the effectiveness 
of octreotide as treatment for 
severe angiodysplasia disease?
Randomized controlled 
trial is needed to 
implement octreotide as 
treatment option in severe 
angiodysplasia disease 
Protocol for a randomized 
controlled trial
4.3 Could tranexamic acid be 
a potential new treatment 
option for treatment resistant 
angiodysplasia bleeding? 
Tranexamic acid could be 
a new treatment agent 
for severe angiodysplasia 
disease, more quantitative 
research is desirable
Case-report
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ABSTRACT
Background
Few studies have assessed factors associated with angiodysplasias during endoscopy or factors 
associated with symptomatic disease. 
Aims
To evaluate risk factors for the presence of and contributing to symptomatic disease in patients 
with angiodysplasias. 
Methods
We performed a systematic MEDLINE, EMBASE and Cochrane Library search according to the PRISMA 
guidelines for studies assessing risk factors involved in angiodysplasias detected during endoscopy 
and that lead to anemia or overt bleeding. Study quality was assessed with the Newcastle-Ottawa 
scale. A risk assessment was performed by selecting risk factors identified by two independent 
studies and / or by a large effect size. 
Results
24 studies involving 94658 participants were included. The overall quality of the evidence was 
moderate. Risk factors for the diagnosis of angiodysplasias during endoscopy confirmed by at least 
2 studies were increasing age (OR 1.09 per year, 95% CI 1.04-1.1), chronic kidney disease (OR 4.5, 
95% CI 1.9-10.5), anticoagulant use (OR 2.7, 95% CI 1.4-5.1) and cardiovascular disease (2.9, 95% CI 
1.4-6.2). The risk of rebleeds is higher in the presence of multiple lesions (OR 4.2, 95% CI 1.1-16.2 and 
3.8, 95% CI 1.3-11.3 and 8.6, 95% CI 1.4-52.6), liver cirrhosis (OR 4.0, 95% 1.1-15.0) and prothrombin 
time <30% (OR 4.2, 95% 1.1-15.4) with a moderate effect size. Inpatient status had a large effect size 
for the association with angiodysplasias causing anemia or overt bleeding (OR 8.7, 95% CI 5.4-14.1).
Conclusions
This systematic review identified age, chronic kidney disease, anticoagulant and cardiovascular 
disease as the most important risk factors for the diagnosis of angiodysplasias during endoscopy. 
Inpatient status and multiple lesions are respectively contributing to anemia or overt bleeding 
angiodysplasias and risk of recurrent bleeding. 
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INTRODUCTION
Angiodysplasias account for up to 5% of all causes of gastrointestinal bleeding, and are probably 
responsible for 60% of cases of small bowel bleeding1. They are a common cause of gastrointestinal 
bleeding in the elderly2. Presentation includes all aspects of iron deficiency anemia and 
gastrointestinal bleeding. The clinical spectrum may range from absence of symptoms to refractory 
anemia with transfusion dependency and frequent hospitalizations.  
Angiodysplasias are thought to arise from chronic low-grade intermittent obstruction of submucosal 
veins leading to capillary congestion and failure of the pre-capillary sphincters.[3] This results in 
dilated veins which are prone to bleeding (figure 1). Angiogenic factors4 such as vascular endothelial 
growth factor and Angiopoietin-2 and -1 may play a role[5]. Thalidomide and somatostatin analogues 
inhibit angiogenesis and may serve as treatment for gastrointestinal angiodysplasias.[6] 
In addition to an increasing age, there are a number of predisposing conditions such as 
Von Willebrand Disease, aortic stenosis (Heyde’s syndrome) and chronic kidney disease11-14. 
The introduction of the colorectal cancer screening program has led to a major increase in number 
of endoscopies performed in the population older than 55 years with a positive immunological 
fecal occult blood test.[15] This will probably contribute to a further increase in diagnosis of 
(asymptomatic) angiodysplasias. Collectively this has led to the increase of angiodysplasia related 
hospitalizations from 0.9 (1996) to 2.6 (2005) per 100.000 person-years16. 
Little is known about the nature of risk factors that contribute to the development of 
angiodysplasias. Better understanding of these factors may help to predict which patient is at risk to 
develop symptoms from angiodysplasias. High risk may warrant preemptive therapeutic argon plasma 
coagulation at time of diagnosis, close follow-up and / or initiation of angiogenesis inhibitors in an 
earlier stage. Secondly, elimination of those triggers that cause bleeding may serve as a preferential 
strategy in patients with recurrent angiodysplasia bleeding or chronic transfusion dependency. 
Finally, there is a wide variety of disease burden in patients with angiodysplasias17. The consequence 
is that most angiodysplasia studies are heterogeneous by nature and that extrapolation of results is 
difficult18-23. We used a systematic review in order to provide a comprehensive overview of risk factors 
associated with different disease stages: angiodysplasias found during endoscopy, angiodysplasias 
that lead to anemia or overt bleeding, and factors of influence on recurrent bleeding and mortality. 
METHODS
This study is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines24.
Literature search 
A systematic search was conducted with the aid of an expert librarian. We retrieved relevant 
publications from MEDLINE and Cochrane Library up to August 2018. For the EMBASE database 
up to August 2016. We used the search terms for the determinant ‘gastrointestinal angiodysplasia’ 
with synonyms for the outcome ‘risk factor’ (supplementary file, search strategy). Titles, abstracts 
and subsequent full-text articles were independently screened by two authors (K.V.G. and M.M.) 
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based on predefined selection criteria. Disagreement on eligibility was resolved through consensus. 
The search was completed by hand-searching the references of the selected articles, related 
reviews, meta-analyses, and guidelines.
Inclusion and exclusion criteria
We selected published articles that reported on studies assessing risk factors for angiodysplasias 
detected during endoscopy or that investigated factors that contribute to symptomatic 
angiodysplasia bleeding, or more severe disease including rebleeds or mortality due to 
gastrointestinal angiodysplasias bleeding. Symptomatic disease is defined as angiodysplasias that 
cause anemia or overt bleeding. We excluded the following type of studies: case-reports, case-
series < 40 patients, reviews, editorials, opinion papers, animal or children studies, nonclinical 
studies. The search was not time limited. Non-Dutch and non-English language articles were 
excluded. Finally, studies that included vascular malformations other than angiodysplasias of the GI 
system, such as portal hypertensive gastropathy, radiation telangiectasia, hereditary hemorrhagic 
telangiectasia and gastric antral vascular ectasia were excluded. The diagnosis of angiodysplasia 
had to be made through endoscopy, which also includes wireless video capsule endoscopy, or 
identification by International Statistical Classification of Diseases(ICD)-codes. 
 Figure 1. Angiodysplasia in the colon. 
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Data extraction 
The following study characteristics were extracted from each study in a standardized manner: year of 
publication, country of origin, study design and population, sample size and type of control group. 
The preferred outcomes were odd’s ratios (OR) or hazard ratios (HR) with their 95% confidence 
intervals (95%-CI). If not available the reported outcomes such as prevalence were drawn from 
the original manuscript. 
Quality assessment 
Eligible articles were critically appraised for relevance and internal validity. The quality of each study 
was assessed with the Newcastle-Ottawa Quality Assessment Scale for nonrandomized studies25. 
The following domains of bias were addressed: representativeness of the cases, adequate selection, 
comparability, outcome assessment and follow-up. Each of the 8 items can be scored as adequate 
using an X, except for the domain comparability which is given two Xs. The overall rating of the risk 
of bias is scored as low (7-9 X), moderate (4-6 X) or high (0-3 X). Publication bias was assessed 
graphically with a funnel plot. 
Statistical analysis and risk assessment
Due to variations in study population, methodologies and measurements between studies, a formal 
meta-analysis was deemed inappropriate here. A 95% confidence interval (95% CI) not including 0 
or a two-sided tested p-value ≤ 0.05 was considered statistically significant.
The risk assessment identifies important risk factors based on two criteria: strength of evidence 
and effect size. When risk factors were identified by at least two independent studies, those factors 
were identified as more important due to the increased strength in evidence26 A risk factor identified 
by one study with a moderate (OR 3.5-6.6) or large effect size (OR ≥6.7) was ought to be important 
as well based on it is effect size27. 
RESULTS
The original search yield 1322 citations, after applying the in- and exclusion criteria for study 
selection, 24 studies were included for qualitative synthesis (see figure 2: flow diagram). Most studies 
were excluded because they did not match our study aim (e.g. focusing on treatment efficacy or 
diagnostic modalities) or because they were case-reports or conference abstracts. Two additional 
studies that fit inclusion criteria were discovered through checking the references of the included 
studies. Within the set of 24 reviewed studies included in our systematic review, 13 (n = 3360 patients) 
were on risk factors associated with the presence of angiodysplasia during endoscopy, 3 dealt with 
the risk of symptomatic angiodysplasias (n = 4687 patient) and 8 assessed risk factors for rebleeds 
and mortality (n = 86611 patients).
Study assessment
Risk of bias was introduced at different levels and were mostly dependent on the design of the study 
(supplementary file, table 1). Funnel plot showed similar estimates (OR) with similar sample sizes, 
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which lead to asymmetry and could be an indication for a risk of publication bias (supplementary 
file, figure 3). No statistical tests were performed to detect bias, because of the large between-study 
heterogeneity. Overall, the risk of bias was judged as high in 6 studies, moderate in 17 studies and 
low in 1 study. The quality of evidence was too low to perform a meta-analysis. 
Risk factors for angiodysplasias found during endoscopy 
Thirteen cohort studies assessed risk factors for the presence of angiodysplasias detected during 
endoscopy (Table 1)15,28-39. Six case-control studies (table 1A) assessed multiple risk factors although 
the outcome ‘presence of angiodysplasia’ was relatively rare, which contributed to wide confidence 
intervals28. Independent risk factors that were confirmed in two or more studies are increasing age 
(OR 1.09 per year, 95% CI 1.04-1.1), chronic kidney disease (OR 4.5, 95% CI 1.9-10.5), anticoagulant 
use (OR 2.7, 95% CI 1.4-5.1) and cardiovascular disease (2.9, 95% CI 1.4-6.2). Independent factors 
that possessed a moderate to large effect size were valvular heart disease (OR 18.8, 95% CI 2.4-
149.6), previous venous thromboembolism (OR 6.4, 95% CI 1.3-31.3), Warfarin use (OR 5.5, 95% CI 
1.1-27.5), proton pump inhibitor use (OR 5.4, 95% CI 2.7-10.7), liver cirrhosis (OR 4.8, 95% CI 1.8-14.5), 
congestive heart failure (OR 4.5, 95% CI 1.2-17.9), arrhythmias (OR 4.4, 95% CI 1.7-11.2) and ischemic 
heart disease (OR 4.3, 95% CI 1.9-9.8).
Cohort studies that focused (table 1B) on chronic kidney disease patients support the evidence 
that comes from case-control studies and discovered a high incidence of angiodysplasias in this 
study population (4.4% in pre-renal transplant patients and 32% in chronic kidney disease with 
Figure 2. Flow diagram of search. 30 
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GI bleeding)36. The following conditions are risk factors for angiodysplasias: left ventricular assist 
devices (LVADs), aorta stenosis, mitral valve regurgitation34, systemic sclerosis and calcinosis, 
Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) 
syndrome (6.3% of GI bleeding due to AD).[35,38] Hypertension was identified as a risk factor for 
small bowel disease (OR 2.8, 95% CI 1.5-5.4)29, although its presence may confer protection against 
bleeding in patients with LVADs (OR 0.2, 95% CI 0.1-0.97).[33]
Triggers for angiodysplasia causing overt or occult bleeding
Only three retrospective cohort studies assessed factors that predicted development to symptomatic 
disease defined as anemia or overt GI bleeding (Table 2)40-42. Independent risk factors identified by 
two studies for symptomatic disease were age above 80 years (OR 5.2 and 1.3) and multiple lesions 
(OR 6.7 and 2.2). The study by Diggs et al. is a population-based study with a large sample size 
(n=4159) investigating colon angiodysplasias42. Inpatient status had the largest effect size in this 
study with an OR of 8.7 (95% CI 5.4-14.1). The two other studies had a much smaller sample size 
(n=435 and n=93) and investigated colon and upper GI bleeding due to angiodysplasias. Nishiruma 
et al. found heart disease in past medical history (OR 6.9, 95% CI 1.0-45.5) and angiodysplasia lesions 
≤5 mm (OR 17.7, 95% CI 4.9-64.0) as risk factors with a large effect size40. In contrast, Kim et al. found 
a larger angiodysplasia size as risk factor for upper GI angiodysplasia bleeding41.
Predictors for rebleeding and mortality in patients with symptomatic 
angiodysplasias
Six retrospective cohort studies investigated factors associated with rebleeds in a population 
of symptomatic patients (Table 3)12,43-49. Two studies assessed risk factors for mortality43,49. One 
scrutinized the natural history of GI bleeding in VWD12. Independent risk factors for rebleeding 
identified by at least two studies are multiple lesions (OR 4.2, 95% CI 1.1-16.2 and 3.8, 95% CI 1.3-11.3 
and 8.6, 95% CI 1.4-52.6)46-48. In addition, liver cirrhosis (OR 4.0), location in the third small bowel 
quartile (OR 4.3), chronic kidney disease (4.5), congestive heart failure (4.5) and a prothrombin time 
<30% (OR 4.2) were detected as bonafide risk factors with a moderate effect size. Prothrombin time 
was studied in the setting of acute GI bleeding48. Multiple (≥3) comorbidities led to an increased risk 
(OR 2.3, 95% CI 1.2-4.3) of in-hospital mortality and inpatient status to an increased 90-day mortality 
(OR 17.7, 95% CI 1.7-185.1) in patients with angiodysplasias49. 
DISCUSSION
This systematic review gives an overview of risk factors associated with detection of angiodysplasias 
during endoscopy, triggers for overt or occult bleeding and factors that contribute to rebleeds 
and mortality as a result of angiodysplasias. Age, chronic kidney disease, anticoagulant use 
and cardiovascular disease are the most important factors associated with the detection of 
angiodysplasias during endoscopy16,28,29. In view of the pathophysiological hypothesis it is plausible 
that age, chronic kidney and cardiovascular disease contribute to development of angiodysplasias. 
However, anticoagulant use is probably associated with bleeding (as shown by Saperas et al.) rather 
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Table 1A. Studies assessing risk factors for the presence of gastrointestinal angiodysplasias (GIAD).
Author  
Country, year Study type
No. of 
controls 
No. of  
GIAD pts Study population / indication Control group / indication
Outcomes
Significant risk factors 
Effect 
OR (95%-CI) / t-test
Igawa et al.
Japan, 201528
RC 97 64 Small bowel GIAD / OGIB No GIAD at SBCE and balloon endoscopy 
/ OGIB
Liver cirrhosis
Cardiovascular disease
4.8 (1.8-14.5)
2.9 (1.4-6.2)
Holleran et al.
Ireland, 201329
RC 95 66 Small bowel GIAD at SBCE / 51% anemia, 23% overt 
bleeding, 15% OGIB, 11% other
No GI bleeding / determined by 2 negative 
FOBT for colorectal cancer screening 
program
Hypertension
Ischemic heart disease
Arrhythmias 
Valvular heart disease
Congestive cardiac failure
CKD
Previous VTE
Anticoagulant use*
Warfarin*
Proton pump inhibitor*
2.8 (1.5-5.4)
4.3 (1.9-9.8)
4.4 (1.7-11.2)
18.8 (2.4-149.6)
4.5 (1.2-17.9)
4.5 (1.9-10.5)
6.4 (1.3-31.3)
2.7 (1.4-5.1)
5.5 (1.1-27.5)
5.4 (2.7-10.7)
Lanas et al.
Spain, 201116
RC 1958 66 GIAD bleeding, selected by ICD-codes 4 groups: peptic / diverticular bleeding, 
peptic / intestinal perforation, selected by 
ICD-codes
Anticoagulants: GIAD 27% vs. Peptic bleeding 6%
NSAID + PPI: GIAD 8% vs. peptic ulcer 2% / ulcer 
perforation 1% / intestinal perforation 1%
P < 0.001
P < 0.01
Macdonald et al.
UK, 201030
RC 91 46 GIAD at SBCE / 72% OGIB No GIAD at SBCE 
/ 72% OGIB
Increasing age 1.09 (1.04-1.1)
Chak et al.
USA, 199831
RC 97 32 GIAD at push enteroscopy / 40% OGIB, 39% overt 
bleeding, 12% diarrhea, 9% mucosal disease
No GIAD at push enteroscopy / 40% OGIB, 
39% overt bleeding, 12% diarrhea, 9% 
mucosal disease
Age 40% >65 yrs vs. 12% < 65 yrs
CKD 54% in GIAD vs. 27% control
P < 0.001
P <0.05, OR 3.2
Clouse et al.
USA, 198532
- 90 30 GIAD at EGD / suspected upper GI bleeding No GIAD at EGD / suspected upper GI 
bleeding
CKD 60% in GIAD vs. 24% control P < 0.001 
OR 4.6
than the development of asymptomatic angiodysplasias48. Inpatient status is strongly associated 
with bleeding disease and multiple lesions increase the risk of rebleeds. 
The over-arching aim of this systematic review is to define factors that determine presence of 
gastrointestinal angiodysplasias and/or affect the progression to symptomatic disease. The use of 
a risk stratification to guide management requires a thorough assessment of the contribution of 
individual risk factors to the clinical picture. Patients who develop bleeding angiodysplasias and 
possess multiple risk factors that amplify the risk for rebleeding deserve close monitoring but 
also reassessment of those conditions that put the patient at a higher risk. For example, (over-) 
anticoagulation and valvular heart disease can be amended or treated. The efforts needed to lower 
the risk profile by treating underlying conditions can be complimentary to aggressive endoscopic 
treatment. Efforts to investigate the efficacy of different treatment strategies in low and high risk 
patients in order to fuel the evidence base are welcome.  
At present, one of the major issues in clinical management of asymptomatic angiodysplasias is 
that evidence on treatment outcome is based on heterogeneous small, and often non-controlled 
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Table 1A. Studies assessing risk factors for the presence of gastrointestinal angiodysplasias (GIAD).
Author  
Country, year Study type
No. of 
controls 
No. of  
GIAD pts Study population / indication Control group / indication
Outcomes
Significant risk factors 
Effect 
OR (95%-CI) / t-test
Igawa et al.
Japan, 201528
RC 97 64 Small bowel GIAD / OGIB No GIAD at SBCE and balloon endoscopy 
/ OGIB
Liver cirrhosis
Cardiovascular disease
4.8 (1.8-14.5)
2.9 (1.4-6.2)
Holleran et al.
Ireland, 201329
RC 95 66 Small bowel GIAD at SBCE / 51% anemia, 23% overt 
bleeding, 15% OGIB, 11% other
No GI bleeding / determined by 2 negative 
FOBT for colorectal cancer screening 
program
Hypertension
Ischemic heart disease
Arrhythmias 
Valvular heart disease
Congestive cardiac failure
CKD
Previous VTE
Anticoagulant use*
Warfarin*
Proton pump inhibitor*
2.8 (1.5-5.4)
4.3 (1.9-9.8)
4.4 (1.7-11.2)
18.8 (2.4-149.6)
4.5 (1.2-17.9)
4.5 (1.9-10.5)
6.4 (1.3-31.3)
2.7 (1.4-5.1)
5.5 (1.1-27.5)
5.4 (2.7-10.7)
Lanas et al.
Spain, 201116
RC 1958 66 GIAD bleeding, selected by ICD-codes 4 groups: peptic / diverticular bleeding, 
peptic / intestinal perforation, selected by 
ICD-codes
Anticoagulants: GIAD 27% vs. Peptic bleeding 6%
NSAID + PPI: GIAD 8% vs. peptic ulcer 2% / ulcer 
perforation 1% / intestinal perforation 1%
P < 0.001
P < 0.01
Macdonald et al.
UK, 201030
RC 91 46 GIAD at SBCE / 72% OGIB No GIAD at SBCE 
/ 72% OGIB
Increasing age 1.09 (1.04-1.1)
Chak et al.
USA, 199831
RC 97 32 GIAD at push enteroscopy / 40% OGIB, 39% overt 
bleeding, 12% diarrhea, 9% mucosal disease
No GIAD at push enteroscopy / 40% OGIB, 
39% overt bleeding, 12% diarrhea, 9% 
mucosal disease
Age 40% >65 yrs vs. 12% < 65 yrs
CKD 54% in GIAD vs. 27% control
P < 0.001
P <0.05, OR 3.2
Clouse et al.
USA, 198532
- 90 30 GIAD at EGD / suspected upper GI bleeding No GIAD at EGD / suspected upper GI 
bleeding
CKD 60% in GIAD vs. 24% control P < 0.001 
OR 4.6
studies18-22,50-54. This results in considerable practice variation55. More understanding of the different 
risk profiles of patients with different severity of the disease helps to make the right decision in 
whether to treat and which treatment modality would be needed. 
This systematic review allows identification of gaps that helps in the management of this 
disease. It also illustrates the complexity and wide phenotypical range of disease severity. In 
comparison with other vascular malformations, such as GAVE, portal gastropathy and radiation-
induced telangiectasias, the most prominent risk factors for the development of angiodysplasias 
and severity of the disease remain to be further investigated.
Our systematic review comes with inherent strengths and limitations. The strength of this 
study is that it includes a broad search strategy with a thoroughly performed quality assessment. 
Moreover, risk assessment based on confirmation of risk factors in a second study and those with 
a moderate effect size (OR >3.5) is performed. To get a clear overview, we subdivided the risk factors 
for different stages of disease, i.e. risk to detect angiodysplasias during endoscopy, angiodysplasias 
that cause overt bleeding or anemia and a more severe course with rebleeds or mortality. In 
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Table 1B. Studies assessing risk factors for the presence of gastrointestinal angiodysplasias (GIAD) in one specific 
patient category.
Author  
Country, year Study type
No. of pts 
controls 
No. of pts 
with GIAD Study population Control group
Outcome
Significant risk factors
Effect
HR (95%-CI) / t-test
Cochrane et al.
USA, 201633
RC 56 14 LVAD and GIAD diagnosed with EGD or colonoscopy LVAD without GI bleeding Age
CKD
Length of stay after LVAD 
Sex: male
Diabetes mellitus
Hypertension
1.3 (1.1-1.6)
21.0 (2.5-181)
5.1 (1.1-23.7)
0.1 (0.01-0.9)
0.9 (0.01-0.6)
0.2 (0.1-0.97)
Blackshear et al.,  
USA, 201434
RC 46 7 Mitral valve regurgitation and GIAD diagnosed with 
endoscopy NS
Mitral valve regurgitation without GIAD 13.2% GIAD in pts with mitral 
valve regurgitation
NA
French et al., 
USA, 201335
RC 31 - LVAD and GIAD diagnosed by EGD, colonoscopy or 
push enteroscopy
LVAD with GI bleeding GIAD as cause in 17.5% of all GI 
bleeding events in LVAD 
NA
Sotoudehmanesh  
et al. Iran, 200336
PC 197 9 GIAD in dialysis pts  / routine EGD before renal 
transplant
No GIAD / routine EGD before renal transplant Incidence in pre-renal transplant 
pts: 4.4% GIAD at EGD 
NA
Duchini et al.
USA, 199837
RC 135 9 SS / CREST and GIAD bleeding / endoscopy or 
radiology NS
SS / CREST without clinical signs of GI bleeding 6.3% have GI bleeding  
due to GIAD
NA
Bhutani et al.
USA, 199538
PC 37 40 GIAD pts / EGD or colonoscopy for: polyps /cancer 
18%, anemia 30%, overt bleeding 35%, dyspepsia 18% 
Matched age, sex and endoscopic examination: polyps /
cancer 19%, anemia 30%, overt bleeding 32%, dyspepsia 19%
0% aortic stenosis NA
Marcuard et al.
USA, 198839
- 32 15 GIAD in dialysis pts / EGD or colonoscopy for overt 
GI bleeding
No GIAD in dialysis pts / EGD or colonoscopy for overt GI 
bleeding
32% of CKD pts with GI bleeding 
have GIAD
NA
RC, retrospective cohort; PC, prospective cohort; GIAD, gastrointestinal angiodysplasias; OGIB, occult gastrointestinal bleeding; OR, 
Odds ratio; VTE, venous thromboembolism; LVAD’s, left ventricular assist devices; GI, gastrointestinal; CKD, chronic kidney disease; 
NSAID, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor; yrs, years; FOBT, fecal occult blood test; -, missing;  
pts, patients; SBCE, small bowel capsule endoscopy; EGD, esophagogastroduodenoscopy; NA, not applicable
* Analysis: not reported univariate or multivariate analysis
addition, the risk factors for each different disease stage include Western and Asian studies, thereby 
increasing the external validity of this review. A limitation of the study is that a meta-analysis was not 
possible due to the methodological heterogeneity between the studies. Moreover, the majority of 
studies identifying risk factors for finding angiodysplasias during endoscopy use different control 
groups and indications for endoscopy or only focus on small bowel angiodysplasias. We excluded 
case-reports and small case-series which could have led to the exclusion of diseases which are 
rare that increase the risk for the presence of angiodyplasias, e.g. bone marrow transplantation. 
We excluded other vascular anomalies, which could have introduced bias due to the inaccuracy of 
correctly distinguishing angiodysplasias from other vascular lesions at video capsule endoscopy. 
In conclusion, this systematic review identified important risk factors for angiodysplasias 
at different disease stages. The risk assessment identified age, chronic kidney disease, 
anticoagulant and cardiovascular disease as the most important risk factors for the presence of 
angiodysplasias during endoscopy, and inpatient status and multiple lesions contributing to disease 
severity. Information on these risk factors aids in accurate phenotyping which benefits clinical 
decision making. 
A
 risk assessm
ent o
f facto
rs fo
r the presence o
f angio
d
ysplasias and
 angio
d
ysplasia bleed
ing
2.1
33
Table 1B. Studies assessing risk factors for the presence of gastrointestinal angiodysplasias (GIAD) in one specific 
patient category.
Author  
Country, year Study type
No. of pts 
controls 
No. of pts 
with GIAD Study population Control group
Outcome
Significant risk factors
Effect
HR (95%-CI) / t-test
Cochrane et al.
USA, 201633
RC 56 14 LVAD and GIAD diagnosed with EGD or colonoscopy LVAD without GI bleeding Age
CKD
Length of stay after LVAD 
Sex: male
Diabetes mellitus
Hypertension
1.3 (1.1-1.6)
21.0 (2.5-181)
5.1 (1.1-23.7)
0.1 (0.01-0.9)
0.9 (0.01-0.6)
0.2 (0.1-0.97)
Blackshear et al.,  
USA, 201434
RC 46 7 Mitral valve regurgitation and GIAD diagnosed with 
endoscopy NS
Mitral valve regurgitation without GIAD 13.2% GIAD in pts with mitral 
valve regurgitation
NA
French et al., 
USA, 201335
RC 31 - LVAD and GIAD diagnosed by EGD, colonoscopy or 
push enteroscopy
LVAD with GI bleeding GIAD as cause in 17.5% of all GI 
bleeding events in LVAD 
NA
Sotoudehmanesh  
et al. Iran, 200336
PC 197 9 GIAD in dialysis pts  / routine EGD before renal 
transplant
No GIAD / routine EGD before renal transplant Incidence in pre-renal transplant 
pts: 4.4% GIAD at EGD 
NA
Duchini et al.
USA, 199837
RC 135 9 SS / CREST and GIAD bleeding / endoscopy or 
radiology NS
SS / CREST without clinical signs of GI bleeding 6.3% have GI bleeding  
due to GIAD
NA
Bhutani et al.
USA, 199538
PC 37 40 GIAD pts / EGD or colonoscopy for: polyps /cancer 
18%, anemia 30%, overt bleeding 35%, dyspepsia 18% 
Matched age, sex and endoscopic examination: polyps /
cancer 19%, anemia 30%, overt bleeding 32%, dyspepsia 19%
0% aortic stenosis NA
Marcuard et al.
USA, 198839
- 32 15 GIAD in dialysis pts / EGD or colonoscopy for overt 
GI bleeding
No GIAD in dialysis pts / EGD or colonoscopy for overt GI 
bleeding
32% of CKD pts with GI bleeding 
have GIAD
NA
RC, retrospective cohort; PC, prospective cohort; GIAD, gastrointestinal angiodysplasias; OGIB, occult gastrointestinal bleeding; OR, 
Odds ratio; VTE, venous thromboembolism; LVAD’s, left ventricular assist devices; GI, gastrointestinal; CKD, chronic kidney disease; 
NSAID, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor; yrs, years; FOBT, fecal occult blood test; -, missing;  
pts, patients; SBCE, small bowel capsule endoscopy; EGD, esophagogastroduodenoscopy; NA, not applicable
* Analysis: not reported univariate or multivariate analysis
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Table 2. Studies assessing triggers for symptomatic angiodysplasia disease. 
Author 
Country, year Study type
No. of pts 
symptomatic 
No. of pts 
asymptomatic Inclusion type of GIAD Control group
Outcomes
Significant risk factors 
multivariate analysis
Effect
OR (95%-CI)
Nishimura et al.
Japan, 201640
RC 29 406 Colon No active bleeding GIAD during colonoscopy Age >80 years
Heart disease
Anticoagulant use
Multiple lesions
AD lesions ≤5 mm
5.15 (1.61-16.5)
6.88 (1.04-45.5)
4.22 (1.21-14.7)
6.67 (1.77-25.2)
17.7 (4.90-64.0)
Kim et al.
Korea, 201641
RC 35 58 UGIB due to GIAD, diagnosed with EGD, 
SBCE or colonoscopy
Asymptomatic health screening Size AD ≥ 1 cm
Site: stomach
- (1.04-15.9)
- (1.2-12.5)
Diggs et al. 
USA, 201142
RC 2320 1839 Colon Indication colonoscopy no occult or overt bleeding Inpatient status
Age > 80 years
ASA class ≥ III
Black race
Hispanic ethnicity
2-10 lesions
> 10 lesions
8.74 (5.4-14.1)
1.32 (1.1-1.6)
1.97 (1.6-2.4)
1.95 (1.5-26.6)
1.71 (1.3-2.2)
1.50 (1.3-1.8)
2.18 (1.7-2.8)
PC, prospective cohort; RC, retrospective cohort; GI, gastrointestinal; No, number; GIAD, gastrointestinal angiodysplasia; pts, patients; UGIB, upper GI bleeding; OR, Odds Ratio; CI, confidence interval; -, missing; ASA, American Society of Anesthesiologists
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SUPPLEMENTARY FILES
File 1: 
Search strategy:
In MEDLINE:
((((((((((risk factor[Title/Abstract] OR riskfactor[Title/Abstract]) OR etiology[Title/Abstract]) 
OR cause[Title/Abstract]) OR epidemiology[Title/Abstract]) OR severity[Title/Abstract]) OR 
prognosis[Title/Abstract]) OR prognoses[Title/Abstract]) OR mortality[Title/Abstract]) OR 
predict[Title/Abstract]) OR prediction[Title/Abstract]) AND (((((stomach[Title/Abstract] OR small 
bowel[Title/Abstract]) OR gastrointestinal[Title/Abstract]) OR colon[Title/Abstract]) OR GI[Title/
Abstract]) AND ((angiodysplasia[Title/Abstract] OR telangiectasia[Title/Abstract] OR ectasia[Title/
Abstract]) OR angioectasia[Title/Abstract]))
The same search terms and combinations were used in the EMBASE database and 
the Cochrane Library. 
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File 2:
Table 1A. Quality assessment of the case-control studies using the Newcastle-Ottawa Scale.
Study Case definition
Representativeness 
of the cases
Selection of 
controls
Definition of 
controls
Comparability of cases 
and controls
Ascertainment of 
exposure
Same exposure 
assessment controls Equal lost to follow-up Total score
Igawa et al.26 X - X X XX - X - 6
Holleran, 201327 X - X - XX - X - 5
Lanas et al.15 - X - - X - X - 3
Macdonald et al.28 X - - - XX - X - 4
Chak et al.29 X - X X - - X - 4
Clouse et al.30 X - X X - - X - 4
Nishimura et al.38 X - X X XX - X - 6
Kim et al.39 X - X X XX - X - 6
Diggs et al.40 - - X X XX - X - 5
Table 1B. Quality assessment of the cohort studies using the Newcastle-Ottawa Scale.
Study
Representative-ness of 
exposed cohort
Selection of non 
exposed cohort
Ascertainment  
of exposure
Certain outcome 
not present at 
baseline
Comparability of 
cohorts
Assessment of 
outcome Duration follow-up Adequacy of follow-up Total score
Cochrane et al.31 - - X X XX X - X 6
Blackshear et al.32 X - X - - - - - 2
French et al.33 X - X X - X - - 4
Sotoudehmanesh et al.34 X - X - - X - - 3
Duchini et al.35 X - X - - X - - 3
Bhutani et al.36 X X X - X X - - 5
Marcuard et al.37 X - X - - X - - 3
Mai et al.43 - X - - XX X X X 6
Kaufman et al.41 - X - - XX X - - 4
Jeon et al.42 - X - - XX X - X 5
Holleran, 201643 - X - - XX X X - 5
Makris et al.12 X - X - - X - - 3
Sakai et al.44       - X - - XX X X X 6
Saperas et al.45    - X - - XX X X X 6
Serrao et al.46 X X - X XX X - X 7
X Symbol indicates that quality measure is met. – Symbol indicates that quality measure is not met. 
Legend: Each of the 8 items can be scored as adequate using  an X, except for the domain comparability which is given two Xs. 
The overall rating of the risk of bias is scored as low (7-9 X), moderate (4-6 X) or high (0-3 X). Representativeness of the study is met
when consecutive patients with angiodysplasias located throughout the GI tract are included. For the analyses, one X was given for 
matched controls for age and sex, two X were given for multivariate analysis of risk factors. Adequate mean follow-up was ought to be≥ 
2 years for the studies assessing risk factors for rebleeds with <20% lost to follow-up.
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Table 1A. Quality assessment of the case-control studies using the Newcastle-Ottawa Scale.
Study Case definition
Representativeness 
of the cases
Selection of 
controls
Definition of 
controls
Comparability of cases 
and controls
Ascertainment of 
exposure
Same exposure 
assessment controls Equal lost to follow-up Total score
Igawa et al.26 X - X X XX - X - 6
Holleran, 201327 X - X - XX - X - 5
Lanas et al.15 - X - - X - X - 3
Macdonald et al.28 X - - - XX - X - 4
Chak et al.29 X - X X - - X - 4
Clouse et al.30 X - X X - - X - 4
Nishimura et al.38 X - X X XX - X - 6
Kim et al.39 X - X X XX - X - 6
Diggs et al.40 - - X X XX - X - 5
Table 1B. Quality assessment of the cohort studies using the Newcastle-Ottawa Scale.
Study
Representative-ness of 
exposed cohort
Selection of non 
exposed cohort
Ascertainment  
of exposure
Certain outcome 
not present at 
baseline
Comparability of 
cohorts
Assessment of 
outcome Duration follow-up Adequacy of follow-up Total score
Cochrane et al.31 - - X X XX X - X 6
Blackshear et al.32 X - X - - - - - 2
French et al.33 X - X X - X - - 4
Sotoudehmanesh et al.34 X - X - - X - - 3
Duchini et al.35 X - X - - X - - 3
Bhutani et al.36 X X X - X X - - 5
Marcuard et al.37 X - X - - X - - 3
Mai et al.43 - X - - XX X X X 6
Kaufman et al.41 - X - - XX X - - 4
Jeon et al.42 - X - - XX X - X 5
Holleran, 201643 - X - - XX X X - 5
Makris et al.12 X - X - - X - - 3
Sakai et al.44       - X - - XX X X X 6
Saperas et al.45    - X - - XX X X X 6
Serrao et al.46 X X - X XX X - X 7
X Symbol indicates that quality measure is met. – Symbol indicates that quality measure is not met. 
Legend: Each of the 8 items can be scored as adequate using  an X, except for the domain comparability which is given two Xs. 
The overall rating of the risk of bias is scored as low (7-9 X), moderate (4-6 X) or high (0-3 X). Representativeness of the study is met
when consecutive patients with angiodysplasias located throughout the GI tract are included. For the analyses, one X was given for 
matched controls for age and sex, two X were given for multivariate analysis of risk factors. Adequate mean follow-up was ought to be≥ 
2 years for the studies assessing risk factors for rebleeds with <20% lost to follow-up.
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File: 3
Figure 3. Funnel plot of studies assessing chronic kidney disease as risk factor for the presence 
of angiodysplasias. 
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ABSTRACT
Background
There is no literature on risk factors for incidentally found angiodysplasias. In clinical practice, 
endoscopists may defer treatment due to uncertainty about a causal role of any found angiodysplasia 
and overt or occult bleeding. The objective is to identify risk factors that distinguish incidental 
angiodysplasias from angiodysplasias that are the cause of symptomatic bleeding.
Methods
A case-control study to compare angiodysplasia groups and a random sample from the general 
population. Angiodysplasia patients were diagnosed between 2010-2015. Controls were from a 2005 
population survey. Determinants were demographics, past medical history, lifestyle, medication 
and angiodysplasia characteristics. Multivariable logistic regression analyses were performed to 
identify independent risk factors. 
Results
270 angiodysplasia patients (59% men, mean age 65 years) and 5594 controls (46% men, mean age 
58 years) were included in this study. Independent risk factors for incidental angiodysplasias are 
male gender (OR 1.6, 95% CI 1.02-2.6), thyroid dysfunction (OR 4.1, 95% CI 2.0-8.4), auto-immune 
disease (OR 2.3, 95% CI 1.2-4.1), COPD (OR 1.8, 95% CI 1.0-3.2), and blood thinners (OR 2.8, 95% CI 
1.6-4.8). Besides angiodysplasia characteristics, factors independently associated with symptomatic 
angiodysplasias are increased age (OR 1.7 per 10 years age band, 95% CI 1.3-2.5), valvular heart 
disease (OR 10.4, 95% CI 1.6-69.2), diabetes mellitus (OR 2.6, 95% CI 1.03-6.7) and hyperlipidemia (OR 
3.7, 95% CI 1.1-12.1). 
Conclusion
The risk factor profile for incidental angiodysplasias differs from symptomatic angiodysplasias and 
is more profound for the latter. This knowledge could help endoscopists in the decision-making 
process to treat an endoscopically detected angiodysplasia.
Risk facto
rs fo
r incid
entally d
etected
 angio
d
ysplasias and
 sym
pto
m
atic angio
d
ysplasia
2.2
47
INTRODUCTION
Angiodysplasias are an important cause of gastrointestinal bleeding in the elderly.1 The disease 
phenotype ranges from the asymptomatic stage to patients dependent on red blood cell transfusions 
with frequent hospitalizations. Most patients with angiodysplasia will develop incidental or 
intermittent gastrointestinal bleeding.2 A small proportion proceed to severe ongoing intestinal 
bleeding, accounting for 37-50% of patients with chronic severe gastrointestinal bleeding.3 This 
impacts health-related quality of life negatively and puts a financial burden on healthcare systems.4
Many risk factors associated with symptomatic angiodysplasias have been identified, such as 
chronic kidney disease, cardiopulmonary comorbidity, age, von Willebrand disease and cirrhosis.5 
Nevertheless, the relative weight of these risk factors in relation to the phenotype remains to be 
explored. In addition, it is unclear whether different factors are associated with incidentally detected 
angiodysplasias and whether this can been viewed as a different disease stage.
There is no indication for treatment of in incidental angiodysplasias.6 In clinical practice, 
endoscopists might defer treatment due to uncertainty about the causal role of detected 
angiodysplasia in relation to overt or occult bleeding for which the endoscopy was performed. 
This may lead to undertreatment or delay proper treatment necessitating a second endoscopic 
procedure. Presence of comorbidities that are bona fide risk factors for symptomatic angiodysplasias 
may lower the threshold for endoscopic treatment and which would allow the endoscopist to 
provide timely endoscopic therapy.
It is of paramount importance to identify risk factors that could distinguish between incidental 
and symptomatic angiodysplasias. In our experience, we have diagnosed patients with angiodysplasia 
who never become symptomatic, while others become symptomatic. We hypothesize there are 
differences between risk factors associated with incidental and symptomatic angiodysplasia. To 
address this question we performed a case-control study and benefited from the presence of a large 
cohort of patients with endoscopic detected angiodysplasias. 
METHODS
Study design 
We designed a case-control study comparing a cohort of patients with endoscopically detected 
angiodysplasias (incidental and symptomatic) with people from the general population. The study 
is performed in the Radboud University Medical Center. The research protocol for this case-control 
study was approved by the institutional ethical review board ‘Commissie Mensgebonden Onderzoek’ 
in October 29th, 2015. Written informed consent was obtained for the control group. The data of 
the angiodysplasia patients was anonymized and retrospectively retrieved, and therefore judged 
as not necessary to obtain written informed consent. The study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki as reflected in approval by the institution’s human 
research committee.
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Participants
Angiodysplasia group
Angiodysplasia patients were identified from a single tertiary center (the Radboud University Medical 
Center) through reports of routine endoscopic procedures from January 2010 to March 2015. 
Endoscopy reports, including esophagogastroduodenoscopy, colonoscopy, balloon enteroscopy 
and video capsule, were assessed through an automated search in RVC Clinical Assistant (RVC 
B.V., Baarn, Netherlands) using the terms ‘angiodysplasia’, ‘ectasia’, ‘angioectasia’, ‘telangiectasia’, 
‘arteriovenous malformation’ and ‘AVM’. Patients with established angiodysplasias were included, 
defined as single or multiple 2–5 mm flat bright red spots with round uniform or slightly irregular 
margins, or lesions appearing as raised and reddened areas with a distinctly irregular margin, 
when larger than 5 mm were seen.7 The presence of angiodysplasias associated with anemia, 
immunohistochemical positive fecal occult blood, hematochezia, or melena were categorized as 
symptomatic angiodysplasias.3 We defined ‘incidental angiodysplasias’ as lesions discovered upon 
endoscopic procedures that were not part of diagnostic analysis for causes of gastrointestinal 
bleeding, e.g. screening for portal hypertension, screening colonoscopy, procedures performed 
for change in bowel movements or endoscopic evaluations for dyspepsia or gastroesophageal 
reflux disease. Exclusion criteria were other vascular malformations such as gastric antral vascular 
ectasia (GAVE), hereditary hemorrhagic telangiectasia (HHT) and radiation proctitis. We excluded 
patients with concurrent disease that was the explanation for gastrointestinal bleeding, such 
as variceal bleeding or peptic ulcers. Data were retrieved from electronic patient records, and 
included patient characteristics (age, lifestyle, past medical history, medication use) and disease 
characteristics (angiodysplasia location, clustering and number). 
Control group
The control group consisted of a sample of the general population. The data were obtained 
from the Nijmegen Biomedical Study, a population-based survey conducted by the Department 
for Health Evidence and the Department of Laboratory Medicine of the Radboud University 
Medical Center.8 In brief, the Nijmegen Biomedical Study is a population-based cross-sectional 
study performed in Nijmegen which is a town in the eastern part of The Netherlands with 156000 
inhabitants, approximately 87% of Caucasian descent. Age and sex stratified randomly selected 
adult (age 18 years and older) inhabitants of Nijmegen (22 452) received an invitation to complete 
a postal questionnaire on lifestyle and medical history. The response to the questionnaire was 43% 
(N=9350). In total, five questionnaires were collected between 2001-2012. Age, medical history, 
body mass index (BMI) and medication were derived from the questionnaire in 2005. A total of 
5594 people participated in this study. Data on lifestyle and use of ACE-inhibitors or angiotensin 
II receptors blockers and beta-blockers are taken from the second questionnaire in 2007 (n=1517). 
Variable definitions and outcomes
Definitions of included variables concerning medical history can be found in Supplementary File 1. 
Odds ratios (ORs) with corresponding 95% confidence intervals (95% CI) were calculated to measure 
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the association between the possible risk factors and the occurrence of incidental angiodysplasia or 
symptomatic angiodysplasia. 
Statistical analyses
Baseline descriptives are presented as mean with standard deviation or median with interquartile 
range for non-normally distributed data. To search for meaningful risk factors we first performed 
univariate multinomial logistic regression analysis associated with incidentally detected 
angiodysplasias or symptomatic angiodysplasias in comparison with the general population. 
Variables with P-value <0.1. were included in the multivariable analyses and subsequently assessed 
with a backward stepwise selection procedure using a P-value greater than 0.05 for removal of 
variables. Odds ratios (ORs) were calculated with 95% CI. A two-sided tested p-value ≤0.05 was 
considered statistically significant. All statistical analyses were performed with the SPSS package 
version 22.0 (SPSS, Inc, Chicago, IL).
RESULTS
Participants
In the angiodysplasia group, 270 participants were included and in the control group 5594 
(see figure 1). Two thirds of all patients diagnosed with angiodysplasias could be diagnosed as 
symptomatic. The baseline demographic characteristics of patients and controls are summarized 
in Table 1. Most angiodysplasias were diagnosed in men (59%) and the median age was 65 years 
(SD 12). Control subjects were more often female (54%) and younger with a median age of 59 
years (SD 17). The angiodysplasia group was noted to have a higher percentage of people with 
comorbidities, smoking, alcohol use and a slightly higher BMI. 
Figure 1. Flowchart patient inclusion.
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Factors associated with incidental angiodysplasias
Various risk factors were associated with incidental angiodysplasias and symptomatic angiodysplasias 
compared to the general population in univariate analysis (see Supplementary File 1, Table 1). For 
the incidentally detected angiodysplasias aspirin (OR 2.4, 95% CI 1.4-4.2), angiotensin-converting-
enzyme (ACE) inhibitor (OR 2.0, 95% CI 1.1-3.5), statins (OR 2.0, 95% CI 1.2-3.3), alcohol use (per 
10 units/week of alcohol OR 1.3, 95% CI 1.05-1.6) and smoking (OR 2.7, 95% CI 1.3-5.4) were found 
to have a significant association. However, due to the different time points (2005 & 2007) these 
questionnaires were distributed, five variables could not be included in the multivariate model.
Table 2 shows the results of the multivariable analysis with factors independently associated 
with incidentally found angiodysplasias compared to the general population. Male gender 
(OR 1.6, 95% CI 1.02-2.6), thyroid dysfunction (OR 4.1, 95% CI 2.0-8.4), auto-immune disease 
(OR 2.3, 95% CI 1.2-4.1), COPD (OR 1.8, 95% CI1.0-3.2) and anticoagulants and antiplatelet agents 
(OR 2.8, 95% CI 1.6-4.8) appeared to be risk factors, whereas hyperlipidemia (OR 0.2, 95% CI 0.1-0.5) 
was a protective factor.  
Factors associated with symptomatic angiodysplasias
Next, we compared the incidental angiodysplasia group with the symptomatic angiodysplasia 
group (Table 3). Various factors were associated with symptoms in univariable regression analysis 
(see Supplementary File 2). Increased age (OR 1.8 per 10 years older, 95% CI 1.3-2.5), valvular heart 
disease (OR 10.4, 95% CI 1.6-69.2), diabetes mellitus (OR 2.6, 95% CI 1.03-6.7), hyperlipidemia (OR 3.7, 
95% CI 1.1-12.1), ≥2 angiodysplasias (OR 4.3, 95% CI 1.3-14.4), small bowel (OR 8.7, 95% CI 1.9-39.5) and 
Table 1. Baseline characteristics of the angiodysplasia and control group. 
Baseline characteristics 
Angiodysplasia group
(n = 270) 
Controls
(n = 5594)
Age - mean (±SD) 65 (12) 58 (17)
Gender: male - n (%) 159 (59) 2559 (46)
Comorbidity - n (%)
 Valvular heart disease
 Chronic kidney disease
 COPD
 Diabetes mellitus
49 (19)
34 (13)
64 (24)
64 (24)
472 (9)
147 (3)
620 (11)
343 (6)
Medication use - n (%)
 Blood thinners
 Platelet inhibitors
Life style - n (%)
128 (51)
84 (34)
796 (15)
525 (10)
 BMI - mean (±SD) 26.5 (5) 25.1 (4)
 Currently smoking 41 (36) 231 (17)
 Weekly units of alcohol 15 (17) 8 (9)
*COPD, chronic obstructive pulmonary disease; BMI, body mass index
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stomach (OR 3.3, 95% CI 1.04-10.2) location and angiodysplasias clustered in groups (OR 4.4, 95% CI 
1.2-16.4) were factors that were independently associated with symptomatic angiodysplasias.
DISCUSSION
This is the first study to determine the difference in risk factors between incidental and symptomatic 
angiodysplasia with the use of a control group. This supports the hypothesis that incidental and 
symptomatic angiodysplasias may be two different disease states corresponding with different 
phenotypes.. Male gender, thyroid dysfunction, COPD, auto-immune diseases as well as the use 
of anticoagulants and antiplatelet agents are risk factors for incidental angiodysplasias, whereas 
Table 2. Variables independently associated with incidentally found angiodysplasias compared to 
the general population.
Clinical feature 
Controls
(n = 5594) 
Incidental AD
(n = 94) OR (95% CI) P-value
Gender: male -  n (%) 2559 (46) 54 (57) 1.6 (1.01-2.6) 0.046
Comorbidity - n (%)
 COPD
 Hyperlipidemia
 Thyroid dysfunction
 Auto-immune disease
 VTE
620 (11)
869 (16)
201 (4)
401 (8)
153 (3)
16 (17.4)
4 (4.3)
10 (10.9)
14 (15.2)
7  (7.4)
1.8 (1.0-3.2)
0.2 (0.1-0.5)
4.1 (2.0-8.4)
2.3 (1.2-4.1)
2.3 (1.0-5.6)
0.05
0.001
<0.001
0.009
0.06
Medication -  n (%)
 Blood thinners 796 (15) 22 (27.2) 2.8 (1.6-4.8) <0.001
*AD, angiodysplasia; VTE, Venous thromboembolism; COPD, chronic obstructive pulmonary disease
Table 3. Variables independently associated with symptomatic compared to incidentally detected angiodysplasias.
Clinical feature 
Incidental AD
(n = 94) 
Sympt. AD
(n = 176) OR (95% CI) P-value
Age - mean (±SD) 59.6 (13.1) 67.3 (10.3) 1.7 (1.3-2.5) <0.001
Comborbidity - n (%)
 Valvular HD
 Diabetes mellitus
 Hyperlipidemia
4 (4.3)
10 (10.9)
4 (4.3)
45 (26.0)
54 (31.2)
30 (17.3)
10.4 (1.6-69.2)
2.6 (1.03-6.7)
3.7 (1.1-12.1)
0.02
0.04
0.03
AD characteristics
 Number (>2) of AD
 Location of AD
  Stomach
  Small bowel
  One group vs single
9 (11.3)
7 (7.4)
4 (4.3)
4 (4.3)
53 (40.5)
45 (25.6)
45 (25.6)
24 (13.9)
4.3 (1.3-14.4)
3.3 (1.04-10.2)
8.7 (1.9-39.5)
4.4 (1.2-16.4)
0.02
0.04
0.005
0.04
*AD, angiodysplasia; Sympt., symptomatic; HD, heart disease
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hyperlipaedemia would be protective. In the symptomatic group the proportion of patients with 
hyperlipaedemia is similar to prevalence rate in the general population, making this a risk factor 
for symptomatic compared to the incidental angiodysplasia. The known risk factors of increasing 
age and valvular heart disease were associated with symptomatic angiodysplasias, whereas 
anticoagulants and antiplatelet agents were not associated in multivariable analysis. 
The association between age and valvular heart disease with angiodysplasias has been 
determined in previous studies.3, 9 However, a limitation of these studies was that the control 
group did not consist of patients with incidental angiodysplasias and hereby making it impossible 
to distinguish specific factors that could be of help to adequately differentiate incidental from 
symptomatic angiodysplasias during endoscopy. Moreover, there was heterogeneity between 
these studies (some only focusing on one gastrointestinal location or risk factor) and most had 
small sample sizes.10-14 We feel that our larger sample size enabled us to identify three variables (e.g. 
COPD, thyroid dysfunction and auto-immune disease) previously with symptomatic angiodysplasias 
as factors solely associated with incidental angiodysplasias.13 
The differential risk profile is important to support endoscopists in the decision to treat or not 
treat the found angiodysplasia. We feel that increased awareness of angiodysplasia will decrease 
under- and overtreatment. However, further research including the development of a prediction 
rule would be useful in this disease where there is a relative high percentage (34%) of angiodysplasias 
that do not have to be treated. 
Our study comes with some limitations. Unfortunately, we found the question to identify 
cirrhosis in the general population inadequate and therefore we were unable to include this known 
risk factor in the analysis comparing with the general population.15 Second, investigation of the small 
bowel is only indicated when there is persistent anemia despite treatment of underlying diseases 
found during upper- and lower endoscopy. This introduces bias by indication as incidentally found 
small bowel angiodysplasias are not included due to the current practice and retrospective nature 
of this study. As last, due to the small number of patients with certain risk factors in the incidental 
angiodysplasia group, the confidence intervals of the estimated effects are very broad. 
Strengths of this study are the relative large angiodysplasia cohort, comparison with the general 
population and the differentiation between incidental and symptomatic angiodysplasias. Finally, 
the angiodysplasia cohort is well established through a systematic endoscopy database search 
which increases the validity of this study.
In conclusion, we have shown that there are different risk factors associated with incidental and 
symptomatic angiodysplasias. This is important in understanding the disease and supports the idea 
that some angiodysplasias might never become symptomatic when certain triggers are not present. 
Moreover, it can facilitate the decision-making process of endoscopists to treat the angiodysplasia 
with argon plasma coagulation during endoscopy.
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SUPPLEMENTARY FILES
File 1
Definitions of predictor variables
Medical history:
•	 Hypertension	(HT):	antihypertensive	use
•	 Ischemic	heart	disease:	when	platelet	aggregation	inhibitors	or	oral	anticoagulants	are	used
•	 Valvular	heart	disease:	asymptomatic	severe	or	symptomatic	diagnosed	by	ultrasound13 
•	 Arrhytmias	 (already	 known):	 atrial	 premature	 beats,	 ventricular	 premature	 beats,	
bradycardias, nonsustained ventricular tachycardia, atrial fibrillation (AF) or atrial flutter, 
supraventricular tachycardia, atrioventricular (AV) block, pacemaker or other
•	 DVT/LE:	Wherefor	anticoagulants	were	prescribed	initially.
•	 DM:	Only	check	the box when oral glucose-lowering agents or insuline is used.
•	 Hyperlipaedemie:	Only	check	the box when a statine is used.
•	 CKD:	Defined:	
 » Moderate: glomerular filtration rate og <60ml/min for > 3 months
 » Advanced: GFR <30
 » Intermittend hemodialysis
•	 Congenital	coagulant	disorder:	Defined:	hemophilia,	von	Willebrand	disease	or	factor	 
V deficiency
•	 Gastro-esophageal	reflux:	Defined:	use	of	proton	pomp	inhibitors	or	diagnosed	 
by endoscopy
•	 Thyroid	dysfunction:	Defined:
 » Hyperthyroid: thyroid-stimulating hormone (TSH) <0.3 μU/ml and no thyroid 
replacement therapy (TRT)
 » Hypothyroid: TSH >5.0 μU/ml and no TRT
 » TRT
•	 Rheumatoid	arthritis:	diagnosed	by	a rheumatologist 
•	 Chronic	obstructive	pulmonary	disease	(GOLD	stage)	or	bronchiectasis
•	 Liver	 cirrhosis:	 stadium	CP-score,	Defined:	 diagnosed	 by	 signs	 on	 radiographic	 imaging/
fibroscan or liver biopsy
•	 Congestive	heart	 failure:	 treatment	with	 the combination of ace-inhibitor, spironolacton, 
betablocker and diuretics (or be intolerant for some) or left ventricular assist device. 
Grading by the NHY-classification. 
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File 2 – Table 1. Univariate multinominal logistic regression for the presence of angiodysplasias and  
angiodysplasia bleeding compared to the general population.
Clinical features 
Controls
(n = 5594)
Incidental AD
(n = 94) OR (95% CI) P value
Bleeding AD
(n = 176) OR (95% CI) P value
Patient characteristics
 Gender: male - n (%) 2559 (46) 54 (57) 1.6 (1.1-2.4) 0.03 105 (60) 1.8 (1.3-2.4) <0.001
 Age - mean (±SD) 58 (17) 59.6 (13.1) 1.1 (0.9-1.2) 0.3 67.3 (10.3) 1.4 (1.3-1.6) <0.001
 BMI - mean (±SD) 25.1 (4.0) 25.3 (4.5) 1.0 (1.0-1.1) 0.79 27.1 (5.5) 1.1 (1.06-1.1) <0.001
Comorbidity - n (%)
 Valvular heart disease
 Chronic kidney disease
 COPD
 Diabetes mellitus
 Hypertension
 Ischemic heart disease
 Congestive heart failure
 Arrhythmias
 Hyperlipidemia
 CVA 
 Hematological bleeding disorder
 Thyroid dysfunction
 Auto-immune diseasev
 Venous thromboembolism
272 (5)
147 (3)
620 (11)
343 (6)
1330 (24)
472 (9)
203 (4)
469 (9)
869 (16)
257 (5)
45 (0.8)
201 (4)
401 (8)
153 (3)
4 (4.3)
1 (1.1)
16 (17.4)
10 (10.9)
26 (28.3)
11 (12.0)
2 (2.1)
9 (9.8)
4 (4.3)
6 (6.4)
1 (1.1)
10 (10.9)
14 (15.2)
7  (7.4)
0.9 (0.3-2.3)
0.4 (0.1-2.9)
1.6 (0.9-2.8)
1.8 (0.9-3.6)
1.2 (0.8-2.0)
1.4 (0.7-2.7)
0.6 (0.1-2.3)
1.1 (0.6-2.3)
0.2 (0.1-0.7)
1.4 (0.6-3.2)
1.3 (0.2-9.6)
3.0 (1.6-6.0)
2.1 (1.2-3.7)
2.8 (1.3-6.1)
0.76
0.36
0.08
0.08
0.37
0.29
0.44
0.71
0.005
0.43
0.79
0.001
0.01
0.01
45 (26.0)
33 (19.1)
48 (27.7)
54 (31.2)
85 (49.1)
47 (27.2)
23 (13.3)
43 (24.9)
30 (17.3)
35 (20.2)
5 (2.9)
15 (8.7)
33 (19.1)
13 (7.5)
6.6 (4.6-9.5)
8.5 (5.6-12.8)
3.0 (2.1-4.2)
6.8 (4.9-9.6)
3.0 (2.2-4.1)
3.9 (2.7-5.5)
4.0 (2.5-6.3)
3.5 (2.4-5.0)
1.1 (0.7-1.6)
5.1 (3.5-7.6)
3.6 (1.4-9.1)
2.4 (1.4-4.1)
2.7 (1.9-4.1)
2.7 (1.5-4.9)
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.64
<0.001
0.008
0.002
<0.001
0.001
Medication use - n (%)
 Blood thinners
 Aspirin
 Beta-blockers
 ACE-inhibitor/ANGII-antagonist
 Statins
Life style - n (%)
 Weekly alcohol intake – EH (±SD)
 Currently smoking
796 (15)
525 (10)
220 (17)
147 (11)
689 (13)
8.3 (9.3)
231 (17)
22 (27.2)
17 (21.0)
17 (21.0)
16 (19.8)
18 (22.2)
12.1 (8.6)
23 (63.9)
2.2 (1.3-3.6)
2.4 (1.4-4.2)
1.3 (0.8-2.3)
2.0 (1.1-3.5)
2.0 (1.2-3.3)
1.3 (1.05-1.6)
2.7 (1.3-5.4)
0.002
0.001
0.29
0.02
0.01
0.02
0.005
107 (62.6)
68 (39.8)
66 (38.8)
60 (35.3)
77 (45.3)
16.5 (19.9)
50 (64.1)
9.7 (7.1-13.4)
6.1 (4.4-8.4)
3.2 (2.3-4.5)
4.4 (3.1-6.3)
5.7 (4.1-7.7)
1.5 (1.3-1.7)
2.7 (1.6-4.3)
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
AD, angiodysplasia; COPD, chronic obstructive pulmonary disease; BMI, body mass index; CVA, cerebrovascular accident  
*ORs for age and weekly alcohol intake are per 10 units, which makes it easier to interpret. For BMI is not adjusted.
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File 2 – Table 1. Univariate multinominal logistic regression for the presence of angiodysplasias and  
angiodysplasia bleeding compared to the general population.
Clinical features 
Controls
(n = 5594)
Incidental AD
(n = 94) OR (95% CI) P value
Bleeding AD
(n = 176) OR (95% CI) P value
Patient characteristics
 Gender: male - n (%) 2559 (46) 54 (57) 1.6 (1.1-2.4) 0.03 105 (60) 1.8 (1.3-2.4) <0.001
 Age - mean (±SD) 58 (17) 59.6 (13.1) 1.1 (0.9-1.2) 0.3 67.3 (10.3) 1.4 (1.3-1.6) <0.001
 BMI - mean (±SD) 25.1 (4.0) 25.3 (4.5) 1.0 (1.0-1.1) 0.79 27.1 (5.5) 1.1 (1.06-1.1) <0.001
Comorbidity - n (%)
 Valvular heart disease
 Chronic kidney disease
 COPD
 Diabetes mellitus
 Hypertension
 Ischemic heart disease
 Congestive heart failure
 Arrhythmias
 Hyperlipidemia
 CVA 
 Hematological bleeding disorder
 Thyroid dysfunction
 Auto-immune diseasev
 Venous thromboembolism
272 (5)
147 (3)
620 (11)
343 (6)
1330 (24)
472 (9)
203 (4)
469 (9)
869 (16)
257 (5)
45 (0.8)
201 (4)
401 (8)
153 (3)
4 (4.3)
1 (1.1)
16 (17.4)
10 (10.9)
26 (28.3)
11 (12.0)
2 (2.1)
9 (9.8)
4 (4.3)
6 (6.4)
1 (1.1)
10 (10.9)
14 (15.2)
7  (7.4)
0.9 (0.3-2.3)
0.4 (0.1-2.9)
1.6 (0.9-2.8)
1.8 (0.9-3.6)
1.2 (0.8-2.0)
1.4 (0.7-2.7)
0.6 (0.1-2.3)
1.1 (0.6-2.3)
0.2 (0.1-0.7)
1.4 (0.6-3.2)
1.3 (0.2-9.6)
3.0 (1.6-6.0)
2.1 (1.2-3.7)
2.8 (1.3-6.1)
0.76
0.36
0.08
0.08
0.37
0.29
0.44
0.71
0.005
0.43
0.79
0.001
0.01
0.01
45 (26.0)
33 (19.1)
48 (27.7)
54 (31.2)
85 (49.1)
47 (27.2)
23 (13.3)
43 (24.9)
30 (17.3)
35 (20.2)
5 (2.9)
15 (8.7)
33 (19.1)
13 (7.5)
6.6 (4.6-9.5)
8.5 (5.6-12.8)
3.0 (2.1-4.2)
6.8 (4.9-9.6)
3.0 (2.2-4.1)
3.9 (2.7-5.5)
4.0 (2.5-6.3)
3.5 (2.4-5.0)
1.1 (0.7-1.6)
5.1 (3.5-7.6)
3.6 (1.4-9.1)
2.4 (1.4-4.1)
2.7 (1.9-4.1)
2.7 (1.5-4.9)
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.64
<0.001
0.008
0.002
<0.001
0.001
Medication use - n (%)
 Blood thinners
 Aspirin
 Beta-blockers
 ACE-inhibitor/ANGII-antagonist
 Statins
Life style - n (%)
 Weekly alcohol intake – EH (±SD)
 Currently smoking
796 (15)
525 (10)
220 (17)
147 (11)
689 (13)
8.3 (9.3)
231 (17)
22 (27.2)
17 (21.0)
17 (21.0)
16 (19.8)
18 (22.2)
12.1 (8.6)
23 (63.9)
2.2 (1.3-3.6)
2.4 (1.4-4.2)
1.3 (0.8-2.3)
2.0 (1.1-3.5)
2.0 (1.2-3.3)
1.3 (1.05-1.6)
2.7 (1.3-5.4)
0.002
0.001
0.29
0.02
0.01
0.02
0.005
107 (62.6)
68 (39.8)
66 (38.8)
60 (35.3)
77 (45.3)
16.5 (19.9)
50 (64.1)
9.7 (7.1-13.4)
6.1 (4.4-8.4)
3.2 (2.3-4.5)
4.4 (3.1-6.3)
5.7 (4.1-7.7)
1.5 (1.3-1.7)
2.7 (1.6-4.3)
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
AD, angiodysplasia; COPD, chronic obstructive pulmonary disease; BMI, body mass index; CVA, cerebrovascular accident  
*ORs for age and weekly alcohol intake are per 10 units, which makes it easier to interpret. For BMI is not adjusted.
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File 3 – Table 2. Univariate analysis of factors associated with symptomatic bleeding (ORs  with  
95% confidence intervals).
Clinical feature 
Incidental 
angiodysplasia
(n = 94) 
Bleeding 
angiodysplasia
(n = 176) OR (95% CI) P-value
Patient characteristics
 Gender: male – n (%)
 Age - mean (±SD)
54 (57)
59.6 (13.1)
105 (60)
67.3 (10.3)
0.9 (0.5-1.5)
1.8 (1.4-2.3)
0.72
<0.001
 BMI - mean (±SD) 25.3 (4.5) 27.1 (5.5) 1.1 (1.01-1.2) 0.02
Comorbidity - n (%)
 Valvular heart disease
 Chronic kidney disease
 COPD
 Diabetes mellitus
 Hypertension
 Ischemic heart disease
 Congestive HF
 Arrhythmias
 Liver cirrhosis
 Hyperlipidemia
 CVA 
 Hematological bleeding disorder
 Thyroid dysfunction
 Auto-immune disease
4 (4.3)
1 (1.1)
16 (17.4)
10 (10.9)
26 (28.3)
11 (12.0)
2 (2.1)
9 (9.8)
5 (5.3)
4 (4.3)
6 (6.4)
1 (1.1)
10 (10.9)
14 (15.2)
45 (26.0)
33 (19.1)
48 (27.7)
54 (31.2)
85 (49.1)
47 (27.2)
23 (13.3)
43 (24.9)
15 (8.5)
30 (17.3)
35 (20.2)
5 (2.9)
15 (8.7)
33 (19.1)
7.7 (2.7-22.3)
21.5 (2.9-159.6)
1.8 (1.0-3.4)
3.7 (1.8-7.7)
2.5 (1.4-4.2)
2.7 (1.3-5.6)
6.9 (1.6-30.0)
3.1 (1.4-6.6)
1.7 (0.6-4.7)
4.6 (1.6-13.5)
3.6 (1.5-9.0)
2.7 (0.3-23.5)
0.8 (0.3-1.8)
1.3 (0.7-2.6)
<0.001
0.003
0.06
<0.001
0.001
0.006
0.01
0.004
0.34
0.005
0.005
0.37
0.56
0.44
 VTE 7 (7.4) 13 (7.5) 1.0 (0.4-2.6) 0.98
Medication use - n (%)
 Blood thinners
 Platelet aggregation inhibitors
Life style - n (%)
 Smoking – currently
 Alcohol consumption
22 (27.2)
17 (21.0)
13 (36.1)
39 (41.5)
107 (62.6)
68 (39.8)
28 (35.9)
79 (44.9)
4.5 (2.5-8.0)
2.5 (1.3-4.6)
1.2 (0.74-2.0)
1.1 (0.7-1.9)
<0.001
0.004
0.42
0.59
AD characteristics Number of AD: >2
  Location of AD
  Stomach
  Small bowel
  Colon
9 (11.3)
7 (7.4)
4 (4.3)
72 (76.6)
53 (40.5)
45 (25.6)
45 (25.6)
97 (55.1)
5.4 (2.5-11.7)
4.3 (1.8-9.9)
7.7 (2.7-22.2)
0.4 (0.2-0.7)
<0.001
0.001
0.005
0.001
Clustered – single AD
 One group 
 Multiple diffuse lesions
62 (66.7)
4 (4.3)
27 (29.0)
51 (29.5)
24 (13.9)
98 (56.6)
7.3 (2.4-22.4)
4.4 (2.5-7.8)
0.001
<0.001
*COPD, chronic obstructive pulmonary disease; BMI, body mass index, VTE; venousnthromboembolism; HF, heart failure; 
AD, angiodysplasia
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ABSTRACT
Background 
Gastrointestinal angiodysplasias may cause anemia. Quality of life (QoL) is a valid patient reported 
outcome and improvement of QoL represents an important treatment goal. There is a paucity of 
data on the effect of angiodysplasias on QoL. Therefore, we aim to evaluate QoL and fatigue in 
angiodysplasia patients. 
Methods
We performed a cross-sectional patient-reported outcome study. We included patients with 
endoscopy proven angiodysplasias and measured QoL with Short Form-36 and level of fatigue using 
Multi Fatigue Inventory-20. We distinguished three subgroups of patients according to disease 
severity: 1) with treatment for angiodysplasias, 2) without treatment for angiodysplasias and 3) 
without recent hospital visits. The primary outcome was the physical component summary (PCS) 
score on the SF-36. Multivariate regression analysis were performed to correct for differences 
at baseline. 
Results
A total of 144 patients completed the questionnaires (response rate = 62%; mean age 68 years; 65% 
men). Angiodysplasia patients have a significant lower PCS compared to the age-matched general 
population (respectively 41.0 vs. 43.3, p=0.01). Disease severity is independently associated with 
a negative outcome on QoL (ß -4.6, 95% CI -7.8- -1.3). Similarly patients score lower on multiple QoL 
subdomains, i.e. role limitations due to physical health problems (40.8 vs. 44.0, p<0.01), general 
health (39.7 vs. 47.3, p<0.01). Angiodysplasia patients are more fatigued compared to the general 
population (male 56.1 vs. 48.5, p<0.01, female 59.2 vs. 51.5, p=0.01). 
Conclusion
Angiodysplasias are independently associated with clinically significant impairments in multiple 
domains of health-related QoL, especially in measures of functional limitation. 
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INTRODUCTION
Angiodysplasias are defined as abnormally dilated mucosal veins that portend gastrointestinal (GI) 
bleeding. The prevalence of GI angiodysplasias in the general population is unknown, but it is seen 
in around 2% of the population subjected to colonoscopy 1. Known risk factors are higher age, aorta 
stenosis, chronic kidney disease and Von Willebrand disease 2. The spectrum of the angiodysplasia 
disease phenotype is wide and ranges from absence of symptoms to chronic anemia with frequent 
red blood cell transfusions and hospitalizations. Anemia is associated with adverse outcomes 
including functional decline, disability, morbidity and mortality 3. 
Conventionally, angiodysplasia related bleeding and associated morbidity are used to define 
clinical outcomes: i.e. hemoglobin levels, rebleeds, need for endoscopic intervention 4, 5. Intuitively, 
improvement of anemia as a response to endoscopic intervention might confer benefits for 
patients but measuring hemoglobin levels does not necessarily capture how patients actually feel 
and can be seen as a surrogate outcome. Patient reported outcomes (PRO’s) are multidimensional, 
unique indicators of the impact of disease on an individual patient 6. Health related quality of life 
(QoL) is a PRO which represents the patient’s general perception of the effect of illness on various 
physical and social aspects of life. It is increasingly recognized that restoration of decreased QoL 
is an important treatment goal and bonafide outcome in clinical research 7. There is a paucity of 
literature on QoL in angiodysplasia patients, but it is known that chronic anemia decreases QoL and 
that severe fatigue specifically impacts QoL in anemic patients 8. 
Based on the prevalence of anemia and the tendency of angiodysplasia bleeding to recur, we 
hypothesize that angiodysplasia patients will have a reduced health-related QoL and higher levels of 
fatigue compared to the general population. Furthermore, we surmise that there is a relation between 
angiodysplasia disease severity and QoL. The primary objective of this study is to investigate health 
related QoL and fatigue in angiodysplasia patients in a cross-sectional patient-reported outcome 
study. Our secondary objective is to evaluate possible differences in QoL between angiodysplasia 
patients who received treatment and those who did not. 
METHODS
Study design and setting 
We performed a cross-sectional patient-reported outcome study at the department of 
Gastroenterology and Hepatology of the Radboud University Medical Center Nijmegen, 
the Netherlands. Patients with endoscopy confirmed angiodysplasias were recruited into 
a longitudinal observational cohort between January 2010 and March 2015, with a follow-up until 
July 2016. We administered validated QoL and fatigue questionnaires in August and September 2016. 
Participants 
Inclusion criterion were age ≥ 18 years and one or more proven angiodysplasias, defined 
by the attending endoscopist reporting the term ‘angiodysplasia‘, ‘angioectasia‘, ‘ectasia‘, 
‘telangiectasia‘ or ‘arteriovenous malformation‘ in reports of esophagogastroduodenoscopy, 
colonoscopy, balloon assisted enteroscopy or video capsule endoscopy. Three subgroups of 
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patients were distinguished to reflect disease severity: 1) treatment in the year prior to 
the questionnaires, 2) without treatment in the year prior to the questionnaires, 3) without hospital 
visits in the year prior to the questionnaires. The group with angiodysplasia patients without 
treatment was further classified according to presence of anemia (defined as Hb <8.5 mmol/L 
for men and <7.5 mmol/L for women). Subjects were required to read and understand Dutch 
language to complete the two patient self-assessment questionnaires. Exclusion criteria were 
cognitive impairment (e.g. severe dementia) or physical inability to complete the questionnaires. 
The questionnaires were sent via e-mail or regular mail, depending on patient’s preference. There 
were at least two attempts to contact eligible patients and one reminder in case of no response. 
Outcomes
Based on the hypothesis that QoL in angiodysplasia patients will be determined by physical rather 
than mental limitations, the primary outcome is the physical summary score (PCS) of the SF-36. 
Secondary outcomes are subdomain scores of the SF-36 and fatigue assessed by the MFI-20. 
The eight subdomains are: physical functioning (PF), role limitations due to physical health problems 
(RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due 
to emotional problems (RE), and mental health (MH).
Measurements
Baseline measurements including patient and disease characteristics were extracted from 
the electronic patient report system. Two patient self-assessment questionnaires, the SF-36 and 
MFI-20, were used to measure the health related QoL and level of fatigue respectively 9, 10. Two 
overall scores can be generated from the eight subdomains of the SF-36: the PCS and mental 
summary score (MCS). A higher score on the 0-100 scale corresponds to a better QoL. The SF-36 
questionnaire has been extensively validated in several populations 11-13. 
The MFI-20 has shown to have a good reproducibility and internal consistency among different 
patient populations 10, 14, 15. Construct validity was demonstrated to be sufficient, by comparing 
MFI-20 to several other questionnaires such as the SF-36 and the Fatigue Assessment Scale 15, 16. 
The MFI-20 consists of 20 items each having a 5-point Likert scale. A higher score reflects a higher 
level of fatigue. 
Sample size calculation
Based on previous literature the mean age in our study was ought to be >65 years 17. Therefore, 
the mean PCS for the general population with age 65-74 years (PCS = 43) was used 18. As there is no 
previous literature on QoL in angiodysplasia patients, the effect size was based on studies in patients 
with chronic kidney disease and anemia 8, 19. With a power of 0.95, a level of significance of 0.05 and 
a mean score on the PCS of 38 (compared to 43) with a SD of 10, the sample size was ought to be 
88 patients.
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Statistical analysis
Descriptive statistics were used to describe patient and disease characteristics. Categorical 
variables are expressed as percentages and continuous variables are expressed as mean ± standard 
deviation (SD) or as median with range for non-normal distributed variables. Differences in baseline 
characteristics were investigated with Chi-square testing.
To deal with missing data in the SF-36, we used personal mean score imputation of subdomain 
means, justified for subdomains missing < 50% 20. Missing questions in the MFI-20 where imputed 
with the contrary formulated question. When there were >50% missing for the SF-36 or missing 
the contrary question for the MFI-20, the patient was excluded from analysis.
We used United States of America (USA) population norm values for the SF-36 and German 
population norm values for the MFI-20 both corrected for age (age group determined based on 
mean age of our included patients) 21. Previous studies justify the use of USA norm values for the Dutch 
population on the SF-36 22. One-sample t-tests were used to compare these general population 
norm values with the study population to assess our primary aim. One-way independent ANOVA 
with post-hoc Tukey testing was used to compare the PCS, subdomain scores and level of fatigue 
between the three subgroups of patients: 1) treatment, 2) non-treatment, and 3) patients without 
hospital visits in the past year. This statistical method was also used to investigate the differences on 
PCS between treated patients and anemic / non-anemic patients in the non-treated group.
 Finally, we performed multivariate linear regression analysis to correct for baseline differences 
(i.e. comorbidities) between the subgroups for the primary outcome. QoL is strongly correlated 
with age and a small (not statistical significant) difference between groups could be of influence. 
Therefore, we included age in the adjusted analysis for the primary outcome. A two-sided tested 
p-value ≤0.05 was considered statistically significant. The analyses were performed using SPSS 
Statistics software version 22.0 (IBM, Armonk, NY, USA).
Interpretation of the results
PRO’s were interpreted by two important tools: the minimal clinically important difference (MCID) 
and Cohen’s standardized effect size. The MCID is defined as the smallest difference in a score which 
patients perceive as beneficial and which would mandate a change in patient management. For 
the SF-36 the MCID ranges between 3-5 points 23, 24. Standardized effect size measures are helpful 
when the metrics of variables that are studied have no intrinsic meaning. The Cohen’s standardized 
effect size is defined as the mean difference divided by the SD. Effect sizes of 0.2 - 0.5 are considered 
as ‘small’, 0.5 - 0.8 as ‘moderate’, and > 0.8 ‘large’ 25. 
Ethical considerations
Oral informed consent was obtained. The medical ethical committee CMO Arnhem - Nijmegen 
concluded that this research is exempt from Dutch national legislation for medical scientific 
research involving humans in view of the minimal burden of two questionnaires. 
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RESULTS
Participants
We identified 301 patients with proven angiodysplasias of which 69 were excluded based on: 
deceased at the time of survey (n=63), severe dementia (n=4), severe psychiatric disorder (n=1) and 
physical inability due to severe Parkinson disease (n=1). We failed to establish contact with 39 eligible 
and 18 patients did not want to participate. In total 175 patients gave informed consent and 155 
patients returned the questionnaires (S1 Fig). Eleven SF-36 questionnaires had to be excluded due 
to >50% missing, and one more could not be included for MFI-20 analysis. Therefore, 144 (response 
rate 62%) patients are analyzed for the SF-36 and 143 (61%) for the MFI-20. 
Disease severity subgroups consisted of patients treated (n=27), not treated (n=58), and patients 
without recent hospital visits (n=45). Fourteen patients could not be included in the subgroup 
analysis due to follow-up in another hospital. Additional subdividing led to 39 non-treated patients 
without anemia and 19 (41% of the patients with anemia) non-treated patients with anemia. 
Baseline characteristics
The majority of responders are men (65%) and the mean age was 68 years. Gender, valvular 
heart disease, anticoagulant use and multiple angiodysplasia lesions were not equally distributed 
between subgroups (Table 1). These differences reflect that these variables constitute risk factors 
for symptomatic angiodysplasia disease 1, 17. There were no significant differences between 
the subgroups in ischemic heart disease, diabetes mellitus, chronic obstructive pulmonary disease, 
liver cirrhosis, congestive heart failure, or cerebral vascular accident. Angiodysplasias were most 
frequently located in the colon (n=90, 69%) with a mean number of 2.4 (SD 3.2) angiodysplasias 
per patient.
Table 1. Descriptive data of all responders and comparison of asymptomatic versus symptomatic responders.
Baseline characteristics 
No hospital vistis  
(n=45)
Non-treatment
(n=58)
Treatment
(n=27) P-value
Age - mean (±SD) 66yr (±10) 67yr (±11) 71yr (±9) 0.14
Gender: male - n (%) 33 (73) 38 (66) 12 (44) 0.04
Comorbidity - n (%)
 Valvular heart disease
 Chronic kidney disease
5 (11)
3 (7)
4 (7)
7 (12)
7 (26)
5 (19)
0.04
0.31
Anticoagulant use - n (%) 13 (29) 18 (31) 19 (70) <0.01
Nr. of angiodysplasias
 mean (±SD) 
Angiodysplasia location
1.5 (0.9) 1.9 (1.2) 5.3 (6.1) <0.01
 Colon 36 (80) 35 (60) 19 (70) 0.10
 Small bowel
 Stomach  
5 (11)
3 (7)
12 (21)
8 (14)
8 (30)
3 (11)
0.14
0.51
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Primary outcome
Our cohort of angiodysplasia patients (n=144) have a significant lower PCS score relative to 
the general population (respectively mean 41.0 vs. 43.3, p=0.01). However, this difference does not 
reach MCID and has a small effect size (effect size: 2.3/10.8 = 0.21). Focusing on the three subgroups 
(Fig 1), we see this is based on a significant lower PCS in the non-treatment and treatment group 
compared to the general population (respectively 39.9 vs. 43.3, p=0.01 and 34.4 vs. 43.3, p<0.01) 
as the patients without hospital visits have a non statistical significant higher PCS score than 
the general population (46.1 vs. 43.3, p=0.06). The differences between the non-treated and treated 
patients and the general population for PCS (resp. 3.4 and 8.9 points) exceeds the MCID threshold 
with a respectively small (3.4/10 = 0.34) and large effect size (8.9/10.3 = 0.86), which suggest that it 
bears clinical relevance.
When we adjust the primary analysis of PCS for differences in baseline characteristics, 
the variables age, gender, valvular heart disease, anticoagulant use and number of angiodysplasias 
are included in the multivariate linear regression model. The association of disease severity covered 
in the subgroups treated, not treated and no recent hospital visits, is despite correction of these 
factors independently negatively associated with PCS (ß -4.6, 95% CI -7.8- -1.3, p=0.006). However, 
the negative impact of angiodysplasia disease becomes smaller than in univariate linear regression 
due to the influence of the comorbidities (ß -5.9, 95% CI -8.2- -3.5). The interpretation of the beta 
coefficient is that the treated group in general scores -4.6 points lower on PCS as the non-treated 
group, which scores -4.6 points worse than the no-hospital visits group.
Comparing the three subgroups with each other, the no-hospital visits patients have a significant 
higher PCS score compared to the non-treatment and treatment groups (respectively 46.1 vs. 39.9 
and 34.4, p=0.01 and p<0.01). However, the PCS of the non-treatment group is not statistically 
significant higher than the treated patients (39.9 vs. 34.4, p=0.051). 
Secondary outcomes
Subdomain analysis for QoL
The study population of all angiodysplasia patients (n=144) have compared to the general population 
a significant lower score on the following QoL subdomains: MCS (48.2 vs. 52.7, p<0.01), RP (40.8 vs. 
44.0, p<0.01), GH (39.7 vs. 47.3, p<0.01), SF (43.7 vs. 47.6, p<0.01), RE (44.2 vs. 48.1, p<0.01) and MH 
(47.6 vs. 51.8, p<0.01). No significant differences were found in PF, BP and VT. 
Comparing the subgroups separately with the general population, we again see the differences 
for the overall angiodysplasia group are mainly based on the non-treatment and treatment 
subgroups, with the non-hospital visit group continuously scoring higher on the 8 subdomains (Fig 
2). The non-treatment group have a significantly lower score compared to the general population 
on GH (47.2 vs. 38.3, p<0.01), SF (47.6 vs. 42.7, p<0.01), RE (48.0 vs. 43.2, p<0.01), MH (51.8 vs. 48.2, 
p=0.02). As last, the treatment group have a significantly lower score compared to the general 
population on PF (41.7 vs. 33.6, p<0.01), RP (41.7 vs. 36.3, p=0.02), GH (47.2 vs. 34.8, p<0.01), VT (49.9 
vs. 43.7, p<0.01), SF (47.6 vs. 41.5, p=0.01), RE (48.0 vs. 42.5, p=0.02), MH (51.8 vs. 46.9, p<0.01). 
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Comparing the three subgroups there are larger differences in scores assessing physical 
subdomains such as PF, RP and GH (Fig 2), with the treated group scoring worse. 
Level of fatigue
Angiodysplasia patients have significant higher levels of fatigue compared to the general population 
(respectively male 56.1 vs. 48.5, p<0.01, female 59.2 vs. 51.5, p=0.01). This difference has a small 
effect size (Fig 3: men=0.43 and women=0.39). The treatment subgroup is the only subgroup with 
a significant higher level of fatigue compared to the general population for males (resp. 63.1 vs. 48.5, 
p<0.01) and females (resp. 66.1 vs. 51.5, p=0.01). This difference has a large effect size (men=1.16 and 
women=0.76).
Additional non-treatment subgroup analysis QoL 
To investigate the effect of anemia in the non-treated group on the QoL, the non-treated group 
was dichotomized according to presence of anemia (Fig 4). The patients without anemia have 
a significantly higher PCS score compared to the non-treated patients with anemia and the treated 
patients (resp. 43.1 vs. 33.2 and 34.4, p<0.01 and p<0.01). 
Figure 1. Comparison of SF-36 Physical component scale (PCS) for subgroups. 
Boxes with whiskers display median and interquartile percentiles of subgroups, + sign indicates mean. Dotted 
line represents mean general population. Asterisks point out significant differences (p<0.05).
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Figure 2. Display of all SF-36 domain scores for the different subgroups. 
Physical functioning (PF), Role limitations caused by Physical health problems (RP), Bodily pain (BP), General 
health (GH), Vitality (VT), Social functioning (SF), Role limitations caused by Emotional health problems (RE) 
and Mental health (MH). Statistical significant (p<0.05) differences compared to general population are shown 
for each subgroup with the following symbols. No hospital visits: ^, non-treatment: *, treatment: +.  
Figure 3. Comparison of MFI-20 scores for males (left) and females (right). 
Boxes with whiskers display median and interquartile percentiles of subgroups, + sign indicates mean. Dotted 
line represents mean general population. Asterisks point out significant differences (p<0.05).
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DISCUSSION
The results of this cross-sectional study show that the presence of GI angiodysplasias is associated 
with a decreased QoL compared to the general population. Angiodysplasia patients have a lower self-
rated QoL and higher fatigue levels, and particularly the physical component of QoL is significantly 
reduced. Moreover, we found a progressive decrease in QoL that corresponds with disease severity. 
Finally, the QoL between treated patients and those not treated with anemia is similar. This supports 
the relevance of a structured approach and suggest that iron supplementation in patients with 
angiodysplasias and mild anemia is warranted. Treatment of mild anemia in angiodysplasia disease 
is often withheld (41%). 
To investigate whether a decreased QoL in our study population depends on co-existing co-
morbidity, we performed a multivariate regression analysis that corrected for differences in co-
morbidities at baseline. It was clear that angiodysplasia disease severity is an independent variable 
that impacts health-related QoL. 
The decrease in PCS associated with angiodysplasias is comparable to that seen in other 
populations such as the elderly with anemia, 8 congestive heart failure or patients with anemia due 
to chronic kidney disease 26. This indicates that anemia in symptomatic angiodysplasias impacts QoL 
to a similar level as other chronic diseases. The MCID data in relation to the effect sizes suggests that 
our findings bear clinical relevance. 
Figure 4. Comparison of SF-36 Physical component scale (PCS) for disease severity subgroups.  
Boxes with whiskers display median and interquartile percentiles of subgroups, + sign indicates mean. 
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The present study has several limitations. First, this is a single center study with retrospective data 
collection of the clinical data, e.g. medical history and treatment. This could introduce reporting bias 
for the variables that have been retrospectively assessed (i.e. not our primary endpoint). Second, 
SF-36 and MFI-20 are tools to measure health-related QoL and level of fatigue respectively. Addition 
of the Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire, specific for 
anemia would have been desirable. However, this tool is not available in a validated Dutch version. 
Third, the definitions used to classify the disease severity subgroups (i.e. treatment in the last year) 
are based on consensus meeting in view of the absence of published criteria. Fourth, categorizing 
of our cohort in subgroups resulted in a small number of patients compromising the study power. 
Last, similar to all questionnaire studies response bias could be present. We have a response rate 
of 62% which is relatively high 27-29. Age, gender and past medical history were compared between 
responders and non-responders to investigate differences that could have affected the results. 
Responders were more often men than non-responders (respectively 64% vs. 49%, p=0.02). Men 
tend to score better on QoL questionnaires and therefore we assume this could have led to a small 
overestimation of the QoL.
The strength of this study is that it measured QoL in angiodysplasia patients in a relatively large 
cohort with the possibility to compare different disease severities. Moreover, our study population 
was a heterogeneous angiodysplasia population. The risk of selection bias was low due to a relatively 
high response rate and absence of clinical relevant differences between responders and non-
responders. Therefore, we think this study has a high external validity. With a multivariate model we 
were able to correct for baseline differences in patient characteristics between the disease severity 
subgroups, which increases the internal validity of this study.  
The results of this study highlight the need for additional clinical trials. For instance, a study 
which evaluates different step-up treatment strategies in patients with angiodysplasias, anemia and 
a reduced QoL. For such studies to have a true impact on practicing physicians, they should reflect 
patient management in clinical practice. This would require a comparative trial with a sufficient 
number of patients using practical inclusion criteria, clear crossing-over criteria, a treatment failure 
scenario, and end-points that are clinically relevant in terms of PRO’s. QoL measurements should be 
an integral part of the study.
In conclusion, this study shows GI angiodysplasias are independently associated with clinically 
significant impairments in multiple domains of health-related QoL, especially in measures of 
functional limitation. Moreover, angiodysplasia patients experience a higher level of fatigue 
compared to the general population. We encourage future research investigating treatment 
strategies in angiodysplasias to take the patient’s perspective into account with the inclusion of 
PRO’s such as the SF-36.
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SUPPLEMENTARY FILES
File 1 - Figure. Flowchart patient inclusion. 
Small-dot lined squares represent ‘non-responders’. The ‘complete returned questionnaires’ are the ‘responders’.
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Small‐dot lined squares represent ‘non‐responders’. The ‘complete return d questionnai s’ 
are the ‘responders’. 
Excluded patients 
 Unable to contact (n = 39) 
 Not  interested (n = 14) 
 On holiday (n = 3) 
 Currently in hospital for prostate 
cancer (n = 1) 
Screened patients with proven AD (n = 301) 
Eligible patients (n = 233) 
E‐mail (n = 91) 
Paper post (n = 85) 
Not eligible patients 
Not living (n = 63) 
Severe dementia (n = 4) 
Physical inability (n = 1) 
Complete returned 
questionnaires (n = 144) 
Incomplete returned 
questionnaires (n = 11)
Not returned questionnaires (n = 21)
 Decided to withdraw (n = 10) 
 Deceased (n = 1) 
 Unknown reason (n = 10) 
Subgroup analyses 
Asymptomatic (n = 58)  
Symptomatic (n = 27)  
No follow‐up (n = 59) 
Included patients (n = 176)
Additional asymptomatic subdividing
 Asymptomatic without anemia (n=39) 
 Asymptomatic with anemia (n=19) 
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ABSTRACT
Objective
Angiodysplasias (ADs) are the second leading cause of gastrointestinal bleeding in elderly. 
The impact extends from no symptoms to chronic anaemia. Treatment guidelines are lacking. 
The aim of this study is to assess the current practice of gastrointestinal ADs and explore possible 
new research areas. Based on existing evidence we would like to propose a treatment algorithm. 
Methods
We administered a 19-item web-based survey to gastroenterologists in the Netherlands between 
February and April of 2015. 
Results
A total of 111 (response rate 28%) gastroenterologists completed the survey (mean age = 47 years; 
24% women). Respondents identified Von Willebrand disease (17%), chronic kidney disease (21%) 
and aortic stenosis (86%) as risk factors for the development of ADs. Colonoscopy (54%) and 
esophagogastroduodenoscopy (43%) were the preferred first tools to screen for ADs. The favoured 
(77%) first treatment option is endoscopic argon plasma coagulation, while 20% start iron 
supplementation or blood transfusions. Treatment strategy is mostly (65%) based on the location 
of the ADs. Small bowel ADs are considered the most difficult to treat, because of the need of 
balloon enteroscopy. Of the gastroenterologists, 13% would treat ADs as a coincident finding 
during endoscopy. Medical therapy is mostly started in refractory ADs, and thalidomide (40%) is 
preferred over octreotide (19%). Thalidomide is more preferred by gastroenterologists working 
in a teaching hospital.  
Conclusions
Identification of risk factors and treatment of ADs varies widely between gastroenterologists 
in the Netherlands. More research is needed to create an evidence based guideline and thereby 
optimize the management of symptomatic ADs.
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INTRODUCTION
Angiodysplasias (ADs) are the most common cause of obscure gastrointestinal bleeding in elderly.1 
The clinical impact of ADs may extend from no symptoms to (acute on) chronic anaemia, resulting 
in blood transfusion dependency with frequent hospitalizations, and a high risk of cardiovascular 
morbidity. Patients with symptomatic AD have a decreased quality of life compared to the general 
population.2 Frequent hospitalizations and endoscopic investigations lead to a significant financial 
burden of healthcare.3  
Endoscopic treatment is effective and results  in a clinical success rate up to 90%.4 If  endoscopic 
treatment fails, there are a number of other options that may  be considered: 1. endoscopic re-
intervention, 2. symptomatic treatment with iron supplementation and/or blood transfusions, 3. 
Thalidomide5, 4. Octreotide6, and 5. surgery.
At present, there are no guidelines that address treatment of ADs. There is one review article 
that contains recommendations for the different treatment strategies of AD. This narrative review 
suggests a flowchart that directs treatment based on clinical presentation.4 The flow chart is not 
evidence based and lacks a clear step-up approach. In view of absence of evidence and clear 
guidelines, we hypothesize that there is a high variation in treatment strategies for gastrointestinal 
ADs among gastroenterologists. Knowledge about current practice is necessary to identify 
discrepancies in the diagnosis and treatment of ADs and ultimately be useful in creating a more 
uniform guideline for the diagnosis and treatment of symptomatic ADs. 
The aim of this study is to investigate current practice concerning diagnosis and treatment of 
gastrointestinal ADs among Dutch gastroenterologists by means of a nationwide survey, to explore 
possible new research areas in bleeding AD. Based on existing evidence we would like to propose 
a treatment algorithm.
METHODS
Study setting and design
Sampling Frame
A survey was sent by e-mail to every gastroenterologist affiliated with the Dutch Association of 
Gastroenterologists in the Netherlands. The survey was submitted to the gastroenterologists, 
regardless of their experience with (endoscopic) treatment of ADs. In total, 395 consultant 
gastroenterologists were asked to participate in this anonymous survey.
Survey distribution and follow-up procedures
The survey was administered between February and April 2015. Respondents received the survey 
electronically using an online questionnaire platform (Sawtooth Software, North Orem, UT). 
Physicians received emails with cover letters that contained the survey. Non-responders were 
reminded after two weeks through a follow-up email. Three weeks after the second email 
correspondence a final reminder to initial non-responders was sent. 
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Questionnaire
We designed the survey to obtain an overview on knowledge and beliefs on AD. The survey included 
19 questions, grouped into five categories: 1 demographic and professional characteristics of 
the gastroenterologist; 2 risk factors for the development of ADs; 3 diagnostic tools; 4 endoscopic 
treatment; and 5 medical treatment. All questions were multiple choice.  
We operationalized provider knowledge level through questions on established risk factors 
for AD: chronic kidney disease , aortic valve stenosis and Von Willebrand disease (VWD). We then 
measured variation in process of care in diagnostic decision-making and the level of agreement 
between respondents by asking them to choose among a number of radiological and endoscopic 
options used for diagnosing ADs. Next, we assessed the preferred therapeutic strategy of care 
providers and offered choices between surgical resection, radiological interventional procedures 
or endoscopic therapies. We asked respondents which endoscopic therapy they prefer in relation 
to location of AD. Lastly we questioned respondents under which circumstances they would start 
pharmacological therapy (thalidomide or octreotide). 
Statistical analysis
All quantitative results will be summarized for continuous variables, depending on distribution, 
values will be presented as mean ± standard deviation (SD) or as median ± interquartile range, 
and qualitative results were expressed as counts and percentages. To calculate differences among 
gastroenterologist in their preferences, we used the chi-square test for normally distributed data 
or the Fisher exact test in non-normally distributed data. A P value <.05 was considered statistically 
significant. All analyses were performed with SPSS Statistics software version 22.0 (IBM, Armonk, 
NY, USA).
RESULTS
Sample Characteristics
A total of 111/395 (28%) gastroenterologists completed the survey.
Characteristics of responders
Seventy-six percent of the responders were men, aged 47±9 years. Twenty-four (21%) 
gastroenterologists worked in an academic hospital, 54 (49%) in a teaching hospital and 33 (30%) in 
a non-teaching hospital. Mean experience as a consultant was 13±10 years. The subspecialisation of 
the gastroenterologists were advanced endoscopy (n=27, 24%), inflammatory bowel disease (n=23, 
21%), oncology (n=17, 15%) and none (n=25, 23%). 
Risk factors for AD
Bonafide risk factors for AD such as chronic kidney disease, VWD and aortic stenosis were identified 
correctly by respondents in respectively 21%, 17%, and 77% of the cases. Additional, but not 
established, risk factors for AD such as: hypertension (6%), diabetes mellitus (4%) and peripheral 
artery disease (12%) were suggested by respondents.
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Measuring diagnostic strategy of AD
Table 1 shows the ranking order of the preferred diagnostic tool for a patient who presents 
with occult gastrointestinal blood loss. The following options were given in a random order; 
esophagogastroduodenoscopy (EGD), colonoscopy, video capsule endoscopy (VCE), balloon 
enteroscopy, and angiography. Gastroenterologists choose colonoscopy (54%) and EGD (43%) as 
first step to diagnose ADs. 
Measuring  treatment strategies
Endoscopy
Endoscopic intervention as initial treatment was preferred by 76% of the gastroenterologists in 
patients with symptomatic gastrointestinal ADs. This was partially (65%) dependent on location of 
the ADs. Jejunum- and ileum-localized ADs were considered the most (88%) difficult to treat by 
endoscopy. Almost all gastroenterologists (99.1%) agreed that argon plasma coagulation (APC) is 
the appropriate endoscopic technique for ADs. 
Asymptomatic ADs incidentally found during endoscopy were treated by 13% of 
the gastroenterologists. Treatment of asymptomatic ADs was not dependent on the following 
gastroenterologist characteristics (yes versus no): age (48 vs. 47 years), experience as a consultant 
(14 vs 13 years), type of hospital (university medical centre 20% vs. teaching hospital 12.7% vs. non-
teaching hospital 15.0%), subspecialisation or sex (85% vs 76% man). 
Medical treatment
Iron supplementation and blood transfusion were the preferred initial treatment for symptomatic 
ADs in treatment naive patients by 21% of gastroenterologists. 
More than half (65%) of gastroenterologists are familiar with prescribing thalidomide or 
octreotide for this indication (Table 2). The role of thalidomide was controversial as the proportion 
that did or did not prefer this drug was equal (40% vs. 41%). Gastroenterologists working in a teaching 
hospital had a significant higher preference for thalidomide compared to those from  non-teaching 
hospitals (university medical centre 60% vs. teaching-hospital 86% vs. non-teaching 50%, P = 0.02). 
This preference is mostly based on assumed effectiveness (48%) and easiness of drug use (30%). 
Gastroenterologists who preferred octreotide (19%), based their opinion on the favourable side-
Table 1. Preferred diagnostic tool in patients with occult gastrointestinal blood loss in percentages. 
Diagnostic tool
First Colonoscopy 54.1 EGD 43.2 Other 2.7
Second EGD 51.4 Colonoscopy 43.2 Other 5.4
Third VCE 86.5 Other 13.5
Fourth Balloon enteroscopy 88.3 Other 11.7
Fifth Angiography 95.5 Other 4.5
* Gastroenterologists had to rank these five diagnostic tools in the preferred order. The first row shows the percentages of 
tools chosen as first approach to diagnosing ADs.
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effect profile. Short-acting octreotide three times daily is most frequently (66%) started prior to 
definite treatment with long-acting repeatable formulation (LAR). Twenty milligrams is the most 
frequent (26%) prescribed LAR dose. Half (50%) of gastroenterologists cited that they do not know 
how they should dose octreotide LAR. 
DISCUSSION
This survey reflects the current opinion of a sample of gastroenterologists regarding diagnostic and 
treatment strategies in patients with gastrointestinal ADs. As such it confirms our hypothesis, that 
there is a high variation in treatment strategies for gastrointestinal ADs among gastroenterologists. 
The gastroenterologists lack a uniform preference for a certain medical treatment in patients with 
refractory bleeding ADs. 
Chronic kidney disease and VWD were poorly identified as risk factors for the development of 
ADs. In patients with VWD the incidence of gastrointestinal bleeding is substantial (38%).7 In reverse, 
the proportion of VWD in patients with symptomatic gastrointestinal AD is relatively low (<1%).8 
This might explain the decreased awareness of VWD as a risk factor among gastroenterologists 
as found in this study. Recognition of VWD or acquired Von Willebrand Syndrome as a possible 
underlying cause is of vital importance, because these patients benefit from medical therapies such 
as desmopressin or Von Willebrand replacement therapy in addition to endoscopic intervention.9 
There was high level of agreement among gastroenterologist on the use of diagnostic tools 
for AD. In accordance to the European10-12 and American13, 14 guidelines (see table 3), colonoscopy 
and EGD are preferred as initial diagnostic modalities in this study, with further work-up by VCE 
and balloon enteroscopy upon indication. Colonoscopy and EGD were almost equally preferred as 
initial investigation. 
Of note, thirteen percent of the gastroenterologists treat asymptomatic ADs which is not 
recommended based on a small prospective cohort with 8 asymptomatic AD patients with a 3-year 
bleeding risk of 0%. 4, 15 In our opinion more research in the field of asymptomatic ADs is necessary 
to increase evidence and make stronger recommendations.  
The present study has some limitations. First, the ideal method of measuring process of care 
is to observe physicians in actual everyday clinical practice not with questionnaires. However, this 
approach is also limited because providers artificially alter their practice when they are knowingly 
Table 2. Reasons for the preferences towards pharmacological therapy (no preference, n = 46).
Thalidomide, n = 44 (%) Octreotide, n = 21 (%)
Efficacy 22 (50) 3 (14)
Side-effects 4 (9) 13 (30)
Ease of use 13 (30) 5 (24)
Costs 9 (20) 2 (10)
Experience 4 (9) 2 (10)
Gastroenterologists were able to select multiple options. 
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observed. This undermines the efforts to capture the true process of care. Second, there is 
a relatively low response rate (28%) which can potentially lead to non-response bias with a decrease 
of validity. To investigate any systematic differences between responders and non-responders we 
compared respectively sex (76% vs. 71% men), experience (13 vs. 13 years as a consultant) and type 
of hospital (academic 21 vs. 22%, teaching hospital 48 vs. 39%, P = 0.22) between responders and all 
members of the Dutch Association of Gastroenterologists. The distribution of these characteristics 
are comparable between the two groups, which decreases the chance of a large non-response 
bias in this study Although we do not know the specific reasons for non-response to this survey, 
the nonresponse rate in our study is comparable to other surveys.16 Third, the survey lacked patient 
characteristics, which can lead to inconsistency among gastroenterologists. 
The findings in this study highlight the unmet need for evidence based guidelines for 
the management of ADs. Based on the current European10-12 and American guidelines 13, 14 (table 3) 
and a systematic review17, it is tempting to propose a step-up approach for the management of ADs 
to facilitate further research (figure 1). In this, repeated endoscopic treatment should be performed 
as a first step in accessible lesions in case of recurrent symptomatic AD bleeding.17 The second step 
in patients who have anaemia despite repeated endoscopy or with inaccessible lesions consists 
of oral iron supplementation.10, 13 In patients who are intolerant for oral iron supplementation or 
when this is insufficient, the next step is parenteral iron supplementation or blood transfusion. 
In severe transfusion dependent patients, pharmacological therapy can be considered before 
surgery.14 Thalidomide is proven to be effective and cheap 5, and therefore this therapy is favoured 
over octreotide, where effectiveness is not established with a randomized controlled trial. 
However, the risk on severe side-effects and teratogenic effects should be taken into account when 
thalidomide is prescribed and strict follow-up with frequent checks for polyneuropathy during 
the course of thalidomide is recommended.18 To increase the generalizability of this proposal, 
prospective trials should include this step up approach. 
In conclusion, there is a high variation in treatment strategies among gastroenterologists in 
the Netherlands for patients with gastrointestinal ADs. These results emphasize the need for further 
studies to determine optimal therapy in patients with AD. 
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Table 3. Guidelines addressing the diagnostic work-up for occult gastrointestinal blood loss.
Guidelines Year Impact Factor Journal Grilli Score1 Topic Recommendations
American Academy of  
Family Physicians13 
2013 2.2 3 Diagnosis and management IDA •	 Colonoscopy and EGD in men and postmenopausal women
•	 SB evaluation only indicated when oral iron therapy is insufficient
•	 Enteroscopy only after identification of lesions with VCE
British Society  
of Gastroenterology10
2011 14.7 2 Management ID0A •	 Colonoscopy and EGD in men and postmenopausal women, exception (no colonoscopy):
 » Gastric cancer
 » Celiac disease: < 50 years, mild anaemia and no family history CRC
•	 SB evaluation only indicated when oral iron therapy is insufficient
American College  
of Gastroenterology14
2015 10.8 3 Diagnosis and management of SB 
bleeding
•	 Second-look EGD is indicated in overt GI bleeding
•	 VCE is indicated after negative EGD and colonoscopy for occult GI bleeding 
•	 CT enterography is indicated after negative VCE in patients with suspected SB bleeding
•	 Push enteroscopy is indicated when proximal lesions are suspected (lower detection rate of VCE)
European Society of 
Gastrointestinal Endoscopy14
2015 5.1 4 SB enteroscopy and VCE for diagnosis 
and treatment
•	 VCE is indicated after negative EGD and colonoscopy for occult GI bleeding 
•	 Enteroscopy only after identification of lesions with VCE
British Society of 
Gastroenterology12
2008 14.7 4 SB enteroscopy and VCE in adults •	 VCE is indicated after negative EGD and colonoscopy for occult GI bleeding
•	 Enteroscopy only after identification of lesions with VCE
*IDA, iron deficiency anaemia; SB, small bowel; CRC, colorectal carcinoma1 Grilli score: quality assessment tool for guidelines addressing 3 topics: description of the involved professionals, description of the sources of information, and explicit grading of evidence. Score range: 0-4. 
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Figure 1. Flowchart of proposed step-up approach for the treatment of occult bleeding due to AD. AVR, aortic 
valve replacement *Consider contraindications and side-effects of thalidomide. Dose 100 mg per day for four 
months with follow-up to assess side-effects. ** Dose 10-20 mg per month IM.  
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ABSTRACT 
Background
The hypothesis is that decision-making for transfusion among gastroenterologists varies 
considerably. The aim is to identify preferences and predictors of transfusion decision-making in 
chronic anemia.
Study design and Methods
Between February and April of 2015, a computerized adaptive choice-based conjoint survey was 
administered to gastroenterologists in the Netherlands. The survey included 7 patient attributes; 
hemoglobin levels, hemoglobin stability, age, iron indices, the presence of anemia related 
symptoms, cardiovascular comorbidities and the number of transfusions in the past half year. 
Predictors of transfusion preferences were assessed by multivariate regression. 
Results
113 gastroenterologists completed the survey (response rate = 29%; mean age = 47 years; 
24% women). Absolute hemoglobin level was the most important incentive of transfusion, 
accounting for 42% of decision-making, followed by age (15%), hemoglobin stability (12%), 
anemia related symptoms (10% and cardiovascular comorbidities (10%). A hemoglobin level > 
9.6 g/dL is an inflection point, where gastroenterologists would not prescribe transfusions. Age 
of the patient is more important in the decision-making process to younger gastroenterologists 
(OR -2.9, 95% CI -5.3 - -0.5).
Conclusion
Absolute hemoglobin level is the most important factor to transfusion decision-making. 
This is contradictory to transfusion guidelines for chronic anemia which address the importance 
of symptoms. 
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INTRODUCTION
Iron deficiency anemia is a common problem in gastroenterology practices and is associated 
with lethargy, weakness, dyspnoea and a decreased quality of life. 1,2 Therefore, treatment of iron 
deficiency anemia is important to improve the related symptoms. Apart from treating the underlying 
cause, iron supplementation and/or blood transfusions can be given to restore hemoglobin (Hb) 
level. However, both undertreatment and overtreatment of anemia are associated with impaired 
clinical outcomes.3 Therefore, a targeted transfusion regimen with clear defined rules in each 
patient is the best route to an increased quality of life and clinical outcome.4
Red blood cell (RBC) transfusion strategies have become more restricted over the past decade.5 
American, European and Australian transfusion guidelines for patients with chronic anemia advise 
transfusion in case of clinical symptoms and below defined Hb level thresholds.6,7,8 There is no 
literature published on transfusion practices in gastroenterology, but it is known that there is a wide 
variation in transfusion practices in perioperative care and critical care patients.9 
It is unknown which clinical factors determine the decision-making process, when and who 
to transfuse or whether there are differences between gastroenterologists. This decision-making 
process is complex and although there are guidelines, the interpretation of these guidelines in 
clinical practice might differ between healthcare professionals. As a corollary we hypothesize 
that transfusion preferences vary, but that certain gastroenterologists characteristics predict 
behaviors such as gender, years of experience, type of hospital or subspecialisation. More 
insight in the understanding of and reasons for variation in transfusion practices could lead to 
targeted strategies to increase awareness among gastroenterologists to adequately prescribe 
RBC transfusions. 
The aim of this study is to identify factors that trigger the use of transfusions in chronic anemia 
due to gastrointestinal bleeding and characterize the heterogeneity among gastroenterologists 
regarding transfusion decision-making through a nationwide survey using the adaptive choice-
based conjoint (ACBC) analysis technique.  
STUDY DESIGN AND METHODS
Study setting 
We administered a survey to every gastroenterologist affiliated with the Dutch Association of 
Gastroenterologists. Over 98% of active gastroenterologists in the Netherlands are member of 
the Dutch Association of Gastroenterologists. In total, 395 gastroenterologists were invited to 
participate in this anonymous survey. The survey was sent to invitees by e-mail between February 
and April 2015, with a reminder up to two times to initial non-responders. 
Overview of ACBC analysis
Conjoint analysis is a quantitative method originally developed in applied sciences which can be 
used to evaluate clinical decision-making in healthcare.10-17 Full control of potentially confounding 
factors can be achieved by having each participant evaluate the same clinical factors with according 
levels. As such, conjoint analysis is considered as a good method to effectively analyze decision-
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making in clinical medicine.18 Compared with other methods to investigate decision making, such as 
self-report or absolute ranking of factors, ACBC is more effective in approximating the real world.19,20 
Because the decision to transfuse depends on complex combinations of clinical factors that may be 
interdependent and are weighed by the individual gastroenterologists, ACBC is a good method to 
investigate this decision-making process. 
The administered survey consists of two parts: the ACBC analysis and a set of stand-alone 
questions regarding provider demographics and practice characteristics. The 7 evaluated clinical 
factors in the ACBC analysis are: Hb level, Hb stability, age, iron indices, the presence of anemia 
related symptoms, cardiovascular comorbidities and the number of transfusions in the past half year. 
Triggers of transfusion were studied in a scenario of chronic anemia due to gastrointestinal bleeding 
from angiodysplasias. This scenario was not changed as we do not want to study the underlying 
disease as a clinical factor, because this is not a trigger according to the guidelines.6,7,8,21,22
The case vignettes were designed on the basis of a fractional factorial design that ensures 
the absence of colinearity. For each case vignette, the gastroenterologist was asked to indicate 
whether he or she would give a blood transfusion (yes or no) according to the 7 predefined clinical 
patient characteristics that are relevant for the decision (table 1). Respondents must choose 
a preferred level for each clinical characteristic to a degree that allows identification of a threshold 
that triggers activity (e.g., Hb level, fatigue, comorbidities, etc.). Then sets of two hypothetical 
patient profiles were presented and gastroenterologists were asked to select the patient that he/
she would transfuse (figure 1). Based on the choices made, the comparisons become increasingly 
complex as the exercise continues. The ACBC method ranks the respondent’s prioritization of 
clinical factors that influence the decision to transfuse. 
Survey Design
To ensure that the survey adequately queried clinical factors related to RBC transfusion decision-
making, we used the British, Dutch and American transfusion guidelines that were current at the time 
of the survey.6,7,21 Moreover, we piloted the validity of clinical characteristics in a small (n=8) group of 
gastroenterologists. The pilot group also advised to include number of transfusions in the past half 
year as a variable. This process further refined the case vignettes and the levels of clinical factors. 
Sample size and Statistical analysis 
The specific sample size for conjoint analysis (n) should satisfy the equation (nta)/c = ≥500, where t is 
the number of tasks, a is the number of alternatives per task, and c is the maximum number of levels 
for a given attribute.10 In this survey, providers completed t=6 tasks with an average a=3 alternatives 
and c≤4 levels, based on these parameters a sample size of 110 can be considered sufficient.  
The main outcome are utilities. The utilities indicate how much the difference between 
the levels of one attribute affects the decision to transfuse. Across the levels of one attribute 
the utilities add up to 0, which leads to a middle weight around 0. Negative utilities for a certain 
level do not trigger gastroenterologists to prescribe a transfusion compared to positive utilities, 
where gastroenterologists do want to prescribe a transfusion. Hierarchical Bayes analysis is used 
to calculate individual importances for each of the 7 clinical factors. The relative importance shows 
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Table 1. Clinical factors and levels tested in conjoint analysis clinical vignettes
Clinical Factor Levels
Haemoglobin level (g/dL) 9.6-11.3
8.0-9.5
6.4-7.9
<6.4
Haemoglobin stability No change in haemoglobin level over the past month
1.6 g/dL drop over the past month
0.8 g/dL drop over the past week
1.6 g/dL drop over the past week
Age (years) < 25
25-50
50-70
>70
Iron indices No iron deficiency
Iron deficiency (e.g. serum ferritin <100 microg/L, TSAT <16%)
Anaemia related symptoms* No
Yes
Cardiovascular comorbidities† No
Yes
Number of RBC transfusions in the past  
half year
0-2
3-5
5-10
>10
TSAT, transferrin saturation.
*Anaemia related symptoms: fatigue and dyspnoe. 
†Coronary artery disease, peripheral artery disease, cerebrovascular accident or myocardial infarction.
the contribution in percentage of each individual factor relative to the other factors and together 
make up 100% of the decision-making. This results in a rank order of the 7 clinical factors from most 
to least important together. We performed descriptive analyses to calculate means and proportions 
for the gastroenterologist characteristics. 
We aimed to predict decision-making behavior (the dependent variable) using clinical factors 
and their levels as independent variables. We conducted multivariable linear regression analysis 
to determine if gastroenterologist or practice type characteristics (sex, age, years as a specialist, 
subspecialisation and type of hospital) predicted individual importances for each of the 7 tested 
clinical factors. Factors were included if the P-value was < 0.2 in univariate analysis. Continues 
independent variables were transformed in binary variables by using the mean /median. For each 
of these gastroenterologists characteristics the association with the individual importance scores 
of the 7 clinical patient factors was calculated by the odds ratio (OR) with 95% confidence intervals 
(95% CIs). The part-worth utility analyses and individual attribute importances are automatically 
calculated by the Sawtooth Software (North Orem, UT). The regression analysis were performed 
with SPSS Statistics software version 22.0 (IBM, Armonk, NY, USA).
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RESULTS
Characteristics of responders
A total of 113/395 (29%) gastroenterologists completed the survey. Seventy-six percent of 
the responders were male (table 2). Mean age was 47 years (SD 9) with a mean duration of 13 years 
(SD 10) of being a specialist. Most gastroenterologists (n = 54, 49%) worked in a teaching hospital. 
The most prevalent subspecialisations were advanced endoscopy (n=27, 24%) and inflammatory 
bowel disease (n=23, 21%).
Rank Order of Clinical Factors
Of the 7 attributes assessed, absolute Hb level is the most important incentive for transfusion, 
accounting for 42% of decision-making, followed by age (15%), Hb stability (12%), anemia related 
symptoms (10%), cardiovascular comorbidities (10%), the number of transfusions in the past half 
year (6%) and iron indices (5%) (supplementary files, figure 1). 
Inflection points of Clinical Factors 
The inflection point is the point where the utility of a specific level increases or decreases significantly 
compared to the other levels of the clinical factor. For Hb level the inflection point is 9.6 g/dL, above 
which phycisians do not prescribe transfusions (supplementary files, figure 2). Inflection points of 
the other clinical factors were also calculated (supplementary files, figure 3). Hb stability is only an 
Figure 1. Example of a case vignette. Anemia related symptoms: fatigue and dyspnoea. Cardiovascular 
comorbidity in the past: coronary artery disease, peripheral artery disease, cerebrovascular accident or 
myocardial infarction Iron deficiency present: serum ferritin <100 μg/L with transferrin saturation <16% Hx, 
history; Nr., number
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Table 2. Gastroenterologists characteristics (n = 113).
Characteristic Number (%)
Sex: male 86 (76)
Age (years) 47, SD 9
Mean duration specialist (years) 13, SD 10
Type of hospital 
 University hospital
 Teaching hospital
 Non-teaching hospital
25 (22)
53 (47)
35 (31)
Subspecialisation (n = 111)
 Advanced endoscopy
 Inflammatory bowel disease
 Oncology
 Hepatology
 None
 Other
27 (24)
23 (21)
17 (15)
9     (8)
25 (23)
10   (9)
important clinical factor in the decision-making process when the extremes are true, which were no 
Hb change or a 1.6 g/dL drop over the past week. The average part-worth utilities for the different 
levels (stable, 1.6 g/dL drop over the past month, 0.8 g/dL drop over the past week, 1.6 g/dL drop 
over the past week) are respectively -37 (SD 18), 1 (SD 20), 0 (SD 15) and 36 (SD 35). The inflection 
point for age of the patient is 25 years, e.g. below this age gastroenterologists are not triggered to 
prescribe transfusions. 
Preferences for transfusion dependent on gastroenterologist characteristics
In multivariate linear regression, age of the gastroenterologists was a predictor for the importance 
in decision-making process of the patient’s characteristic age (OR -2.9, 95% CI -5.3 - -0.5). Younger 
gastroenterologists (< 47 years) value the patient’s age 2.9 times more than older gastroenterologists 
in their decision-making process to transfuse. Sex, type of hospital and subspecialisation were no 
predictors in multivariate regression analysis for the importance of any of the seven clinical factors 
in the decision-making process. 
DISCUSSION
This study provides insight in the decision-making process concerning blood transfusion in everyday 
gastrointestinal practice. Of all clinical factors, absolute Hb level is the most important incentive of 
RBC transfusion in patients with chronic anemia. The inflection point in decision making is a Hb level 
of 9.6 g/dL, above which gastroenterologists are averse in prescribing RBC transfusions. Symptoms, 
age of the patient and iron indices are less important in the decision making process. Transfusion 
preferences are dependent on the gastroenterologists’ age. 
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This variation between gastroenterologists in transfusion strategies is similar to data from  other 
studies investigating transfusion strategies in other fields of medicine.9,10 However, the relative 
minor impact of patient’s age and symptoms on the decision-making process in our study, is not 
in line with American, European and Australian RBC transfusion guidelines.6,7,8,21,22 The guidelines 
advise to integrate Hb levels with data on symptoms, age and iron indices, while our respondents 
were mainly guided by absolute Hb levels (table 3). Possible explanations for non-adherence 
are a lack of awareness of the new guidelines, low exposure rate of deciding to prescribe a RBC 
transfusion by the specialist gastroenterologists themselves or difficulty with the interpretation of 
the recommendations (e.g. what is considered as cardiovascular comorbidity).6,21 This hypothesis of 
lack of awareness and low exposure rate by the specialist is supported by our finding that younger 
gastroenterologists value the clinical factors recommended in the guidelines (e.g. age) more than 
the older gastroenterologists. 
The present study comes with limitations. First, we determined the clinical factors and 
the corresponding levels used in this ACBC analysis technique by using the guidelines and pilot testing 
for comprehensibility. However, there may be unidentified factors that influence the decision-
making process. For example, our survey did not offer parenteral iron supplementation as an option 
to treat anemia. In daily clinical practice RBC transfusion can be preceded by parenteral iron. This 
may increase the likelihood of measurement error, which could have led to a higher inflection point 
of Hb for RBC transfusion than in real life. Second, there is a risk of response bias due to the relatively 
Table 3. Guidelines recommending transfusion strategies in (chronic) anaemia.* 
Guidelines Year
Impact Factor 
Journal Grilli Score† Topic Recommendations
American Association of Blood Banks (6) 2012 17.8 4 RBC transfusion •	 restrictive transfusion strategy (7 to 8 g/dL) in hospitalized, stable patients
•	 transfusion decisions be influenced by symptoms as well as Hb concentration
American Society of Anesthesiologists task 
force (22)
1996 5.9 4 Blood component therapy •	 RBC transfusion is rarely indicated when Hb ≥ 10 g/dL and is almost always indicated when Hb ≤ 6 g/dL
•	 when Hb 6-10 g/dL decision should be based on the risk of complications of inadequate oxygenation
British Committee for Standards in 
Haematology (7)
2001 5.0 1 RBC transfusion •	 based on patients’symptoms (using functional assessment scales)
•	 there is no universal trigger (e.g. Hb) for RBC transfusion 
Australian and New Zealand Society of Blood  
Transfusion (8)
2001 - 2 RBC transfusion •	 the decision to transfuse RBC should be based on clinical assessment incl. symptoms, reaction previous 
transfusion and Hb level
•	 RBC when Hb is > 10 g/dL is inappropriate
Dutch Blood Transfusion Guideline (21) 2011 7.9 4 Blood transfusions •	 strict indications for RBC are symptomatic anaemia or Hb < 4.8 g/dL
•	 decision for prophylactic RBC should be based on Hb-level in combination with age and  
cardiopulmonary comorbidity
National Comprehensive Cancer Network (1) 2012 4.2 3 Cancer- and chemotherapy 
induced anaemia
•	 no transfusion in asymptomatic patients without significant comorbidities
•	 transfusion is indicated in the presence of symptoms
•	 asymptomatic patient with severe comorbidities is Hb goal 7-9 g/dL
RBC, red blood cell; Hb, haemoglobin; incl., including 
* Guidelines addressing peri-operative care, critically ill patients, children are excluded.
† Grilli score: quality assessment tool for guidelines addressing 3 topics: description of the involved professionals, description of the sources of information, and explicit grading of evidence. Score range: 0-4. 
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Australian and New Zealand Society of Blood  
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transfusion and Hb level
•	 RBC when Hb is > 10 g/dL is inappropriate
Dutch Blood Transfusion Guideline (21) 2011 7.9 4 Blood transfusions •	 strict indications for RBC are symptomatic anaemia or Hb < 4.8 g/dL
•	 decision for prophylactic RBC should be based on Hb-level in combination with age and  
cardiopulmonary comorbidity
National Comprehensive Cancer Network (1) 2012 4.2 3 Cancer- and chemotherapy 
induced anaemia
•	 no transfusion in asymptomatic patients without significant comorbidities
•	 transfusion is indicated in the presence of symptoms
•	 asymptomatic patient with severe comorbidities is Hb goal 7-9 g/dL
RBC, red blood cell; Hb, haemoglobin; incl., including 
* Guidelines addressing peri-operative care, critically ill patients, children are excluded.
† Grilli score: quality assessment tool for guidelines addressing 3 topics: description of the involved professionals, description of the sources of information, and explicit grading of evidence. Score range: 0-4. 
low response rate (29%). We do not know the specific reasons for non-response, but to assess if 
there are systematic differences we compared respectively characteristics of responders and 
members of the Dutch Association of Gastroenterologists. Sex (76% vs. 71% men), experience (13 vs. 
13 years as a consultant) and type of hospital (academic 21 vs. 22%, teaching hospital 49 vs.39%) are 
comparable between the two groups, which  lowers the chance of a large non-response bias in this 
study. Moreover, the response rate in our study is comparable to other surveys.23 
As this study is designed to get insight in the decision-making process, we can only speculate 
about the underlying causes for the discrepancy with guidelines. Further research should be 
performed to investigate the causes of non-adherence. This is study however is the first step in 
understanding the decision-making. This is important to instigate the debate about the correct 
use of RBC transfusion, which eventually should lead to strategies to improve guideline awareness 
and adherence. Ultimately, this might decrease the undertreatment and overtreatment of chronic 
anemia with an improvement of clinical outcomes and quality of life. 
To conclude, absolute Hb level trumps all other factors as the most important trigger to 
transfusion decision-making. Current transfusion guidelines address the importance of other 
factors like the presence of symptoms.1,6,7,8,21 This discrepancy might reflect a lack of awareness of 
these guidelines by gastroenterologists. 
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SUPPLEMENTARY FILES
Figure 1. The relative importance of each of the 7 clinical factors that trigger RBC transfusion. 
Figure 2. Inflection point of hemoglobin level (part-worth utilities).
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Figure 3. Inflection points of all clinical factors for the according levels (part-worth utilities).
See table 1 in the full-text manuscript for the corresponding levels of the clinical factors.
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ABSTRACT
Background and aims
In the minority of patients, active bleeding angiodysplasias are observed  during endoscopy. 
Non-bleeding angiodysplasias can be an incidental finding. This makes the decision to ablate 
angiodysplasias during endoscopy difficult. The aim of this study is to assess need for repeat 
endoscopy with argon plasma coagulation (APC) in angiodysplasia patients who were left untreated 
during index endoscopy performed for anemia or overt bleeding.
Methods
We initiated an international, multicentre, retrospective cohort study to collect clinical, laboratory 
and endoscopic data from angiodysplasia patients. Cases were identified through endoscopy 
reports from 2010-2015 with follow-up until July 2016. Inclusion criteria was endoscopic detection 
of angiodysplasia in the context of overt bleeding or anemia. The primary outcome was repeat 
endoscopy with APC.
Results
A total of 189 patients diagnosed  with angiodysplasia in the setting of anemia or overt bleeding 
were included (mean age = 68 years; 58% male). Median follow-up was 33 months. In 52% of 
the cases (n=98) APC was performed at index endoscopy, whereas 48% (n=91) of patients did not 
receive initial APC therapy. Repeat endoscopy with APC was necessary in 17 patients (19%) in whom 
angiodysplasias were detected but left untreated during the index endoscopy, with a median time 
to  repeat endoscopy of 11 weeks. A total of 48 patients (53%) who received a purely diagnostic 
index endoscopy received other treatment modalities than APC (e.g. iron supplementation, blood 
transfusion, stop anticoagulants). Anemia and / or overt bleeding resolved without treatment in 21 
patients (23%) in the non-direct APC patients and resolved after one APC treatment in 17 patients 
(17%) in the APC group.
Conclusion
A substantial proportion of patients with symptomatic angiodysplasia bleeding do not receive APC 
at index endoscopy and undergo repeat endoscopy with APC.
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INTRODUCTION
Angiodysplasias are the most common vascular lesions of the gastrointestinal tract and are most 
frequently found in the right-sided colon.1, 2 Diagnosis is made by endoscopy where they appear 
as single or multiple flat bright red spots with round uniform or slightly irregular margins most 
often sized 2–5 mm, or as raised and reddened areas when larger.3 Prevalence is estimated to be 
1% in the healthy asymptomatic population, but the incidence and risk for symptomatic bleeding 
angiodysplasias increases with the presence of risk factors, i.e. an increasing age, valvular heart 
disease, chronic kidney disease, von Willebrand’s Disease, use of anticoagulant medication.4-6 
Bleeding angiodysplasias that lead to anemia compromise quality of life in these patients.2
Ablation therapy with argon plasma coagulation (APC) or gold probe therapy has become 
a  first line treatment for angiodysplasias that cause anemia or overt gastrointestinal bleeding. 
However, the rebleeding rate has been reported to be 20-36% in 22 months.7, 8 Ablation therapy 
for asymptomatic incidental angiodysplasias is not indicated.9 In only 7% of patients with suspected 
gastrointestinal bleeding and angiodysplasias, active bleeding angiodysplasias are seen during 
endoscopy.6 However, when endoscopy is performed in the setting of overt bleeding or anemia, 
non-bleeding angiodysplasia may not be treated and be regarded as incidental finding. Additionally, 
the endoscopist might regard that the severity of the gastrointestinal bleeding is not caused by 
angiodysplasia and will probably search for alternative causes of gastrointestinal bleeding. 
We hypothesize that non-bleeding angiodysplasias in the setting of gastrointestinal bleeding 
are largely left untreated during the index endoscopy in the settings of occult or overt bleeding 
introducing the need for repeat endoscopy with ablative therapy. We performed a retrospective, 
cohort study to identify endoscopic treatment practices in patients with symptomatic 
bleeding angiodysplasias. 
METHODS
Design
We performed a multicenter, retrospective cohort study in two tertiary referral centers, i.e. Radboud 
university medical center in the Netherlands and Tallaght Hospital in Ireland.  The research protocol 
for this cohort study is approved by the institutional review boards of both institutes (Radboud 
University Medical Center, Nijmegen and Tallaght Hospital, Dublin).
Participants
Angiodysplasia patients were identified through an automated search using the terms ‘angiodysplasia’, 
‘angioectasia’, ‘ectasia’, ‘telangiectasia’ and ‘arteriovenous malformation’ in endoscopy reports of 
routine endoscopic procedures from January 2010 to March 2015 with follow-up until July 2016. 
Endoscopy reports included esophagogastroduodenoscopy, colonoscopy, balloon enteroscopy 
and video capsules. Patients with endoscopic detected angiodysplasia (defined as single or multiple 
2–5 mm flat bright red spots with round uniform or slightly irregular margins, or lesions appearing 
as raised and reddened areas with a distinctly irregular margin, when larger than 5 mm were seen3) 
with the presence of anemia or overt gastrointestinal bleeding were included.1 Exclusion criteria 
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Figure 1. Flowchart of patient selection and received treatments.
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Figure 1. Flowchart. 
were: 1) other vascular anomalies; gastric antral vascular ectasia (GAVE), hereditary hemorrhagic 
telangiectasia (HHT), radiation proctitis, 2) incidental angiodysplasias, defined as lesions discovered 
during endoscopy performed for another indication than overt gastrointestinal bleeding or 
anemia, e.g. colorectal cancer screening (positive iFOBT) of inflammatory bowel disease patients, 
procedures performed for change in bowel movements, 3) other cause of gastrointestinal bleeding 
identified, e.g. carcinoma, varices. Clinical, laboratory, endoscopic and outcome data with follow-up 
were collected.
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Outcomes
The primary outcome of the study is the percentage of patients in need for repeat endoscopy with 
APC for angiodysplasia bleeding within six months of index endoscopy without APC. Secondary 
outcomes were treatment for bleeding angiodysplasias within one year, defined as endoscopy 
with APC, iron supplementation, blood transfusion, switch / stop platelet aggregation inhibitor 
or anticoagulant drug, hormone therapy and somatostatin analogues. Differences in baseline 
characteristics between the APC-group and no APC at index endoscopy (‘no-direct APC group’) 
were identified to assess clinical characteristics that might have influenced the decision-making to 
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Table 1. Baseline characteristics of the study population and differences in baseline characteristics between 
the APC-group and the no-direct APC group.
Baseline characteristics 
Total
(n=189)
APC-group
(n=98)
No-direct APC 
group (n=91) P-value OR (95% CI)
Patient characteristics  
1.04 per year (1.008-1.06)
4.3 (2.1-8.6)
 
2.3 (1.1-4.8)
2.6 (1.3-5.3)
 Age 68 (11) 70 (10) 66 (12) 0.01
 Gender - male 110 (58) 59 (60) 51 (56) 0.56
 Valvular heart disease 57 (30) 43 (44) 14 (15) <0.001
 Chronic kidney disease 49 (26) 27 (28) 22 (24) 0.60
 Anticoagulant / platelet inhibitor 
  Acenocoumarol
134 (71)
40 (21)
74 (76)
27 (28)
60 (66)
13 (14)
0.15
0.03
Disease characteristics
 Multiple angiodysplasias 105 (56) 61 (62) 44 (48) 0.02
 Colon location 76 (40) 34 (35) 42 (46) 0.11
 Small bowel location
 Stomach location
97 (51)
39 (21)
63 (64)
20 (20)
34 (37)
19 (21)
0.001
0.94
3.0 (1.7-5.5)
 Hemoglobin level (g/dL) 9.7 (2.4) 9.4 (2.4) 10.1 (2.3) 0.06
 Oral iron at index endoscopy 59 (31) 39 (40) 20 (22) 0.008 2.3 (1.2-4.5)
         -
-
 Occult vs. overt bleeding 130 (69) 68 (69) 62 (68) 0.88
Method of diagnosis
 Esophagogastroduodenoscopy 106 (56) 56 (57) 50 (55) 0.77
 Colonoscopy 125 (66) 64 (65) 61 (67) 0.88
 Balloon enteroscopy 38 (20) 31 (32) 7 (8) <0.001
 Videocapsule endoscopy 107 (57) 69 (70) 38 (42) <0.001
*Mean with standard deviation are shown for continuous variables and number with percentage for categorical variables
Table 2. Method of diagnosis for small bowel angiodysplasias and the difference between the APC-group and 
the no-direct APC group.
Method of diagnosis
Total 
n=97 (%)
APC-group
n=63 (%)
No-direct APC group 
n=34 (%) P-value
Esophagogastroduodenoscopy 43 (44) 32 (51) 11 (32) 0.09
Colonoscopy 51 (53) 40 (63) 11 (32) 0.005
Balloon enteroscopy 29 (30) 25 (40) 4 (12) 0.005
Videocapsule endoscopy 90 (93) 58 (92) 32 (94) 1.0
*The frequent diagnosis with esophagogastroduodenoscopy and colonoscopy is partially due to multiple locations of 
angiodysplasias in the gastrointestinal tract within patients. 
treat the detected angiodysplasia with APC. Last, we assessed differences baseline characteristics 
and outcome between the two countries.
Statistical analysis 
Baseline descriptives are presented as percentages, or mean with standard deviation (SD) or 
median with interquartile range (IQR) for non-normally distributed data. To assess differences 
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between countries and in baseline characteristics between the APC-group and the no-direct APC 
group, univariate regression analysis were performed. Odds ratios (ORs) were calculated with 95% 
confidence interval (CI). A two-sided tested p-value ≤0.05 was considered statistically significant. 
All statistical analyses were performed with the SPSS package version 22.0 (SPSS, Inc, Chicago, IL).
RESULTS
Participants
We identified 360 unique patients. Based on the exclusion criteria, 171 patients were not included 
leaving a total 189 patients with angiodysplasia(s) to evaluated (see Figure 1). Ninety-eight (52%) 
patients were treated with APC during index endoscopy and in 91 (48%) patients were not. 
The majority were males (n=110, 58%) and the mean age at diagnosis was 68 years (SD 11). Risk factors 
for presence of angiodysplasias were valvular heart disease (30%, n=57) chronic kidney disease (26%, 
n=49) or use of anticoagulant drugs and / or platelet aggregation inhibitor (71%, n=134) (see table 
1). Videocapsule endoscopy was performed in 57% (n=107) of the patients (see table 2 for method of 
diagnosis of the small bowel lesions). The most common location angiodysplasia was the small bowel 
(n=97, 51%) and 31% of the patients (n=58) had angiodysplasias in multiple locations. The majority of 
patients with small bowel angiodysplasias received APC treatment (n=56, 58%). Around two-third of 
the patients presented with anemia (n=130, 69%). Median follow-up was 33 months.
Differences in baseline characteristics between groups
There were differences in baseline characteristics between the APC-group and the non-direct APC 
group (table 1). The patients directly treated with APC during the index endoscopy were older (66 
vs. 70, p=0.01, OR 1.04 per year 95% CI 1.008-1.06), were more likely to have valvular heart disease 
(44 vs. 15%, p<0.001, OR 4.3 95% CI 2.1-8.6), use of acencoumarol (28 vs. 14%, p=0.03, OR 2.3 95% CI 
1.1-4.8), multiple angiodysplasias (62 vs. 48%, 0.02, OR 2.6 95% CI 1.3-5.3), small bowel location (64 
vs. 37%, p=0.001, OR 3.0 95% CI 1.7-5.5) and were more likely to using  oral iron supplementation 
(40 vs. 22%, p=0.008, OR 2.3 95% CI 1.2-4.5) at time of index endoscopy. As a consequence of 
the more often small bowel localization, the patients in the APC-group were more often diagnosed 
by videocapsule (70 vs. 42%, p<0.001) and balloon enteroscopy (32 vs. 8%, p<0.001). No differences 
were found for ischemic heart disease, diabetes mellitus, hyperlipidemia, chronic obstructive 
pulmonary disease, congestive heart failure, auto-immune disease and thyroid dysfunction. Also, 
there were no differences in use of ACE-inhibitors, statins, beta blockers and acetylsalicylic acid. 
The percentage of patients presenting with occult in contrast to overt bleeding was similar between 
the APC- and non-direct APC group (69 vs. 68%, p=0.88). Overall, we can conclude that the groups 
are not similar on baseline characteristics and therefore we did not analyze the difference of direct 
APC- and non-direct APC group on outcome measures such as efficacy and rebleeding percentage.
Outcomes
Ninety-one patients (48%) did not receive APC treatment during index endoscopy for occult or 
overt bleeding when angiodysplasias were observed. 76% of these patients were noted to have 
continued to occult or overt bleeding in a mean follow-up period of 40 months. Of these patients, 
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(n=65, 71%) received additional therapies for occult or overt bleeding. Only seventeen patients (26%) 
of the 65 patients who received additional therapy, received APC treatment for continued anemia 
and/or angiodysplasia bleeding during follow-up (see flowchart). Median time between index 
endoscopy without APC and repeat endoscopy with APC was 11 weeks. Other treatments initiated 
by the treating physician (+/- in combination with APC) for anemia and / or bleeding were iron 
supplementation (n=49, 54%), red blood cell transfusions (n=33, 36%), stop or switch anticoagulants 
(n=6, 7%), octreotide (n=2, 2%) and estrogen-progesterone (n=1, 1%). Recurrent bleeding or anemia 
occurred in 21 (23%) patients within one year after index endoscopy. 
The majority (n = 67, 68%) of patients with APC treatment during the first endoscopy for occult 
or overt bleeding needed additional treatment during follow-up (mean 35 months), of which half 
underwent repeat APC therapy (n=33, 49%). Localization of the angiodysplasias in these patients 
undergoing repeat APC treatment was similar to the overall cohort with overrepresentation of 
small bowel lesions (stomach 24%; small bowel 67%; colon 36%). Median time between the first and 
second APC treatment was 14 weeks. Other treatments given were iron supplementation (n=39, 
58%), red blood cell transfusions (n=49, 73%), thalidomide (n=2, 3%) or octreotide (n=16, 24%) or 
other (n=10, 15%). Fourteen patients received endoscopic treatment alone.
Reasons not to treat found angiodysplasias during endoscopy for occult and 
overt bleeding
Reasons not to treat with APC described in the endoscopy report were (see table 3): sclerotherapy 
applied (n=1), the goal of the endoscopy was only to exclude colon carcinoma (n=3), no complete 
evaluation (colonoscopy and gastroscopy) with negative findings on the complementary 
endoscopy (n=8), use of anticoagulants (n=4), polyps during index endoscopy were thought to 
Table 3. Reasons not to treat detected angiodysplasias with APC during index endoscopy for occult and 
overt bleeding. 
Characteristics Reasons Total n=58 (%)
Patient Use of anticoagulants 4 (7)
Pain / discomfort during endoscopy 6 (10)
Concurrent disease more plausible explanation for anemia 3 (5)
Disease No active angiodysplasia bleeding seen during endoscopy 2 (3)
Endoscopist Applied sclerotherapy 1 (2)
Goal of endoscopy excluding gastrointestinal carcinoma 3 (5)
Not yet bidirectional endoscopy performed 8 (14)
Technically not possible 3 (5)
Angiodysplasia assumed to be insufficient explanation 7 (12)
Polyps were thought to be the cause of anemia 4 (7)
APC complication risk not outweigh the benefit of treatment of overt 
bleeding without the presence of anemia
4 (7)
Other Diagnosis made by videocapsule not followed by balloon enteroscopy 4 (7)
No reason reported 9 (16)
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be the cause of anemia however persistent anemia remained during follow-up after polypectomy 
(n=4), no reason reported but angiodysplasia as cause of anemia / overt bleeding stated (n=9), 
assumed angiodysplasia was an insufficient explanation for the anemia / overt bleeding with no 
other explanation either (n=7), technically not possible (n=3), pain or discomfort of the patient 
during the procedure (n=6), diagnosis made by VCE not followed by balloon enteroscopy (n=4), 
no active angiodysplasia bleeding seen during endoscopy (n=2), only presence of overt bleeding 
without anemia which according to the endoscopist did not outweigh the risk of complications 
of APC (n=4), concurrent disease more plausible explanation for anemia (n=3). Reasons for not 
performing or treating with APC during a second endoscopy were: small bowel location and 
conservative management with iron supplementation +/- red blood cell transfusions given (n=5), 
iron supplementation given despite the angiodysplasia was not localized in the small bowel (n=13), 
discomfort during second endoscopy for APC therapy (n=1), unknown (n=4).
Differences between countries
Fifty-six patients (30%) of the cohort were from the Tallaght Hospital in Ireland. The distribution 
between sexes was different between the Netherlands and Ireland (resp. men 63 vs 46%, p=0.03). 
The Irish cohort were mostly diagnosed by videocapsule (98%) and therefore had a significantly 
higher rate of small bowel location (33% vs. 95%, p<0.001). The presentation with occult or overt 
bleeding was similar (anemia 72 vs 61%, p=0.12), as was the proportion of patients directly treated 
with APC at index endoscopy (50 vs 57%, p=0.34). However, in the Irish cohort octreotide was more 
frequently prescribed in addition to endoscopic APC (2 vs 30%, p<0.001) according to the local 
protocol. Other baseline characteristics were not significantly different between countries.
DISCUSSION
This study evaluates the treatment practices for bleeding angiodysplasia. This study includes 
the reasoning behind the decision-making process to endoscopic treat angiodysplasias. Our 
findings confirm the hypothesis that there is a substantial proportion of patients with symptomatic 
angiodysplasia bleeding who do not receive APC at index endoscopy and continue to be dependent 
on iron supplementation, blood transfusions or have to undergo repeat endoscopy with APC. 
The main reason for not providing APC therapy during initial endoscopy was secondary to incomplete 
bidirectional endoscopy in the presence of angiodysplasia. During follow-up angiodysplasias were 
recognized as the cause of the anemia, and led to initiation of conservative therapies such as 
iron supplementation and red blood cell transfusions. Treating physicians seem to be hesitant to 
perform repeat endoscopy with APC for continued anemia due to angiodysplasias, as only a quarter 
of the patients received APC treatment during follow-up.
Patients were more likely to be treated with APC at index endoscopy when they were older, had 
valvular heart disease (and related to this use of acenocoumarol, multiple angiodysplasias, small 
bowel location and when patients needed iron supplementation. These factors are known risk 
factors for more severe bleeding10-12 and seem to correctly play a role in the decision-making process 
of the endoscopist. Other known risk factors, such as chronic kidney disease, were not significantly 
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different between the group that received direct APC versus non-direct APC. We hypothesize 
endoscopists may take other risk factors, e.g. chronic kidney disease, use of anticoagulants and 
multiple comorbidities6, 12, 13, that are associated with symptomatic bleeding angiodysplasias less into 
account. This might be due to lack of awareness. Moreover, we saw that once the decision was made 
to perform balloon enteroscopy other angiodysplasia locations were more likely to be treated in 
the same patient. 
Based on these results, we believe that with understanding of known risk factors for 
symptomatic angiodysplasia bleeding timing of endoscopic APC treatment can be improved by 
given APC during the index endoscopy more often. APC is classified as a low-risk procedure for 
the risk of bleeding in the ASGE guideline.14 Therefore, antiplatelet and anticoagulant drugs should 
not be discontinued for APC therapy, which makes this an incorrect reason not to treat when there 
is an indication for APC. In addition, continuing antiplatelet drugs might be useful to detect active 
angiodysplasia bleeding and thereby helpful to initiate APC therapy.15 Furthermore, the complication 
risk for APC therapy in general is low16, so this should not be a reason to withhold APC therapy.9 In 
case pain or discomfort made APC therapy undesirable at index endoscopy, we suggest to plan 
another endoscopy with a more experienced endoscopist and / or to use propofol sedation as this 
sedation method is more painless in comparison with the combination of benzodiazepines and 
opiods.17 What was surprising to us, is that in some cases the videocapsule showed small bowel 
angiodysplasias and iron supplementation was started, but enteroscopy was not performed. 
Apparently the anemia was not severe enough to undergo this invasive procedure. The indication 
for videocapsule endoscopy must be considered carefully when there are no clinical consequences. 
Guidelines state that small bowel evaluation is unnecessary after negative colonoscopy and 
oesophagogastroduodenoscopy, unless there is inadequate response to iron therapy, especially if 
red blood cell transfusion dependent.18 On the other hand, in 13 patients iron supplementation was 
started while the angiodysplasia was not localized in the small bowel and could have been treated 
during diagnosis at index endoscopy. If the anemia is severe enough to start iron supplementation, 
APC should have been performed to treat the cause instead of the symptom. Only the exclusion 
of a colon carcinoma in patient presenting with iron deficiency anemia was another reason for not 
treating with APC. This can be a valid reason, however mild anemia also has a negative impact on 
quality of life in patients with angiodysplasias.2 The absence of bleeding was noted to be a reason 
not to treat even though nonbleeding angiodysplasias are more likely to be  found in the setting 
or anemia or over bleeding. Therefore, more awareness of risk factors and an understanding of 
the setting could decrease the undertreatment of angiodysplasia patients with hopefully less need 
for repeat endoscopy with APC during follow-up. Especially because there seem to be a threshold 
to perform repeat endoscopy for APC treatment. Prognostic tools distinguishing incidental from 
symptomatic bleeding angiodysplasias would be very useful to guide endoscopists in the decision-
making process. 
This study comes with certain limitations. First, it is a retrospective cohort study. Reasons for 
not performing APC are therefore sometimes unknown. For example, in the Netherlands APC 
technology is not ubiquitous and is a contributing factor on why direct APC cannot be performed. 
However, this was never mentioned in the endoscopy report and therefore maybe reporting bias. 
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Moreover, possible reasons that were not mentioned are experience of the endoscopist and time 
strain based on elective or emergency endoscopy program. Second, we observed  that once 
the decision to treat small bowel angiodysplasias with balloon enteroscopy other locations were 
also more likely to be treated in that specific patient. Third, there were some differences between 
countries in the type of patients. Due to the Irish videocapsule cohort there were relatively a large 
proportion of small bowel angiodysplasias, besides the upper gastrointestinal and colon locations. 
Strengths of the study are the long follow-up period and hereby we were able to investigate 
the long-term outcome and also be more certain of angiodysplasia causing the overt bleeding or 
anemia compared to the time index endoscopy. For example, during index endoscopy the anemia 
was judged as mainly due to polyps. After removal of the polyps the anemia persisted and repeated 
endoscopy with APC was performed, after which the anemia recovered. Moreover, this cohort 
includes two countries which increases the external validity of the results. 
In conclusion, a substantial proportion of patients with clinical symptomatic angiodysplasia 
bleeding do not receive direct APC and continue to be dependent on iron supplementation, blood 
transfusion or undergo repeat endoscopy with APC. Reasons not to treat were partially based 
on lack of awareness of the guideline addressing antithrombotic agents for patients undergoing 
gastrointestinal endoscopy and the guideline for management of iron deficiency anemia.14, 18 More 
aggressive endoscopic therapy should be encouraged during index endoscopy as there seem to be 
a threshold to perform repeat endoscopy for APC treatment. 
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ABSTRACT
Introduction
Cohort studies have shown the effect of octreotide in decreasing the rebleeding rates in patients 
with gastrointestinal angiodysplasias. The small sample size makes it difficult to estimate the true 
effect on clinical relevant outcomes and to investigate predictors for clinical response. 
Aims & Methods
The aim of this individual patient data meta-analysis is to investigate effectiveness  of somatostatin 
analogues (SSA) on transfusion dependency and identify subgroups of patients that benefit 
most. A systematic search up to February 2016 in MEDLINE, EMBASE and the Cochrane Library 
was performed to identify articles reporting the effect of SSA in gastrointestinal angiodyplasias. 
The primary outcome was response to SSA, defined as good: ≥ 50% reduction of red blood cell (RBC) 
transfusions; or poor: < 50% reduction of RBC transfusions. We used multivariate logistic regression 
to determine the effects of patient and disease characteristics on SSA. 
Results
We identified 9 studies and obtained individual data from 6 (n = 180) cohorts and aggregated data 
were available for another 2 studies (n=36). We analyzed data of 174 patients (mean age 70 years, 
55% men). 86.6% of the patients had a more than 50% reduction of RBC transfusions. There was 
a reduction between the number of RBC transfusions between the year prior to SSA and during 
SSA (13.0 vs. 2.9, p<0.001). Localization of angiodysplasias in the small bowel are independently 
associated with a good treatment response (OR 17.2, 95% CI 1.8-32.7). Side-effects occurred in 23.5% 
(31/132) of the patients. In 9 patients (6.8%) SSA was discontinued due to side-effects.
Conclusions
SSA treatment is effective and safe in the majority of patients with transfusion dependent 
angiodysplasia bleeding. A difference in treatment efficacy was found with patients with small bowel 
angiodysplasias responding better. 
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INTRODUCTION
Gastrointestinal angiodysplasias are vascular malformations  consisting  of thin-walled, dilated 
communications between veins and capillaries that easily bleed, and may lead to iron deficiency 
anaemia or overt bleeding.1 Elderly patients frequently suffer from  symptomatic disease  ranging 
from mild chronic anaemia to severe transfusion dependency necessitating hospitalizations. 
The most effective treatment is endoscopic argon plasma coagulation with a clinical response rate 
up to 90%.2 However, re-bleeding rates can be as high as 78% after two and a half years of follow-up 
for small bowel angiodysplasias.3 Indeed, repeated rebleeds in elderly patients, who have exhausted 
endoscopic therapy, results in refractory anaemia. Repeated blood transfusion as an option to 
correct anaemia is intuitive. However, the dilemma is that clinical studies emphasize the paradox 
that both anaemia and transfusion are associated with unfavourable outcomes, including organ 
injury, cardiovascular events, lower quality of life, and increased morbidity and mortality across 
patient populations.4
This has prompted the search for alternative strategies in angiodysplasia patients who have 
become dependent on blood transfusions. Somatostatin analogues (SSA) have emerged as an 
attractive alternative treatment modality in severe angiodysplasia bleeding. SSA reduce splanchnic 
blood flow, enhance platelet aggregation and possess anti-angiogenic effects.5, 6 In particular, 
octreotide as the prototype somatostatin analogue has been studied in this condition. Small 
cohort studies have shown a beneficial effect of octreotide in decreasing the rebleeding rates and 
transfusion requirements in patients with gastrointestinal angiodysplasias.7, 8 This lends credibility 
to the use of octreotide in endoscopic refractory angiodysplasias but most studies have been in 
small and underpowered. There has been one randomised controlled trial that have examined 
the efficacy of SSA in refractory bleeding angiodysplasia disease.9 It is unknown how effective SSA 
are, whether these drugs come with a dose response relation, and  whether there are predictors 
of response.
Heterogeneity among studies preclude direct comparison and explaining heterogeneity 
with data on  study level is very difficult and does not relate effects of treatment to the individual 
patient.10 To overcome these limitations and increase statistical power, we performed an individual 
patient data (IPD) pooled analysis using data from eight cohort studies.11-18 
We hypothesize that patient and angiodysplasia characteristics affect the effectiveness of 
SSA and that there is a dose-response relationship.  The aim of the current IPD pooled analysis is 
to estimate the effect of SSA on transfusion requirements in angiodysplasia subgroups based on 
underlying treatment (i.e. doses), patient and angiodysplasia characteristics to identify patients 
that benefit the most from SSA. 
METHODS
Literature search
This study is performed according to the PRISMA-IPD guideline.19 We performed a systematic 
literature search using the following electronical databases: MEDLINE, Embase, the Cochrane 
Library and clinicaltrials.gov in January 2015, with an update on 14 November 2016. A clinical librarian 
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assisted in creation of correct and complete search syntax. The search terms ‘angiodysplasia’ 
(synonyms: vascular malformation, angioectasia, ateriovenous malformation, ectasia, vascular 
lesion, vascular abnormality, vascular abnormalities or watermelon stomach) and ‘octreotide’ 
(synonyms: somatostatin, or sandostatin) were combined and Mesh terms were used (see appendix 
1 for the search strategy). 
Study selection
We included all original studies that were published as full articles that investigate the effect of SSA on 
transfusion requirements in patients with angiodysplasias. Angiodysplasias had to be diagnosed by 
endoscopy, i.e: gastroduodenoscopy, colonoscopy, balloon assisted enteroscopy or videocapsule 
endoscopy. Studies including patients with a left ventricular assist device (LVAD) were excluded 
because of the very specific aetiology of bleeding. Moreover, conference abstracts, case-reports 
and cohort studies with less than 10 patients were excluded because of risk of  selective reporting. 
Searches were not limited by language or time period. The search was completed by a forward 
citation search which included scanning and tracking references in footnotes and bibliographies 
of the identified articles. To obtain the individual patient data we adopted the following strategy 
to establish communication with  authors: 1. first authors, 2. last authors, 3. any co-author, 4. 
the department where the research was conducted, 5. retrieve correct contact information through 
the national gastrointestinal society of the country where the research was conducted, and 6. 
attending a conference where one of the authors was a speaker. 
Data extraction
An electronic standardized form containing all variables with corresponding definitions was 
used to obtain data from the collaborators. One author (K.G.) who had not participated in any of 
the included studies, extracted, pooled and analysed all patient data. Subsequently, databases were 
checked for completeness and internal consistency and when appropriate corrections through 
correspondence with the collaborators were made. The quality and risk of bias was assessed using 
Methodological Index for Non-Randomized Studies (MINORS) quality assessment scale.20 This is 
a validated tool with 12 items that are scored as not reported (0 points), reported but inadequate 
(1 point) or reported and adequate (2 points). The global ideal score being 16 for non-comparative 
studies and 24 for comparative studies. The following domains were included for assessment of risk 
of bias: the selection of the study groups; appropriate study design and analysis; the comparability 
of the groups; and the ascertainment of outcome of interest. Authors were contacted for additional 
information in case the methodological quality of a study was not adequately described in 
the original article. 
At the individual data level, we excluded patients with the following characteristics: no RBC 
transfusions in the year prior to initiating SSA, GI bleeding due to unknown cause and other causes 
apart from  angiodysplasias (e.g. gastric antral vascular ectasias). 
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Outcomes
The primary outcome was response to treatment, defined as good: ≥ 50% reduction of red blood cell 
(RBC) transfusions; or poor: < 50% reduction of RBC transfusions in the first year of SSA treatment 
compared to the year prior to initiating SSA.14 To provide more insight on the primary outcome we 
show the mean percentual and absolute mean difference in number of red blood cell transfusions 
between the year prior to SSA treatment in comparison to the first year on SSA therapy. Secondary 
outcomes are haemoglobin level and safety defined as the percentage of patients SSA treatment 
stopped due to adverse events (AEs) and tolerability, defined as the percentage of side-effects and 
AEs. Patient subgroups were based on patient characteristics (i.e. age at time of study inclusion, 
gender, comorbidities, use of anti-aggregation / anti-coagulants), angiodysplasia characteristics 
(i.e. location, extensiveness throughout the gastrointestinal tract) and treatment characteristics 
(i.e. doses). 
Statistical analysis
Only studies of which actual data were obtained were used in the pooled analysis. Baseline 
characteristics of patients will be presented as mean (standard deviation (SD)) or median (interquartile 
range (IQR)) in case of non-normally distributed continues variables. Binary and categorical variables 
will be presented as frequencies and percentages. In the primary pooled analysis overall treatment 
effect of SSA will be assessed by descriptive statistics of the number of responders, partial- and non-
responders. To compare the transfusion requirements and haemoglobin level between the year 
prior of treatment and treatment a paired two-sided students t-test or Mann Whitney U test will 
be used. Linear regression analysis will be performed to identify factors (e.g. dose, anti-coagulant 
use, age) associated with a response to SSA therapy with the continuous outcome of percentual 
decrease in RBC transfusions. For this prediction analysis, multiple imputation methods will be 
performed in case there are <50% missing cases and conditions for imputation are met. Outcomes 
will be displayed as Odd’s ratios (OR) with 95%-confidence intervals (95%-CI). Correction for study 
effect was enabled by putting the variable study into the model. 
Sensitivity analyses will not be performed. All statistical analyses are performed with SPSS 
statistical software package version 20.0 (SPSS Inc., Chicago, IL). All P-values calculated were 
2-tailed, and the level of significance was set at a α = .05.
Role of funding source
This study was not supported by any third party. The costs were fully covered by 
the authors’ institution. 
RESULTS
Study selection and IPD obtained
The initial search yield 248 articles, resulting in 180 unique publications for title and abstract 
screening (figure 1). After applying inclusion- and exclusion-criteria we retrieved 8 eligible articles. 
With forward citation searching we identified one additional article  which was not indexed in 
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the used search databases. In total we sought individual data of 9 studies and were successful in 
obtaining data from 6 of these studies (n = 179). The individual patient data were  not available for 
3 studies with a total of  68 patients. We were unable to establish contact with authors (n=19) or 
original data were destroyed (n=17 patients), however of these two studies some of the needed 
individual data were available from the published manuscript (n=36 patients ) and included.14, 16 For 
the third missing study (n=32 patients) we extensively tried to get in contact with the authors, but 
we stopped our attempts after it became clear that the principal investigators retired and data were 
probably deleted.21 Therefore of only one study (n=32 patients) data was not included in the dataset.
We excluded 37 patients from the merged dataset because of absence of  RBC transfusions in 
the year prior to initiating SSA (n = 37), unknown cause of GI bleeding (n=2) or GAVE (n=5).
Study characteristics
All 9 cohort studies (n=245) investigated the effect of SSA in patients with transfusion dependency 
because of  proven gastrointestinal angiodysplasia disease. The sample size per study was relatively 
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Figure 1. Study selection and obtained IPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study characteristics 
All 9 cohort studies (n=245) investigated the effect of SSA in patients with transfusion 
dependency because of  proven gastrointestinal angiodysplasia disease. The sample size per 
study was relatively small (range 11‐32), except for one study with 98 participants.[17] The 
median treatment duration between studies ranges between 6‐26 months with a follow‐up 
No. Studies identified through other sources: 1 
No. Studies after duplicates removed: 181
No. Studies excluded: 172 
 
No original patient data: 22 
Not about AD: 86 
Case‐reports: 24 
Patients with LVAD’s: 3 
Not about SSA treatment: 10 
No. of patients <10: 14 
Abstracts: 4 
Animal studies: 8 
No full‐text available: 1
No. Studies screened for eligibility: 181
No. Studies for which IPD were sought: 9 
No. Studies for which subtracted individual data 
were available: 2 
Excluded study: no IPD in published data 
No. patients excluded: 32 
Analyzed individual subtracted data 
       No. studies included in the analysis: 2 
     No. participants in analysis: 36 
No. Studies for which IPD were not provided: 3 
Reason: unable to contact the authors 
and data not available anymore  
No. patients: 68 
No. Patients excluded based on: 
       No RBC transfusions at baseline: 37 
       Unknown cause OGIB: 2 
       Other cause than AD bleeding: 5 
No. Studies for which IPD were provided: 6 
        No. patients with available data: 182 
        No. patients without available data: 0
Analyzed IPD data 
       No. studies included in the analysis: 6 
      No. participants in analysis: 138 
No. Studies identified through search: 248
Figure 1. Flowchart of study selection and obtained IPD.
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small (range 11-32), except for one study with 98 participants.17 The median treatment duration 
between studies ranges between 6-26 months with a follow-up period ranging from 13-78 months. 
The primary endpoint in 7 studies was the percentage of responders, defined as no blood and iron 
transfusions during octreotide therapy.12-17, 21 The other 2 included studies focussed on transfusion 
requirement; one study compares the average monthly transfusion rate18 another targeted in the 
blood transfusion requirements before and after starting SSA.11 
Assessment of risk of bias within studies
The methodological quality was assessed with the MINORS quality assessment tool. The 9 cohort 
studies were moderate quality with scores ranging from 7-15 (table 1). Most studies had a clear stated 
study aim and mentioned  inclusion of  consecutive patients. Five studies were prospective and had 
predefined  endpoints. There were no blinded studies and none of the studies had included a power 
calculation. All studies had a minimum or median follow-up of > 1 year, except for one study that 
reported  a 6 months follow-up.11 Half of the analyses of the included cohort studies were inadequate 
due to the lack of a paired test, which should have accounted for the dependent variations before 
and after treatment. Publication bias was not assessed by a funnel plot as this requires a minimum 
of 10 studies.22 
Baseline characteristics 
We analyzed data of 174 patients (mean age 70 years, 55% men) with RBC transfusion dependency 
due to gastrointestinal angiodysplasia bleeding that were treated with SSA (table 2). Two-third of 
the patients uses a form or combination of blood thinners, with 38% using antiplatelet drugs and 
Table 1. Methodological study quality assessment by the MINORS.
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Holleran + + + + - +/- +/- - - NA NA +/- 11
Klímová + + +/- + - + +/- - - NA NA +/- 11
Salgueiro + + +/- + - + - - - NA NA +/- 10
Nardone2 +/- + +/- +/- - + - - - NA NA + 8
Bon + + + + - + + +/- - NA NA + 15
Molina +/- + + + - + - - - NA NA +/- 10
Scaglione +/- + + + - + + - - NA NA + 13
Junquera + + + + - + +/- +/- + +/- +/- +/- 17
Nardone1 + - - +/- - + - - - NA NA + 7
FU, follow-up; NA, not applicable, 1, first publication 1999; 2, second publication 2014
-, not reported (0 points); +/-, reported but inadequate (1 point); + reported and adequate (2 points
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41% anticoagulants. Almost half (48%) of the patients had angiodysplasias at multiple sites, with 
the small bowel as most frequent location (73%), and an equal distribution in colon (44%) and 
stomach (44%). Prior to starting SSA, 55% had endoscopic treatment with argon plasma coagulation. 
Octreotide LAR in a dosage of 20 mg (64%) or and 10 mg (26%) per 28 days were prescribed in most 
patients. Median haemoglobin level was 7.0 g/dL (IQR 1.9) at baseline, with a median number of RBC 
transfusions in the year preceding  SSA treatment of 8.0 (IQR 13.4). The median follow-up was 15 
months (IQR 27). 
Primary outcome
Only 23 patients (13.4%) had a poor response to SSA treatment defined as  a percentual decrease 
of <50% in RBC transfusions between the year prior to initiating SSA and the first treatment year. 
Ninety-three patients (53.5%) had a full response with nil RBC transfusions during SSA treatment. 
There was a significant difference between number of RBC transfusions between the year prior 
to SSA and during SSA (13.0 vs. 2.9, p<0.001) (Figure 2). To correct for differences in baseline RBC 
transfusion requirements, the percentual decrease is shown in Figure 3. The mean decrease is 74% 
in number of RBC transfusions between prior year and first year of SSA therapy. The study of Klimova 
et al. has a very broad 95% CI, this is due to one patient who had an increase in RBC transfusions from 
2.5 to 15 (i.e. 500% increase).
The one study not included in this analysis is of Junquera et al. Compared with the control group 
there was no significant difference in RBC transfusion requirements found with patients receiving 
octreotide (resp. 0.7 vs. 1.1, p >0.05).
Secondary outcomes
Hemoglobin levels increased significantly during SSA therapy from a baseline level of 6.4 g/dL to 
10.6 g/dL (p<0.001). Side-effects occurred in 23.5% (31/132, missing values n=42) of the patients, 
with most commonly gastrointestinal symptoms such as  diarrhoea, abdominal pain, flatulence 
(n = 15, 11.5%), and erythema / pain at the injection site (n=8, 6.2%). Cholelithiasis occurred in 
Table 2. Baseline characteristics of individual patient data and subtracted IPD data (n=174).
Variable Characteristic N (%) Missings, N (%)
Gender Men 86 (55) 18 (10)
Age mean 70 years, SD 12 
Multiple locations 75 (48) 18 (10)
Location Stomach 69 (44) 18 (10)
Small bowel 114 (73) 18 (10)
Colon 69 (44) 18 (10)
Comorbidities CKD 33 (34) 78 (45)
Valvular heart disease 25 (26) 78 (45)
Blood thinners Yes 66 (66) 74 (43)
Antiplatelet 38 (38) 74 (43)
Anticoagulants 41 (42) 74 (43)
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Figure 3. Plot of the individual studies and combined IPD data with the percentual decrease in RBC transfusions 
in the year before and after start of SSA treatment.
Figure 2. Plot of the individual studies and combined IPD data with their absolute mean difference in RBC 
transfusions in the year before and after start of SSA treatment. 
3 patients (2.3%). In 9 patients (5.2%) SSA therapy was discontinued due to the following side-
effects: splenic infarction (n=1), allergic skin reaction (n=1), diarrhoea (n=1), cholelithiasis (n=2), pain 
at the injection side (n=1), thrombocytopenia (n=1) and for unknown reasons (n=2).  
Clinical treatment response
One study did not meet the criteria for multiple imputation and was therefore excluded from 
this analysis.14 Results of the univariate analysis and multivariable analysis are shown in table 3. 
The outcome treatment response was the continuous variable of the percentual decrease of RBC 
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transfusions in the year of SSA treatment compared to the year prior to SSA initiation. Localization 
of angiodysplasias in the small bowel were independently associated with a good treatment 
response (OR 17.2, 95% CI 1.8-32.7). Localization of angiodysplasias in the colon (OR -14.6, 95% CI 
-28.2- -1.0) and Lanreotide 90 mg (equivalent to octreotide 30 mg) (OR -48.6, 95% CI -93.7- -3.5) 
were associated with a poor treatment response. 
Risk of bias across studies
We were unable to retrieve the data of 1/9 study that were eligible for inclusion.21 Therefore, 
the overall representativeness of the available studies is high. However, almost all studies treated 
patients with SSA dose of 10 mg (n = 45) or 20 mg (n = 112). In one study the treating physician had 
the opportunity to treat patients with Lanreotide 90 mg LAR (equivalent to octreotide 30 mg LAR).11 
The small patient numbers (n = 3) in the SSA dose 30 mg dose leads to a wide confidence interval 
and makes interpretation of SSA dose 30 mg LAR (n = 3) in comparison to the lower doses difficult.
DISCUSSION
This meta-analysis using individual patient data of 8 studies shows that SSA treatment in patients 
with active bleeding  gastrointestinal angiodysplasia bleeding is effective and safe in the majority of 
patients. We are the first to investigate factors influencing treatment response and found that small 
bowel localization is associated with a good treatment response (≥50% decrease of RBC transfusion 
requirements) and colon localization with a poorer SSA treatment response. The finding that 
the dose equivalent of 30 mg octreotide LAR is associated with a poor response of <50% reduction 
Table 3. Factors associated with response to SSA therapy. 
Variable
Univariate Multivariable
Odd’s (95% CI) p-value Odd’s (95% CI) p-value
Gender: men 0.96 (-10.8-12.8) 0.87
Age: per year 0.2 (-0.4-0.7) 0.52
Multiple locations -1.7 (-13.6-10.1) 0.78
Stomach -8.8 (-21.4-3.8) 0.17 -9.3 (-22.7-4.1) 0.17
Small bowel 9.9 (-4.2-24.1) 0.17 17.2 (1.8-32.7) 0.03
Colon -11.0 (-23.3-1.2) 0.08 -14.6 (-28.2- -1.0) 0.04
CKD -12.1 (-26.7-2.5) 0.11 -8.9 (-24.5-6.6) 0.26
Valvular heart disease -3.2 (-19.4-13.0) 0.70
Blood thinners -4.1 (-18.9-10.7) 0.58
Antiplatelet -6.7 (-23.3-10.0) 0.43
Anticoagulantia -3.4 (-20.9-14.2) 0.70
Prior APC therapy -0.4 (-13.3-12.5) 0.44
No. RBC before SSA -9.2 (-23.3-4.8) 0.197 -9.6 (-24.0-4.7) 0.19
SSA dose: 30 mg -20.3 (-37.6- -3.0) 0.02 -48.6 (-93.7- -3.5) 0.04
1 No. RBC before SSA: the number of RBC transfusions before start of therapy.
Eff
ectiveness to
 so
m
ato
stain analo
gues in angio
d
ysplasia bleed
ing
4.1
131
of RBC transfusions should be interpreted with caution due to the very small patient numbers 
and the possible bias of patients selected with severe disease to a higher dose. Considering 
the sample size of this meta-analysis the results add to current knowledge of therapeutic options in 
the management of patients with angiodysplasias. The results of this meta-analysis support the use 
SSA therapy in a step-up approach for the treatment blood transfusion dependent angiodysplasia 
bleeding not responding to endoscopic therapy.   
The response to SSA therapy in patients with angiodysplasia bleeding was not influenced by 
the known risk factors 23, 24 for the development of angiodysplasias: age, gender, the presence of 
valvular heart disease, use of anticoagulants and antiplatelet agents. Moreover, prior endoscopic 
therapy with APC did not influence treatment response to SSA, which makes SSA therapy a good 
option following ineffective  APC therapy. SSA probably act through the reduction of splanchnic 
blood flow.6 
Current treatment strategy for angiodysplasia bleeding include endoscopic therapy, 
symptomatic treatment with iron and/or RBC transfusions and angiogenesis inhibitors.25 In 
patients with aortic valve stenosis, aortic valve replacement is one of the options that is effective 
in approximately 80%.26 The available reviews state that angiogenesis inhibitors can be considered 
in patients that are RBC transfusion dependency.1, 7, 10, 25 Thalidomide is an effective angiogenesis 
inhibitor  27, but has the drawback of the risk of irreversible side-effects such as polyneuropathy.28 
Recently, the first double-blinded randomized controlled trial (n = 22) with the primary endpoint 
RBC transfusions showed a 83% success rate of pasireotide-LAR 60 mg in the per protocol analysis 9, 
which is in comparison with our main findings. Side-effects were relatively mild with 3 patients 
having glycemic dysregulation. 
This IPD establishes the role of SSA therapy for patients with bleeding angiodysplasia who 
are in need of frequent RBC transfusions despite multiple endoscopic procedures. On the basis 
of our clinical practice we advice to start octreotide LAR 10 mg intramuscular every 4 weeks and 
evaluate side-effects (such as diarrhea) 1 month after the first injection. Most side-effects such as 
gastrointestinal discomfort should be resolved. After 3 months a reduction in RBC transfusions should 
be noticeable. In case there is less than 50% reduction in monthly RBC transfusions, the patient 
might be a non-responder. Doses increase to 20 mg can then be considered, although there are 
no studies underlining this statement. When there is no treatment effect found at 6 months SSA 
therapy should be discontinued.
The main strength of this study is that we included the individual patient data of almost all 
studies published in this subject area. In addition, the raw patient data gave us the opportunity 
to investigate the influence of baseline characteristics on therapeutic response. Limitations of this 
study are that none of the included studies had a control group, by which regression to the mean 
could have resulted in an overestimation of the treatment effect we found. However, the recent 
first randomized trial in this field shows a comparable success rate to our study, which supports 
our findings. Moreover, due to the small number of patients in the individual studies the estimated 
treatment effect can vary widely, partially due to study dependent factors. Therefore, we included 
study as variable to correct for study effect in our pooled analysis. 
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Future studies should be randomized with a control group, whereby regression to the mean is 
eliminated and a more precise estimation of SSA treatment can be calculated. Treatment duration 
and follow-up period varied in the included studies of this meta-analysis. A recent study investigated 
different doses of lanreotide, but only reported the overall effect of lanreotide without reporting 
dose-dependent treatment effects.8 Therefore, future trials  are needed to investigate the optimal 
duration and doses of SSA treatment and the duration of the prolonged effect after discontinuation 
of SSA therapy. 
In conclusion, this meta-analysis with individual patient data shows that SSA treatment is effective 
and safe in the majority of patients with refractory gastrointestinal angiodysplasia bleeding. Patients 
with small bowel angiodysplasias seem to have the most substantial SSA treatment effect.
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SUPPLEMENTARY FILES
File 1 - Search strategy (in MEDLINE):
((((octreotide[Title/Abstract] OR somatostatin[Title/Abstract] OR somatostatine[Title/Abstract] 
OR sandostatine[Title/Abstract] OR sandostatin[Title/Abstract])) OR “Octreotide”[Mesh])) AND 
(((Angiodysplasias[Title/Abstract] OR angiodysplasia[Title/Abstract] OR vascular malformation[Title/
Abstract] OR vascular malformations[Title/Abstract] OR arteriovenous malformation[Title/
Abstract] OR arteriovenous malformations[Title/Abstract] OR angioectasia[Title/Abstract] OR 
angioectasias[Title/Abstract] OR vascular ectasia[Title/Abstract] OR vascular ectasias[Title/
Abstract] OR vascular lesion[Title/Abstract] OR vascular lesions[Title/Abstract] OR vascular 
abnormalities[Title/Abstract] OR vascular abnormality[Title/Abstract] OR watermelon 
stomach[Title/Abstract] OR watermelon stomachs[Title/Abstract])) OR “Angiodysplasia”[Mesh])
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ABSTRACT
Introduction
Gastrointestinal angiodysplasias are an important cause of difficult to manage bleeding, especially 
in older patients. Endoscopic coagulation of angiodysplasias is the mainstay of treatment, but 
may be difficult for small bowel angiodysplasias because of inability to reach them for endoscopic 
intervention. Some patients are red blood cell (RBC) transfusion dependent due to frequent 
rebleeding despite endoscopic treatment. In small cohort studies, octreotide appears to decrease 
the number of bleeding episodes in patients with RBC transfusion dependency due to gastrointestinal 
angiodysplasias. This trial will assess the efficacy of octreotide in decreasing the need for RBC 
transfusions and parenteral iron in patients with anaemia due to gastrointestinal bleeding of small 
bowel angiodysplasias despite endoscopic intervention.
Study design
Randomized controlled, superiority, open-label multicenter trial.
Participants
Sixty-two patients will be included with refractory anaemia due to small bowel angiodysplasias, 
who are RBC transfusion or iron infusion dependent despite endoscopic intervention and oral iron 
supplementation. 
Intervention
Patients will be randomly assigned (1:1) to standard care or 40 mg long-acting octreotide once every 
four weeks for 52 weeks, in addition to standard care. Follow-up 8 weeks.
Main outcome measures
The primary outcome is the difference in the number of blood and iron infusions between 
the year prior to inclusion and the treatment period of one year. Important secondary outcomes 
are the percent change in the number of rebleeds from baseline to endpoint, adverse events and 
quality of life.
Ethics and dissemination
The trial received ethical approval from the Central Committee on Research Involving Human 
Subjects and by the local accredited Medical Research Ethics Committee of the region Arnhem-
Nijmegen, the Netherlands (reference number: 2014-1433). Results will be published in a peer-
reviewed journal and presented at international conferences.
Trial Registration
This trial is registered with ClinicalTrials.gov (NCT02384122; 4 March 2015) and EudraCT 
(2014-004032-19; 23 September 2014). 
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INTRODUCTION
Angiodysplasias (ADs) are the most common vascular anomalies of the gastrointestinal tract and 
the second leading cause of gastrointestinal bleeding in the elderly.1 The presentation extends from 
absence of symptoms to occult and  sometimes overt gastrointestinal bleeding. Approximately 
90% of haemorrhagic ADs cease spontaneously, but recurrence is high.2 The impact on the patient 
may be large with need for multiple red blood cell (RBC) transfusions, frequent hospitalizations 
and surgery.3 Decreased quality of life and the financial burden on healthcare systems are 
legitimate  concerns. 
There are different treatment options for symptomatic ADs; 1. conservative management with 
iron supplementation and when necessary RBC transfusions, 2. endoscopic intervention with argon 
plasma coagulation (APC), 3. radiological intervention with artery coiling, 4. pharmacological 
therapies and 5. surgical resection. Endoscopic APC is the preferred treatment. Recurrent bleeding 
rates in patients treated with APC  remain high, with rates up to 20% over a two year follow-up.4-6 
ADs located in the small bowel are associated with an even high re-bleeding rate, up to 45%. This 
could be related to their relative inaccessibility with standard endoscopy.7 As a result, some of these 
patients develop  refractory anaemia and become dependent on symptomatic treatment with 
parenteral iron supplementation and RBC transfusions.  
Determining the most effective pharmacological treatment in this patients with small bowel AD 
associated refractory anaemia is challenging. Oestrogen and progesterone are not effective and 
while 8-12 Thalidomide has been advocated for bleeding ADs, side effects are considerable.13
Therapy with octreotide is promising, because of its anti-angiogenic properties, decrease in 
splanchnic blood flow and enhanced platelet aggregation.14,15 Moreover, it is easy to use and has 
a relative mild side-effect profile. There is limited evidence for the efficacy of octreotide in reducing 
AD bleeding .16-21 One non-randomized study included 32 patients with refractory AD comparing 
octreotide with an external placebo control group showed a significant decrease in re-bleeding 
rate and need for oral iron.16 Recently a small randomized controlled trial was performed with 
the somatostin analogue pasireotide, with promising results.22 However, no statistical difference in 
RBC transfusions was observed. Other cohort studies showed a significant decrease of more than 
50% in RBC transfusion requirements.17-21 Extrapolation of these results is difficult in view of the very 
small size of cohorts and  absence of  control groups.
We designed a randomized, open-label controlled trial to evaluate clinical efficacy of octreotide. 
We hypothesize that octreotide decreases the need for RBC transfusions and iron supplementation 
in patients with refractory anemia due to small bowel ADs. The primary aim of this study is to assess 
the efficacy of octreotide to decrease the RBC- and iron transfusions in patients with refractory 
anaemia due to small bowel ADs. Also, we determine if octreotide decreases the number of rebleeds, 
assess safety and cost-effectiveness compared to standard care. 
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METHODS AND ANALYSIS 
Study design 
We will conduct a phase III, randomized, open-label, parallel-group, superiority, multicenter trial 
of standard care plus octreotide, compared to standard care in 62 patients with anaemia despite 
endoscopic intervention due to small bowel ADs (OCEAN). This protocol is according the standard 
protocol items for randomized trials (SPIRIT) statement. 
Study population
Patients older than 45 years who are diagnosed with refractory anaemia due to small bowel ADs. 
Refractory anaemia is defined as a haemoglobin level of < 7.5 mmol/L with intravenous iron or 
blood transfusion dependency despite ≥ 1 endoscopic intervention in the year after diagnosis (or 
unsuitable for / refusing endoscopy or surgery) and oral iron supplementation. It is known that 
gastrointestinal AD is mostly a disease of the elderly, younger patients with symptomatic AD might 
have another etiology (e.g. Rendu-Osler-Weber). Therefore, we exclude patients younger than 45 
years, to obtain a homogeneous patient group
Inclusion criteria
•	 Older than 45 years.
•	 Proven small bowel ADs: single or multiple 2–5 mm flat bright red spots with round 
uniform or slightly irregular margins. Or lesions appearing as raised and reddened areas 
with a distinctly irregular margin, when larger than 5 mm. Found during upper, lower 
gastrointestinal endoscopy and video capsule or enteroscopy.
•	 Intravenous transfusion dependency: at least four blood transfusions and/or iron infusions 
in the year before inclusion, despite an attempt to supplement iron orally.
•	 Failure of endoscopic therapy: at least one endoscopic attempt to coagulate the ADs within 
the year of diagnosis or unsuitable for / refusing endoscopy or surgery.
•	 Able to provide informed consent (IC).
Exclusion Criteria
•	 Liver cirrhosis Child-Pugh C, liver failure or diagnosed portal hypertension
•	 Any other possible source of gastrointestinal bleeding found during diagnostic endoscopy
•	 Previous unsuccessful  treatment with octreotide for the same indication (refractory 
anaemia due to ADs)
•	 Current thalidomide treatment which is effective (no parenteral iron or RBC transfusion 
dependency)
•	 Normalization of haemoglobin level under oral iron supplementation alone 
•	 Patients with chronic renal failure who have a eGFR < 30 ml/min 
•	 Life expectancy < 1 year
•	 Patients with left ventricular assist devices (LVAD’s)
•	 Hereditary hemorrhagic telangiectasia
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•	 Pregnant or nursing women
•	 Uncontrolled diabetes as defined by HbA1C >64 mmol/ml, despite adequate therapy
•	 Hereditary hemorrhagic diseases or haematological disorders with active treatment
•	 Patients with a known hypersensitivity to somatostatin analogues or any component of 
the octreotide (Sandostatin®) LAR formulations
•	 Symptomatic cholecystolithiasis
•	 Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized 
by the treatment with this study treatment
•	 Cancer currently undergoing chemotherapy or radiation therapy
Randomization and treatment allocation
Patients will be randomized in a 1:1 ratio to receive standard care or open-label octreotide plus 
standard care for one year. Stratification will be based on two variables with each two groups: 1. 
The use of anticoagulants and platelet aggregation inhibitors versus no anticoagulant drugs; 
2. Only iron infusion dependent versus iron and blood infusion dependency. Therefore, block 
randomization will consist of block sizes of 4. The trial is not blinded for patients and treating 
physicians but the outcome adjudication committee is. 
A web-based patient randomization service for clinical trials will be used (Castor Electronic Data 
Collection). When the screening visit data is entered in the electronical case record form (eCRF), 
and information regarding use of anticoagulants and/or platelet aggregation inhibitors is given, 
randomization will be performed. 
Trial treatments
Octreotide
Patients in the intervention group will receive two simultaneously injections of 20 mg Sandostatin 
LAR (octreotide)  intramuscular every 28 days on top of standard of care. Treatment duration is one 
year with 2 months follow-up for all patients. Long-acting octreotide (LAR formulation) is chosen 
for patient comfort to only have injections once monthly and thereby optimize patient adherence. 
This dose is higher than existing evidence on octreotide for this indication. The reason is that it 
is still not proven with a RCT that SST is effective in these patients and this is a proof-of-principle 
study rather than a dose-finding study. Moreover, for other indications  higher monthly dosages of 
somatostatin analogues are  more effective 23,24. If patients develop severe but not life-threatening 
adverse events (i.e. grade 3; hospitalization required or limitation of patient’s ability to care for 
him/herself), we will reduce the dosage with 10 mg until adverse events disappear. When a grade 3 
adverse event (AE) persists despite dosage reduction, Sandostatin LAR will be discontinued. Those 
patients will be followed after discontinuation and will not be excluded from analyses. If patients are 
unresponsive to octreotide (Sandostatin ®)LAR 40 mg monthly we will not increase the dose any 
further. Sandostatin® LAR will be administered at the patients’ home by experienced nurses from 
Novanurses, a service provided by Eurocept Homecare. 
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Standard care
To align clinical practices in the participating centers, a standard of care protocol is developed to 
treat patients similar during the treatment phase of this trial. A summary of this protocol is given 
below. 
Anticoagulant therapy can be modified after randomization according to local practice of 
the attending  physician and is registered as adjustment in the standard of care. However, in most 
patients with such severe AD bleeding the option of withdrawal antiplatelet and/or anticoagulant 
therapy would have  been considered prior to entry in the trial. 
The first choice of therapy is oral iron supplementation and must be initiated prior to  starting 
parenteral iron as maintenance therapy. When oral iron is insufficient and iron deficiency anaemia 
persists, parenteral iron may be administered (max. 20 mg/kg bodyweight). 
RBC transfusion is only indicated when anaemia  persists despite parenteral iron supplementation. 
A distinction  is made between patients with and without hemodynamic instability:
•	 Occult gastrointestinal bleed or acute gastrointestinal bleed without hemodynamic 
instability: RBC transfusion is given following the “4-5-6” rule (see additional file 1) or when 
symptoms associated with anaemia arise.25
•	 Acute gastrointestinal bleed with hemodynamic instability: haemoglobin target value 
> 5.0 mmol/L.26 In case of symptoms of hypoxia, the target value is  > 6mmol/L.
Study procedures
This study consists of seven visits including one screening visit, five visits during treatment and one 
follow-up visit (see Figure 1). Data will be collected into an electronically case record form (Castor) 
designed to capture all visit information including medical history, results from laboratory analysis 
and adverse events. Study duration for all patients is 60 weeks in total, divided in a screening phase 
and a 52 week treatment phase and a 8 week follow-up phase (Figure 1). At screening, each subject 
will be screened for eligibility after written IC is obtained. In women with childbearing potential 
a pregnancy test is performed. Within the treatment phase of the trial, patients are seen at week 
0, 4, 16, 28 and 52. One week after the first injection, the patient will receive a phone call to assess 
adverse events. The follow-up visit takes place 2 months after the octreotide concentration is below 
therapeutic doses, which is 8 weeks after the last treatment phase visit. This study visit aims to detect 
late AEs rather than establish  the long-term effect of octreotide after discontinuation. During 
each visit, medical history, medication use, adverse events, tolerability and drug accountability are 
assessed. In addition, a physical examination is performed and blood samples are drawn. Glucose, 
liver enzymes and lipid profile are checked to assess possible side-effects of octreotide. Patients 
have to fill out two questionnaires (SF-36 and PSQ-An) three times, i.e. at the start (week 0) and end 
of treatment (week 52), and follow-up (week 60). The requested parameters at the different visits 
are listed below: 
Screening visit
•	 Written IC
•	 Eligibility criteria check
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•	 General AD characteristics
•	 Pregnancy test in pre-menopausal females 
Baseline, end-of-treatment and follow-up visit
•	 SF-36	questionnaire:	quality	of	life
•	 PSQ-An	questionnaire:	patient	satisfaction	for	anaemia	treatment
Every visit
•	 Adverse	events
•	 Concomitant	therapy
•	 Drug	accountability	
•	 Physical	examination,	including	vital	signs	and	weight
•	 Laboratory	tests:	haematology	(haemoglobin,	haemotocrit,	leukocytes,	platelets,	absolute	
neutrophil count, prothrombin time), biochemistry (serum iron, ferritin, transferring and 
transferring saturation, calcium, phosphate, glucose, alanine aminotransferase, aspartate 
aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, 
albumin, creatinine) and lipid profile (total cholesterol, high density lipoprotein, low density 
lipoprotein, triglycerides) 
Study endpoints
Primary outcome
The mean/median difference in blood and parenteral iron requirements between the one year prior 
to inclusion and the treatment period of one year compared between the intervention and control 
Figure 1. Study design of the OCEAN trial.
IC, informed consent; PL, physical examination, laboratory tests, safety assessment; Q, assessment of PSQ-An 
and SF-36 questionnaires.
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arm. All blood transfusions that are given with another indication than gastrointestinal blood loss 
are registered, but excluded for analysis for the primary outcome.  
Secondary outcomes 
•	 The percentual decrease in blood and iron requirements between the year prior to 
inclusion and the treatment period of one year in the intervention arm compared to 
the control group
•	 Percentage of hemoglobin increase from baseline until end of treatment for patients 
treated with octreotide compared to the control group  
•	 The mean difference in hemoglobin level from baseline until end of treatment for patients 
treated with octreotide compared to the control group  
•	 Number of patients requiring red blood cell transfusions from baseline until end of 
treatment for patients treated with octreotide compared to the control group  
•	 Number of patients requiring  other transfusions or medication to correct coagulation 
between baseline until end of treatment for patients treated with octreotide compared to 
the control group  
•	 The change in number and severity of bleeding episodes between start and end of 
treatment for patients treated with octreotide compared to the control group  
•	 The change in number of patients free of rebleeding between start and end of treatment 
for patients treated with octreotide compared to the control group  
•	 Reduction in oral iron requirement between start and end of treatment for patients treated 
with octreotide compared to the control group  
•	 The change in level of serum ferritin between baseline until end of treatment for patients 
treated with octreotide compared to the control group  
•	 The number and type of adverse events (cardiac, pulmonary, neurological, other) between 
the control and treatment arm during the treatment period 
•	 Difference in number of hospitalizations, ICU admissions and duration of hospitalization 
between the control and treatment arm during the treatment period 
•	 The need for rescue therapy using argon plasma coagulation, coiling or surgery compared 
between the control and treatment arm during the treatment period 
•	 Change in Quality of Life as measured by SF36 between baseline and end of treatment for 
patients treated with octreotide compared to the control group  
•	 Mortality and cause of death compared between the control and treatment arm during 
the treatment period
Study withdrawal
Subjects can withdraw IC and leave the study at any time. The investigator will withdraw a subject 
from the study for any of the following reasons: pregnancy, consistent failure to adhere to protocol 
requirements, unacceptable toxicity of study medication, surgical interventions during the study or 
any other reason in the best interest of the patient. In case of withdrawal by the physician, all data 
generated from the study will be analysed and the reason(s) for discontinuation will be recorded.
Pro
to
co
l o
f the O
C
EA
N
 Trial
4.2
145
Sample size considerations
We aim to analyze 56 patients based on a sample size calculation with 80% power to detect 
a  difference of 2 RBC transfusions or iron infusions in one year. This accounts for an expected 
decrease of 2 transfusions in the intervention arm and no decrease in the control arm, with an 
estimated standard deviation of 2.6 and a significance level of 0.05 using a Mann-Whitney U 
test. The estimated mean difference is based on the five available prospective cohort studies at 
the time of designing the study and the difference in blood transfusion requirements before and 
after treatment with octreotide.16-20 Those studies show a decrease of more than 50% of the blood 
transfusion requirements.  We estimate a baseline dependency of 4 blood or iron transfusions in 
the last year, as this is intermediate of the studies of Junquera16 (1.1), Scaglione17 (3.6), Nardone18 
(8.8) and Bon20 (10). A transfusion difference of 2 units is clinically relevant which is in the same vein 
as  a recent  meta-analysis that detected a mean difference of  2.2 units.27 The standard deviation of 
2.6 is derived from the study of Junquera et al.16 Taken into account a dropout rate of 10%, the total 
sample size has to be 62 for the complete cohort with 31 patients in each treatment group.
Data management
All data is entered electronically according Good Clinical Practice in the data-management system 
Castor EDC at the participating site where the data is originated. Checks will be applied at the time 
of data entry into a specific field and/or before the data is written (committed) to the database. 
Modifications in the database will be documented through either the data change system or an 
inquiry system. Data is retrievable for viewing through the data entry applications. The type of 
activity that an individual user may undertake is regulated by the privileges associated with his/her 
user identification code and password. A complete back-up of the database is regularly performed. 
After study completion the data will be locked and transferred to SPSS. Data are stored for at least 
15 years after study completion.
Statistical analysis 
Each patient that received at least one injection of Sandostatin® LAR or has been included in 
the observational arm for 1 month, will be included in the intention-to-treat analysis. Parallel 
analyses will be performed on the per-protocol population. The per-protocol population is defined 
as all patients who have received at least 80% of the total amount of dosages of octreotide at 52 
weeks from baseline.
Data on demographic and baseline characteristics will be summarized for continuous variables, 
depending on distribution, values will be presented as mean ± SD or as median ± interquartile range. 
Discrete variables (e.g. sex) will be summarized by proportions (percentages). Differences between 
the intervention and standard of care will be analyzed using the student’s t test for normally 
distributed data or Mann Whitney U test for non-normally distributed data. Pearson’s chi-square 
test will be used to compare dichotomized outcomes between the two arms. Frequency tables 
will be compiled for (serious) adverse events classified according to the standard World Health 
Organization - Adverse Reaction Terminology (WHO-ART) Body System Dictionary and preferred 
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terms. All statistical analyses will be two-sided with a critical significance level of 5%. Missing data 
and loss to follow-up will be reported as percentage and if known the reason will be reported. 
Analyses will be performed with IBM SPSS Statistics version 22.0 (SPSS Inc., Chicago, IL, USA).
Subgroup analysis will be performed for stratified variables: 1. Use of anticoagulants 2. Iron 
infusion or iron and blood transfusion dependent. The SF-36 will be used to calculate quality-
adjusted life years to determine cost-effectiveness. 
Monitoring
Site monitoring
Two independent monitors of the St. Antonius Hospital will visit the sites to review 
the records, compare with source documents, and observe and discuss the conduct of the trial with 
the investigators and Site Coordinator. The monitors are responsible for monitoring adherence to 
the protocol and guidelines,
 
as well as ensuring completion of the eCRF and other documentation. 
In order to ensure the accuracy of data, the monitors, regulatory agencies and members of 
the Steering Committee, have direct access to source documents. Anonymity of participants will 
be maintained at all times.
Trial monitoring
An independent Data Safety Monitoring Board (DSMB) will meet periodically to monitor the safety 
and progression of the trial. The responsibilities and procedures of the board  are included  in 
a DSMB Charter. An interim analysis of effectiveness and safety end points once 31 participants 
have completed the trial will be performed. The DSMB may recommend continuing the trial, early 
termination of the trial, or modification of the trial. A recommendation to terminate the trial early 
will only be made if there is clear evidence of a clinically important beneficial or harmful effect.
Ethics and dissemination
Ethical considerations
Ethical approval of the study protocol was given by the Central Committee on Research Involving 
Human Subjects and by the local accredited Medical Research Ethics Committee of the region 
Arnhem-Nijmegen, the Netherlands (reference number: 2013/354). An independent data safety 
monitoring board has been constituted to monitor patient safety and treatment efficacy during 
the trial.
Dissemination plan
Data from all centres will be analysed together and published as soon as possible. Individual 
participants may not publish data concerning their patients that are directly relevant to questions 
posed by the trial until the sponsor has published its report. The sponsor will have access to 
the final data set, form the basis of the Writing Committee and advise on the nature of publications. 
The trial will be presented at regional and national conferences. The final results will be presented 
at scientific meetings and published in a peer-reviewed journal (authorship will be according to 
the journal’s guidelines).
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DISCUSSION
The OCEAN study is the first to prospectively investigate the efficacy of octreotide in patients 
with small bowel AD associated refractory anaemia in a randomized controlled trial. It is designed 
to determine whether and to which extent octreotide treatment can decrease parenteral iron 
and RBC transfusion requirements. This trial has a relevant clinical endpoint, i.e. 50% reduction 
in parenteral iron and/or RBC transfusions, with an adequate powered sample size. A statistical 
significant outcome has direct implications for current practice of patients with refractory anaemia 
due to gastrointestinal ADs. Furthermore this design provides an opportunity to study the safety of 
octreotide in a monthly dose of 40 mg in patients with ADs. Last, we incorporate patient reported 
outcome measurements (PROMs) to investigate the effect of octreotide on quality of life and 
cost-effectiveness. A retrospective study suggests octreotide LAR treatment is cost-effective in 
these patients 28, but no previous studies evaluated treatment of ADs from the most important 
perspective: the patient’s perspective. 
Some possible concerns need to be addressed. First, although a double-blind, placebo-
controlled designed trial would have been superior in minimizing the chance of information 
bias, an advantage of this current design is that it more resembles the effect in clinical practice 
after implementation of the intervention in comparison to a blinded trial.29 Second, the primary 
outcome at baseline (parenteral iron and RBC transfusion requirements before start treatment 
phase) is determined retrospectively in both groups, which could lead to regression to the mean 
and information bias. However, comparing the outcomes between the two groups should wash 
out any effect of regression to the mean. We think the risk of information bias as a consequence 
of the retrospective retrieval is low due to the fact that parenteral iron administration or RBC 
transfusion must be registered and therefore retrievable in the patient’s electronic record. Third, 
with other somatostatin analogues (e.g. pasireotide) intramuscular use could cause hematomas, 
especially in patients on anticoagulants. This might lead to reduction in injections compared to 
the protocol and could influence the results. Fourth, the strict in- and exclusion criteria will slow 
down our inclusion rate with possible delay in gaining the final results. Last, we did not stratify for 
any possible differences between centres. Due to the small number of patient inclusions per centre, 
centre stratification might lead to more unbalanced randomization than it would correct for an 
influence due to differences in practice. 
Despite these concerns, our study will add significant value to the existing body of literature on 
treatment of patients with refractory anaemia resulting from small bowel ADs bleeds. The rigorous 
design of  the OCEAN trial will address  the efficacy of octreotide in  therapy resistant  anaemia from 
small bowel ADs.
Trial Status
The Medical Ethics Committee of the Radboud University Medical Center Nijmegen approved 
the protocol in August 2015. Patient recruitment started in September 2015.
By the medical ethical committee approved amendment 
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Inclusion criteria
•	 ADs at any location in the gastrointestinal tract, which are transfusion dependent and fail 
endoscopic therapy. 
•	 Because of the broadening in localization of the ADs, it is not always necessary to perform 
a video capsule endoscopy. 
Exclusion criteria
•	 Chronic renal failure who have a eGFR < 30 ml/min is removed as exclusion criterion 
Study procedures
•	 The PSQ-An questionnaire is replaced for the validated multidimensional fatigue 
inventory (MFI-20)
•	 Physical examination is only performed at baseline, visit T28 and end of study visit. 
•	 There is no blood samples taken at the follow-up visit (week 60).
•	 The following laboratory tests are not measured: haemotocrit, absolute neutrophil 
count, prothrombin time, transferring, calcium, phosphate, ALT, cholesterol 
(total, HDL, LDL), triglycerides. 
Pro
to
co
l o
f the O
C
EA
N
 Trial
4.2
149
REFERENCES
1. Foutch PG, Rex DK, Lieberman DA. Prevalence 
and natural history of colonic angiodysplasia 
among healthy asymptomatic people. Am J 
Gastroenterol 1995;90(4):564-7.
2. Richter JM, Christensen MR, Colditz GA, 
et al. Angiodysplasia. Natural history and 
efficacy of therapeutic interventions. Dig Dis 
Sci 1989;34:1542–6.
3. Gupta N, Longo WE, Vernava 3rd AM. 
Angiodysplasia of the lower gastrointestinal 
tract: an entity readily diagnosed by colonoscopy 
and primarily managed nonoperatively. Dis 
Colon Rectum 1995;38:979–82.
4. Jackson CS, Gerson  LB. Management of 
gastrointestinal angiodysplastic lesions 
(GIADs): a systematic review and meta-analysis. 
Am J Gastroenterol 2014;109(4):474
5. Sami SS, Al-Araji SA, Ragunath K. Review article: 
gastrointestinal angiodysplasia - pathogenesis, 
diagnosis and management. Aliment Pharmacol 
Ther 2014;39(1):15-34.
6. Dray X, Camus M, Coelho J, et al. Treatment 
of gastrointestinal angiodysplasia and unmet 
needs. Dig Liver Dis 2011;43(7):515-22. 
7. Holleran G, Hall B, Hussey M, et al. Small 
bowel angiodysplasia and novel disease 
associations: a cohort study. Scand J 
Gastroenterol 2013;48(4):433-8. 
8. Junquera F, Feu F, Papo M, et al. A multicenter, 
randomized, clinical trial of hormonal 
therapy in the prevention of rebleeding 
from gastrointestinal angiodysplasia. 
Gastroenterology 2001;121:1073–
9. Lewis BS, Salomon P, Rivera-MacMurray 
S, et al. Does hormonal therapy have any 
benefit for bleeding angiodysplasia? J Clin 
Gastroenterol 1992;15:99–103.
10. Van Cutsem E, Rutgeert P, Vantrappen G. 
Long-term effect of hormonal therapy for 
bleeding gastrointestinal vascular malformations. 
Eur J Gastroenterol Hepatol 1993;5:439–43.
11. Barkin JS, Ross BS. Medical therapy for chronic 
gastrointestinal bleeding of obscure origin. Am 
J Gastroenterol 1998;93:1250–4.
12. Van Cutsem E, Rutgeerts P, Vantrappen G. 
Treatment of bleeding gastrointestinal vascular 
malformations with oestrogen–progesterone. 
Lancet 1990;335:953–5.
13. Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of 
thalidomide for refractory gastrointestinal 
bleeding from vascular malformation. 
Gastroenterology 2011;141(5):1629-37.
14. Kurosaki M, Saegert W, Abe T, et al. Expression 
of vascular endothelial growth factor in growth 
hormone-secreting pituitary adenomas: 
special reference to the octreotide treatment. 
Neurol Res 2008;30:518–22.
15. Ludwig D, Terai S, Bruning A, et al. Long-term 
haemodynamic effects of octreotide on 
postprandial splanchnic hyperemia in humans: 
a placebocontrolled echo-doppler study. 
Aliment Pharmacol Ther 1999;13:1119–29.
16. Junquera F, Saperas E, Videla S, et al. Long-term 
efficacy of octreotide in the prevention of recurrent 
bleeding from gastrointestinal angiodysplasia. Am 
J Gastroenterol 2007;102:254–60.
17. Scaglione G, Pietrini L, Russo F, et al. Long-
acting octreotide as rescue therapy in chronic 
bleeding from gastrointestinal angiodysplasia. 
Aliment Pharmacol Ther 2007;26:935–42.
18. Nardone G, Rocco A, Balzano T, et al. 
The efficacy of octreotide therapy in chronic 
bleeding due to vascular abnormalities of 
the gastrointestinal tract. Aliment Pharmacol 
Ther 1999;13:1429–36.
19. Molina Infante J, Perez Gallardo B, Hernandez 
Alonso M, et al. Octreotide long acting 
release for severe obscure gastrointestinal 
haemorrhage in elderly patients with serious 
comorbidities. Med Clin 2009;133:667–70.
20. Bon C, Aparicio T, Vincent M, et al. Long-
acting somatostatin analogues decrease blood 
transfusion requirements in patients with 
refractory gastrointestinal bleeding associated 
with angiodysplasia. Aliment Pharmacol 
Ther 2012;36:587–93.
21. Holleran G, Hall B, Breslin N, et al. Long-acting 
somatostatin analogues provide significant 
beneficial effect in patients with refractory 
small bowel angiodysplasias: Results from 
a proof of concept open label mono-centre 
trial. United European Gastroenterology 
Journal 2014;0(0):1-6.
Pro
to
co
l o
f the O
C
EA
N
 Trial
4.2
150
22. Benamouzig R. Essai de phase II randomisé 
évaluant l’efficacité du pasiréotide pour le 
traitement des angiodysplasies digestives 
en échec de traitement endoscopique. 
Presentation JFHOD. 2016.
23. Ludlam WH, Anthony L. Safety review: dose 
optimization of somatostatin analogs in 
patients with acromegaly and neuroendocrine 
tumors. Adv Ther. 2011 Oct;28(10):825-41. 
24. Temmerman F, Gevers T, Ho TA et al. Safety 
and efficacy of different lanreotide doses in 
the treatment of polycystic liver disease: pooled 
analysis of individual patient data. Aliment 
Pharmacol Ther. 2013 Aug;38(4):397-406. 
25. CBO (Centraal BegeleidingsOrgaan) Guideline: 
bloodtransfusion. Utrecht; 2011. URL: https://
nvic.nl/sites/default/files/CBO%20Richtlijn%20
Bloedtransfusie.pdf, date accessed Jan 2016. 
26. Villanueva C, Colomo A, Bosch A, et al. Transfusion 
strategies for acute upper gastrointestinal 
bleeding. NEJM 2013;368(1):11-21.
27. Brown C, Subramanian V, Wilcox CM, et al. 
Somatostatin analogues in the treatment 
of recurrent bleeding from gastrointestinal 
vascular malformations: an overview and 
systematic review of prospective observational 
studies. Dig Dis Sci 2010;55(8):2129-34. 
28. Klímová K, Padilla-Suárez C, Giménez-
Manzorro Á et al. Octreotide long-active 
release in the treatment of gastrointestinal 
bleeding due to vascular malformations: Cost-
effectiveness study. Rev Esp Enferm Dig. 2015 
Feb;107(2):79-88.
29. Hansson L, Hedner T, Dahlöf B. Prospective 
randomized open blinded end-point (PROBE) 
study. A novel design for intervention trials. 
Blood Press 1992;1(2):113-9.

 
 
 
 
 
 
4.3
TRANEXAMIC ACID IN TREATMENT-
RESISTANT CHRONIC TRANSFUSION 
DEPENDENT GASTROINTESTINAL 
ANGIODYSPLASIA BLEEDING
K.V. Grooteman1, E.J.M. van Geenen1, J.P.H. Drenth1
BMJ Case Rep. 2017 Nov 1;2017. pii: bcr-2017-221832.
1 Department of Gastroenterology and Hepatology, Radboud university 
medical centre, Nijmegen, 
Tranexam
ic acid
 fo
r angio
d
ysplasias
4.3
154
ABSTRACT
A small proportion of gastrointestinal angiodysplasia bleeding leads to chronic blood cell transfusion 
dependency. There are no guidelines supporting decision-making among various treatments in 
patients with gastrointestinal angiodysplasia bleeding. When endoscopic argon plasma coagulation 
is ineffective, the angiogenesis inhibitors thalidomide and octreotide can be considered. We 
describe a 77-year old woman who had side-effects of these angiogenesis inhibitors which caused 
her to have continued bleeding. She was successfully treated with tranexamic acid with a substantial 
decrease in need for red blood cell transfusions.
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BACKGROUND
Angiodysplasias are the most common vascular malformation of the gastrointestinal tract.1 A small 
proportion of angiodysplasia patients develop severe ongoing bleeding with red blood cell (RBC) 
transfusion dependency. This group accounts for up to 50% of patients with chronic severe 
gastrointestinal bleeding.2 These patients have a lower quality of life and put a financial burden 
on healthcare.
There are no guidelines that aid in clinical decision making of bleeding angiodysplasias, but 
accepted first-line therapy is endoscopic argon plasma coagulation (APC). However, rebleeding 
is frequent despite APC. In those cases, symptomatic treatment with iron supplementation and/
or RBC transfusion is a common second step.3 Pharmacological therapies that inhibit vascular 
proliferation of angiodysplasias are desirable. Thalidomide and octreotide act as angiogenesis 
inhibitors and may be used in RBC transfusion dependent patients. However, side-effects and costs 
preclude widespread use. Therefore, alternative strategies are needed. We describe one patient 
with treatment-resistant angiodysplasias who benefited from tranexamic acid (TXA), a competitive 
plasminogen antagonist.
CASE PRESENTATION
A 77-year-old woman was referred to our university medical centre with chronic transfusion 
dependency (3 RBC units / 2 weeks) due to small bowel angiodysplasia bleeding in September 2015. 
She had already been known with iron deficiency anaemia since 1990 when the diagnosis of duodenal 
and jejunal angiodysplasias was made by endoscopy. She does not fulfil the Curacao criteria for 
hereditary hemorrhagic telangiectasia. Her past medical history included insulin-dependent type II 
diabetes mellitus, cholecystectomy, hysterectomy, hypertension and hyperlipidemia. She had been 
analysed for angina pectoris in 2014, but there were no signs for coronary artery disease. However, 
the cardiologist prescribed a platelet aggregation inhibitor.   
TREATMENT
In 2014 oral iron supplementation became insufficient and RBC transfusions had to be administered 
due to symptomatic anaemia. Hormonal therapy with estrogen / progesterone was initiated and 
repeat colonoscopy was performed, which did not show colonic lesions. Acetylsalicyclic acid 
was stopped. With progressive need for RBC transfusions thalidomide was given. However, it was 
discontinued after two months due to the side-effects of nausea, vertigo and severe fatigue. In three 
APC sessions with single balloon enteroscopy more than 100 angiodysplasia lesions were coagulated 
in the duodenum and jejunum. All these treatments were without or had only a temporary effect 
on transfusion rate. Long-acting octreotide 40 mg/month was started in September 2015, but 
a hypoglycaemic episode necessitated withdrawal after one administration. Rechallenge with low 
dose short-acting octreotide again led to glycaemic dysregulation and was stopped. Finally, in 
November 2016 oral TXA 1000 mg daily was started after a new increase in need for RBC transfusions.
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OUTCOME AND FOLLOW-UP
TXA treatment led to stable haemoglobin levels over six months and decreased the need for RBC 
transfusions tremendously (figure 1). Side-effects, specifically thrombosis, did not occur  during this 
treatment period. Currently, she is using TXA on a continuous basis.
DISCUSSION
TXA produces its hemostatic effect through forming a reversible complex that displaces 
plasminogen from fibrin resulting in inhibition of fibrinolysis. It also inhibits the proteolytic activity 
of plasmin. It is registered for heavy cyclic menstrual bleeding and tooth extraction in haemophilia 
patients, but is also recommended in the European guidelines for hemorrhagic shock in the trauma 
setting. 4,5 The literature contains two cases on hemodialysis patients who were treated with TXA for 
angiodysplasias. In one patient TXA ceased acute and chronic gastrointestinal bleeding with three 
months of therapy.6 Ensuing thrombosis of the arteriovenous fistula in another patient precluded 
adequate evaluation.7
The pathogenesis of gastrointestinal angiodysplasias is not fully understood. Increased 
expression of angiogenic factors is associated with colonic angiodysplasias.8 Pharmacological 
therapy with angiogenesis inhibitors like thalidomide, are thought to be effective by intervening 
in this pathophysiological mechanism.9 On the other hand of the coagulation process, increased 
plasma fibrinolytic activity has been shown to be present in bleeding angiodysplasias.10 As TXA 
works by inhibition of the fibronolysis, we hypothesize this mechanism of action led to treatment 
success in our patient.
Figure 1. Changes in amount of RBC transfusions and hemoglobin levels associated with the administration of 
tranexamic acid (TXA) in a patient with severe gastrointestinal bleeding.
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In conclusion, we saw a good clinical response with TXA in a RBC transfusion dependent 
angiodysplasia patient who was treatment resistant to all currently accepted treatments.3 
TXA might be a new promising therapy for selective angiodysplasia patients, but is not 
a panacea. Further research with TXA is desirable in patients with treatment-resistant transfusion 
dependent angiodysplasias.
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GENERAL DISCUSSION
The aims of this thesis were to better understand the risk profile of different angiodysplasia 
disease stages, to assess the impact of angiodysplasias disease on quality of life, and to evaluate 
and investigate current and new therapies for the treatment of symptomatic angiodysplasias. 
Therefore, we designed and conducted the studies described in this thesis. This general discussion 
addresses the outcomes of these studies, focussing on interpretation and implications of results, as 
well as identification of knowledge gaps that could serve as possible directions for future research. 
It also addresses the difficulties in performing investigator-initiated trials with limited funding. To 
guide the discussion, table 1 provides an overview of the main findings, implications and limitations 
presented in this thesis.
FINDINGS FROM THIS THESIS
I. Characterization of gastrointestinal angiodysplasia disease
Chapter 2.1 describes a systematic review aiming to evaluate risk factors for the presence and 
contributing to symptomatic disease in patients with angiodysplasias. The overall quality of evidence 
of the 24 included studies was moderate. We divided the studies in 3 categories to investigate if 
there were different risk factors for different disease stages: risk factors for the presence of anemia, 
risk factors for symptomatic bleeding and risk factors that are associated with rebleeds. We found 
that age, chronic kidney disease, anticoagulant use and cardiovascular disease are the most 
important factors associated with the detection of angiodysplasias during endoscopy. Inpatient 
status is strongly associated with bleeding disease and multiple lesions increase the risk of rebleeds. 
The large heterogeneity between studies precluded execution of a proper meta-analysis. Many 
studies included cohorts consisting of patients with either (nonsymptomatic) angiodysplasias 
found incidentally during endoscopy and symptomatic angiodysplasias. Moreover, the control 
groups used, varied among studies making comparison difficult. The overall conclusion is that 
angiodysplasia disease is associated with many more risk factors than the classic triad of Von 
Willebrand disease, aortic stenosis and chronic kidney impairment. Awareness of these associated 
risk factors can direct treatment targets, such as discontinuation of anticoagulant use. 
In chapter 2.1 we outlined that there were no studies comparing asymptomatic with 
symptomatic angiodysplasias, so we developed a case-control study comparing these two 
groups. The differentiation is important due to the fact that only symptomatic angiodysplasias 
have a treatment indication. Chapter 2.2 describes a retrospective cohort of 270 angiodysplasia 
patients of which 176 symptomatic, and 5594 controls. This gave us the opportunity to find specific 
factors associated with asymptomatic angiodysplasias (etiologic factors) and factors that trigger 
symptomatic bleeding. Male gender, thyroid dysfunction, COPD, auto-immune diseases as well 
as the use of anticoagulants and antiplatelet agents are risk factors for incidental angiodysplasias. 
The often cited risk factors such as valvular heart disease and older age were identified as triggers 
for symptomatic bleeding. Multiple angiodysplasia and localization in stomach and/or small 
bowel increased the likelihood for symptomatic disease. We advocate to use these risk factors, 
including angiodysplasia characteristics, to differentiate between symptomatic and asymptomatic 
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Table 1. Overview of main findings, implications and limitations of this thesis. 
Chapter Main findings Implications Limitations
Characterization of gastrointestinal angiodysplasia disease
2.1 •	 Age, chronic kidney disease, anticoagulant and cardiovascular disease are the most important risk 
factors for the diagnosis of angiodysplasias
•	 Inpatient status is related to symptomatic angiodysplasia bleeding
•	 Multiple lesions are a risk factor for recurrent bleeding
•	 Information on these risk factors aids in accurate 
phenotyping which benefits clinical decision making
•	 Underlining the complexity and multifactorial 
etiology  of angiodysplasia disease
•	 Heterogeneity between studies with respect to 
patient selection, location of the angiodysplasia, 
indication for endoscopy and used control group
2.2 •	 The risk factor profile for incidental angiodysplasias differs from symptomatic angiodysplasias •	 This knowledge helps endoscopists in 
the decision-making sprocess to treat 
endoscopic detected angiodysplasia.
•	 Bias by indication leading to no incidental small 
bowel angiodsplasias
•	 It is unknown if the control group (general population) 
was truly negative for angiodysplasia disease
2.3 •	 Angiodysplasias are independently
•	 associated with clinically significant impairments in multiple domains of health-related QoL
•	 Patient reported outcomes should be included 
in clinical trials investigating efficacy for 
the treatment of angiodysplasias
•	 No disease specific questionnaire available
•	 Disease severity subgroups were based on consensus
•	 Response bias can be present
Evaluation of current treatment strategies
3.1 •	 Identification of risk factors and treatment of angiodsplasias vary widely between 
gastroenterologists
•	 1/8 of gastroenterologists would incorrectly treat asymptomatic angiodysplasias
•	 Better awareness and an evidence-based 
guideline is necessary to improve and uniform 
patient care for angiodysplasia disease
•	 Low response rate
•	 Survey did not include patient characteristics 
3.2 •	 Hemoglobin level is the most important factor to transfusion decision-making
•	 Age of the patient is
•	 more important in the decision-making process to younger gastroenterologists
•	 Discrepancy between guidelines as trigger for 
transfusion and the outcome of this study
•	 Parenteral iron was not included as an option to 
treat anemia
•	 Low response rate
3.3 •	 A substantial proportion of patients with angiodysplasias who were initially left untreated undergo 
repeat endoscopy with APC
•	 APC treatment should be more often 
administered during index endoscopy
•	 Retrospective study
•	 APCand non-APC group differed in baseline 
characteristics and thereby not comparable on 
clinical outcome
Investigating new therapies for symptomatic angiodysplasias
4.1 •	 Somatostatin analogues are effective in reducing the transfusion need in angiodysplasia bleeding
•	 Patients with small bowel angiodysplasias seem to have the most substantial SSA treatment effect
•	 Somatostatin analogues should be considered 
as treatment option in patients with severe 
angiodysplasia bleeding
•	 No randomized controlled trials were included
•	 Small patient numbers in the individual studies 
leading to wide estimates
4.2 •	 Randomized controlled trial is needed to implement octreotide as treatment option in severe 
angiodysplasia disease
•	 Performing a investigator-initiated RCT with a drug is is challenging with limited resources 
•	 Dutch network collaboration was set up to make 
this RCT feasible
•	 Not a blinded RCT, which can introduce bias
•	 The sample size is relatively large for the severe 
bleeding patient group, leading to a long duration 
of the trial
4.3 •	 Tranexamic acid was successful in reducing blood transfusion requirements in one patient •	 Tranexamic acid might be a new potential 
pharmacological therapy that deserves more 
research attention 
•	 It is case-report, which can only be used as 
hypothesis generating 
Legend: APC, argon plasma coagulation; SSA, somatostatin analogues; RCT, randomized controlled trial
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angiodysplasias. This is especially clinically significant in the clinical-decision making process 
to treat an angiodysplasia during endoscopy or not. This strategy should reduce the number of 
angiodysplasias that are incorrectly left untreated.
We initiated studies of the quality of life in angiodysplasia patients because of three reasons: 1) It 
had never been done before, 2) Patient reported outcomes gain importance as outcome measures 
in clinical research, 3) To create evidence that angiodysplasia disease is important and patients 
quality of life is affected by the disease. This is useful for future grant applications. Chapter 2.3 
describes a cross-sectional cohort of 144 angiodysplasia patients where we measured the quality 
of life with the SF-36 and the level of fatigue with the multi fatigue inventory-20. We concluded that 
angiodysplasia patients have a significant lower physical component summary, a measure for quality 
of life in relation to physical fitness, compared to the age-matched general population (respectively 
41.0 vs. 43.3, p = 0.01). Disease severity was independently associated with a negative outcome on 
QoL (ß -4.6, 95% CI -7.8±-1.3). Moreover, angiodysplasia patients are more fatigued compared to 
the general population (male 56.1 vs. 48.5, p<0.01, female 59.2 vs. 51.5, p = 0.01). In the subgroup 
analysis we showed that these findings are mainly driven by the presence of anemia. The patients 
that had no hospital visits for angiodysplasia disease in the past year had a comparable quality of 
life to the age-matched general population. Confounding factors can be comorbidities that are 
associated with symptomatic angiodysplasia disease and a reduced quality of life, for example aortic 
stenosis or chronic kidney disease. The clinical implication of our finding of reduced quality of life 
in anemia is that treatment of angiodysplasias should be indicated even for cases with mild anemia. 
II. Evaluation of current treatment strategies
To evaluate current treatment strategies, we assessed current practice of angiodysplasias 
among Dutch gastroenterologists using a web-based survey (chapter 3.1). A total of 111 (28%) 
gastroenterologists responded. The risk factors Von Willebrand disease and chronic kidney disease, 
were only correctly identified by 1/5 of the gastroenterologists. We concluded that there was a high 
agreement on diagnostic tools used for the diagnosis of angiodysplasias, but that there was a high 
variation in choice of treatment strategies. The majority favored endoscopic therapy as first line 
treatment, however a large proportion of gastroenterologist would start symptomatic treatment 
with iron supplementation. The major limitation of the study is the low response rate, which could 
have given response bias. Overall, this study reflects the lack of an evidence-based guideline for 
the treatment of angiodysplasias, which results in treatment variation among gastroenterologists. 
Around 2/3 of the symptomatic angiodysplasia patients present with anemia. To evaluate 
transfusion practices for chronic anemia due to gastrointestinal bleeding among gastroenterologists, 
we performed a computerized adaptive choice-based conjoint (ACBC) analysis (chapter 3.2). A total 
number of 113 gastroenterologists completed the survey. We identified absolute hemoglobin level as 
the most important incentive of transfusion, accounting for 42% of decision-making. Other factors 
influencing transfusion management were age (15%), hemoglobin stability (12%), anemia-related 
symptoms (10%) and cardiovascular comorbidities (10%). Age of the patient is more important 
in the decision-making process to younger gastroenterologists. International guidelines address 
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the importance of anemia related symptoms when deciding to transfuse red blood cells for chronic 
anemia. The clinical implication of these findings is that better understanding of the decision-
making process may fuel the debate about correct use of blood transfusion. Ultimately, this might 
help to prevent under- and overtreatment of chronic anemia. The limitation of this study is the low 
response rate.
The last study (chapter 3.3) that evaluates treatment strategies specifically focused on 
the use of argon plasma coagulation (APC) in the treatment of symptomatic angiodysplasias. 
This international multicenter retrospective cohort study includes 189 patients diagnosed with 
angiodysplasia in the setting of anemia or overt bleeding. Only 52% of the cases (n=98) were 
treated by APC at the index endoscopy, whereas 48% (n=91) of patients did not receive initial APC 
therapy. Repeat endoscopy with APC was necessary in 17 patients (19%) in whom angiodysplasias 
were detected but were left untreated during the index endoscopy. A total of 48 patients (53%) 
received other treatment modalities than APC (e.g. iron supplementation, blood transfusion). 
Anemia and / or overt bleeding resolved without treatment in 21 patients (23%) in the non-direct 
APC patients. We conclude that a substantial proportion of patients with angiodysplasias who 
were initially left untreated undergo repeat endoscopy with APC and that lack of awareness of 
guidelines is a barrier to APC therapy in some cases. The clinical implication is that there is space for 
optimization of the timing and goal of the endoscopy procedure. The major limitation of this study 
is the retrospective nature of the cohort and the difference in baseline characteristics between the 2 
groups, which made comparison of outcome measures impossible. 
III. Investigating new therapies for symptomatic angiodysplasias
In chapter 4.1 we performed an individual patient data meta-analysis to investigate 
the effectiveness of somatostatin analogues (SSA) on blood transfusion in patients with 
angiodysplasia bleeding. We identified 9 studies and obtained individual data from 8 of these 
cohorts with a total of 174 patients (mean age 70 years, 55% men). There was a high SSA response 
with 86.6% of the patients having >50% reduction of their RBC transfusions. There was a reduction 
between the number of RBC transfusions between the year prior to SSA and during SSA (13.0 vs. 
2.9, p<0.001). Localization of angiodysplasias in the small bowel is independently associated with 
a good treatment response (OR 17.2, 95% CI 1.8-32.7). We concluded that SSA treatment is effective 
and safe in the majority of patients with transfusion dependent angiodysplasia bleeding. The major 
limitation of the meta-analysis is that it does not include any randomized controlled trial, which 
puts the evidence level at 2a according to the Oxford Centre of Evidence-Based Medicine. There 
is a randomized controlled trial with the angiogenesis inhibitor thalidomide, which makes the use 
of this agent more evidence-based. The side effect profile of SSA is better acceptable than that of 
Thalidomide. As a consequence we advocate to take a SSA into account as an alternative therapy. 
The above paragraph illustrates the need for a randomized controlled trial with a SSA in patients 
with severe angiodysplasia bleeding. In chapter 4.2 we published the protocol of the clinical trial 
that we designed to fill the knowledge gap for octreotide as therapy for angiodysplasia bleeding. 
This multicenter RCT is currently recruiting patients. There are many learning points taken from 
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the initiation of this trial. I only want to point out the most important: 1) The need for collaboration 
to make certain trials feasible with a relatively large sample, 2) The importance and influence of 
a proper sample size calculation on duration of the trial, 3) That new regulations and stricter medical 
ethical approval can hamper investigator-initiated research which will never be performed by 
the pharmaceutical industry. 
In chapter 4.3 we describe the case of a 77-year old woman who was chronic transfusion 
dependent due to angiodysplasia bleeding and was treatment resistant despite receiving all 
treatments known in the literature. Eventually, she responded to tranexamic acid with a substantial 
decrease in need of blood transfusions. With this case-report we want to be hypothesis generating 
that this drug might be a new potential therapeutic choice in this rare patient category. 
STRENGTHS AND LIMITATIONS
The major strength of this thesis is its focus on improvement of care for patients with symptomatic 
angiodysplasias. In order to do so we have used various methodologies. First, we have identified 
risk factors that differentiate between asymptomatic and symptomatic disease. This is relevant, 
because asymptomatic angiodysplasias do not have a treatment indication. The knowledge that 
the quality of life is reduced in these patients can and should be used in trials that investigate new 
treatment therapies. With the two survey studies we assessed current practice and created more 
awareness for the available guidelines and recommendations. The cohort study is one of the largest 
available cohorts in the literature with information on a detailed level, leading to new insights in 
the importance of localization of the angiodysplasia. The collaboration between centres leads to 
a greater external validity of the case-control study. Moreover, it made the clinical trials feasible 
to execute. 
The limitation of the thesis is that the available literature investigating treatment options are 
cohort studies, which leads to risks of bias and thereby the results of the individual patient data 
meta-analysis should be taken into perspective. This results in a lower level of evidence for practical 
guidelines that impact daily clinical practice. The study that we designed that can change clinical 
practice (OCEAN-study) is still in the recruitment phase. 
FUTURE PERSPECTIVES
The results described in this thesis could serve as a starting point for new research initiatives and 
questions that remain to be answered. A few key questions need to be answered to impact and 
improve patient care for angiodysplasia patients. 
What is the role of endoscopic ablation therapy for symptomatic bleeding angiodysplasias? 
To answer this question we should be able to stratify patients according to the risk of rebleeding. 
The next issue comes once we have selected our patient for endoscopic ablation therapy. Modality 
provides the best results? Answers to these questions would require randomized clinical trials, but 
the issue is that large groups of patients are needed with a long-term follow-up. This is a consequence 
of a yearly 20% rebleeding rate. To detect a difference in effectiveness a trial would require a large 
sample size, which is less attractive. Although it is not the optimal design, a large prospective 
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multi-centre cohort including patient reported outcomes is more feasible and realistic in view of 
the infrequency of the disorder. For example using cohort studies it is possible to compare a direct-
ablation group with a non-direct ablation group and correct for baseline differences between 
groups. Another interesting question is to compare endoscopic therapy with anti-angiogenesis 
therapy as first-line treatment. Lastly, more evidence for tranexamic acid in angiodysplasia patients 
should be collected, to create more support for a prospective cohort. Unfortunately, most of these 
studies are not attractive for the pharmaceutical industry to support. 
The national collaboration we initiated for the OCEAN study, also led to a sidekick project not 
incorporated in this thesis. In the OCEAN study we excluded patients with hereditary hemorrhagic 
telangiectasia, because this is a different disease entity than angiodysplasia disease in the general 
older population. Due to the need for new therapeutic options we performed a pilot study where 
we treated 10 patients with HHT and gastrointestinal bleeding with octreotide. The promising data 
resulted in successful ZonMW grant application for the SAIPAN-trial: a multicenter, international, 
randomized controlled trial investigating the efficacy of octreotide in HHT patients with 
gastrointestinal bleeding. In the end, more research in this field and large collaborative networks 
will hopefully lead to the first evidence-based guideline. 
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ENGLISH SUMMARY
Gastrointestinal angiodysplasias are vascular malformations that are typically found in older patients 
with chronic kidney disease and / or a history of cardiac disease. People with angiodysplasias can be 
asymptomatic or the angiodysplasias can bleed, by which presenting symptoms are overt bleeding 
or anemia-related. There are no guidelines concerning treatment strategies in these symptomatic 
patients. Well accepted treatment options are endoscopic argon plasma coagulation or pragmatic 
with iron supplementation and if necessary red blood cell transfusion. For severely affected patients 
with recurrent need for blood transfusions anti-angiogenic treatment can be considered. This 
thesis concerns research to further characterize gastrointestinal angiodysplasia disease, evaluate 
current treatment strategies and investigate possible new therapeutic options. 
I. Characterization of gastrointestinal angiodysplasia disease
Chapter 2.1 gives an overview of former research concerning risk factors for the development of 
angiodysplasias and the trigger for symptomatic angiodysplasias. Besides the often cited risk factors 
such as increased age, chronic kidney disease and cardiovascular disease, we found that anticoagulant 
use is a risk factor for the presence of angiodysplasias. The difficulty in the studies included was 
that there was no clear difference between asymptomatic and symptomatic angiodysplasias. 
Therefore, we performed a study (Chapter 2.2) that compared risk factors between asymptomatic 
and symptomatic patients. We found new risk factors that were only associated with symptomatic 
bleeding, such as localization in the stomach and small bowel. We advocate to use these risk factors 
to evaluate if the endoscopic found angiodysplasia is symptomatic and thereby in the decision-
making process of treating the angiodysplasia. 
Chapter 2.3 investigates the health-related quality of life of patients with angiodysplasias. 
We found that the quality of life is comparable to age-related people for asymptomatic patients. 
A reduced quality of life was found in those with symptomatic bleeding, especially the patients 
with anaemia. 
II. Evaluation of current treatment strategies
In chapter 3.1 current treatment strategies are evaluated in the Netherlands by a web-based 
survey among Dutch gastroenterologists. We concluded that there was a high level of agreement 
on diagnostic tools used for the diagnosis of angiodysplasias, but that there was a high variation 
in choice of treatment strategies. In chapter 3.2 we further analyze the different treatment 
practices focusing on the factors influencing the decision-making process of when to give a blood 
transfusions for chronic anemia. Absolute hemoglobin level was the most important incentive 
accounting for 42% of the decision-making, while international guidelines address the importance 
of anemia related symptoms. Gastroenterologists should be aware of the guidelines to prevent 
under- and overtreatment of anemia. Chapter 3.3 describes endoscopic treatment strategies 
for patients where angiodysplasia(s) are found in the setting of overt bleeding or anemia. Half of 
the patients were directly treated with argon plasma coagulation, in the other half repeat endoscopy 
for angiodysplasia treatment was performed in 19%. This illustrates a window of opportunity for 
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improvement with less need for repeat endoscopy by means of the patients who are in need of 
treatment, e.g. who are symptomatic, more carefully. 
III. Investigating new therapies for symptomatic angiodysplasias
Chapter 4.1 is a meta-analysis of studies investigating the effectiveness of somatostatin analogues 
in patients with blood transfusion dependent angiodysplasia bleeding. We found an average 
reduction of 10 units of blood between the year prior to somatostatin analogue initiation and 
the year of treatment. Small bowel localization of angiodysplasias was associated with 
a good treatment response and therefore we advocate to take somatostatin analogues into 
consideration as an alternative therapy in these patients. Chapter 4.2 describes the study protocol 
of the randomized controlled trial we designed and initiated, which is still running. Results are 
expected in 2020. In the last chapter 4.3, a case of a woman is described with treatment resistant 
angiodysplasia bleeding, who responded successfully to tranexamic acid. With this publication we 
want to generate the hypothesis that tranexamic acid might be a potential
Conclusion
The results of this thesis show that angiodysplasia disease is a multifactorial disease, with different 
risk factors for the presence of angiodysplasias and symptomatic bleeding angiodysplasias. Where 
symptomatic angiodysplasias affect quality of life negatively. In the evaluation of current treatment 
strategies we found a high variation between gastroenterologists in the use of endoscopic therapy 
and symptomatic treatment with iron and / or blood transfusions. Somatostatin analogues are 
effective in decreasing the need of red blood transfusions and should be considered in patients 
severely affected by angiodysplasia bleeding. 
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NEDERLANDSE SAMENVATTING
Gastrointestinale angiodysplasieën zijn vasculaire malformaties die met name in oudere patiënten 
worden gevonden met chronische nierziekten en/of bekend zijn met cardiale comorbiditeit. 
Mensen met angiodysplasieën kunnen asymptomatisch zijn of de angiodysplasieën kunnen bloeden, 
anemie gerelateerde symptomen ontstaan of rectaal bloedverlies. Er zijn geen richtlijnen 
betreffende hoe symptomatische patiënten te behandelen. Geaccepteerde behandelopties 
zijn endoscopische argon plasma coagulatie of pragmatisch suppletie van ijzer en indien nodig 
bloedtransfusie. Voor ernstig aangedane patiënten met chronische bloedtransfusie-behoefte kan 
anti-angiogenese medicamenteuze therapie overwogen worden. Deze thesis omvat onderzoek 
naar het verder karakteriseren van gastrointestinale angiodysplasieën, de evaluatie van huidige 
behandelopties en het onderzoeken van nieuwe medicamenteuze therapieën. 
I. Karakteriseren van gastrointestinale angiodysplasieën
Hoofdstuk 2.1 geeft een overzicht van eerder gedaan onderzoek naar risicofactoren voor 
het ontwikkelen van angiodysplasieën en de triggers die ervoor zorgen dat ze gaan bloeden. 
Naast de vaak genoemde risicofactoren van oudere leeftijd, chronische nierziekten en 
cardiovasculaire comorbiditeit, ontdekten  wij dat gebruik van anticoagulantia een risicofactor 
is voor de aanwezigheid van angiodysplasieën. De gevonden studies maakten echter geen 
duidelijk onderscheidt tussen asymptomatische en symptomatische angiodysplasieën. Daarom 
hebben wij een studie gedaan die risicofactoren onderzoekt tussen deze twee verschillende 
patiëntencategorieën (hoofdstuk 2.2). We vonden nieuwe factoren die alleen geassocieerd zijn 
met symptomatisch bloeden, zoals lokalisatie in de maag en dunne darm. We pleiten ervoor om 
deze risicofactoren mee te nemen in de besluitvorming om tijdens een endoscopie te beslissen 
of het om een symptomatische angiodysplasie gaat en daarmee of behandeling geïndiceerd is. 
Hoofdstuk 2.3 onderzoekt de gezondheidsgerelateerde kwaliteit van leven van patiënten 
met angiodysplasieën. De kwaliteit van leven blijkt vergelijkbaar te zijn met leeftijdsgenoten 
voor asymptomatische patiënten. Er was een verminderde kwaliteit van leven in patiënten met 
symptomatische ziekte, met name in de patiënten met anemie. 
II. Evaluatie van huidige behandelstrategieën
In hoofdstuk 3.1 worden huidige behandelstrategieën geëvalueerd door middel van een 
webgebaseerde enquête onder Nederlandse maag-, darm- en leverartsen. We concludeerden 
dat er hoge overeenkomst was over hoe diagnostisch onderzoek in te zetten voor de diagnose 
angiodysplasie ziekte, maar dat er een hoge variatie was in welke behandeling werd ingezet. In 
hoofdstuk 3.2 focussen we ons op factoren die van invloed zijn op de besluitvormingsproces voor 
het geven van bloedtransfusies in de setting van chronische anemie. Het absolute hemoglobine 
gehalte was de belangrijkste factor van invloed, welke voor 42% bijdroeg aan het besluit. In 
internationale richtlijnen wordt de nadruk gelegd op anemie gerelateerde symptomen. Maag-, 
darm- en leverartsen zouden bewuster moeten zijn van de richtlijnen om over- en onderbehandeling 
van anemie te voorkomen. Hoofdstuk 3.3 beschrijft endoscopische behandelstrategieën voor 
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patiënten met angiodysplasieën die gevonden zijn bij patiënten die een endoscopie ondergingen 
in het kader van anemie of rectaal bloedverlies. De helft van de patiënten werd direct behandeld 
met argon plasma coagulatie, terwijl in de andere helft van de patiënten in 19% een tweede 
endoscopie werd gedaan om te behandelen. Dit percentage geeft de ruimte voor verbetering weer, 
waarbij directe argon plasma behandeling mogelijk tot minder endoscopieën had geleidt. Er moet 
zorgvuldiger worden afgewogen welke patiënten symptomatisch zijn en daarmee de indicatie voor 
endoscopische behandeling vaststellen.
III. Onderzoek naar nieuwe therapieën voor symptomatische  
angiodysplasieën 
Hoofdstuk 4.1 is een meta-analyse van studies die de effectiviteit van somatostatine analogen 
hebben onderzocht in patiënten met bloedtransfusie afhankelijke angiodysplasie bloedingen. 
We vonden een gemiddelde reductie van 10 zakken bloed tussen het jaar voor de start van 
een somatostatine analoog en het jaar van behandeling. Angiodysplasieën in de dunne darm 
waren geassocieerd met een goede behandelrespons. Wij zijn van mening dat somatostatine 
analogen overwogen moeten worden als alternatieve behandeloptie in deze patiëntencategorie. 
Hoofdstuk 4.2 beschrijft het studieprotocol van de gerandomiseerde trial die we hebben 
opgezet en geïnitieerd, welke nog steeds loopt. De resultaten worden in 2020 verwacht. In het 
laatste hoofdstuk (hoofdstuk 4.4), wordt de casus van een vrouw met behandel resistente 
angiodysplasie bloedingen beschreven, welke goed reageerde op tranexaminezuur behandeling. 
Deze publicatie is hypothese genererend dat tranexaminezuur mogelijk een nieuwe therapeutische 
optie kan zijn. 
Conclusie
De resultaten van deze thesis laten zien dat het ontstaan van angiodysplasieën een multifactoriële 
ziekte is met verschillende risicofactoren voor de aanwezigheid van en symptomatisch bloedende 
angiodysplasieën. Daarnaast blijken symptomatische angiodysplasieën van negatieve invloed te zijn 
op de kwaliteit van leven. In de evaluatie van huidige behandelstrategieën, vonden we grote variatie 
tussen maag-, darm- en leverartsen in het gebruik van endoscopische therapie en het inzetten van 
symptomatische behandeling met ijzer suppletie of bloedtransfusie. Somatostatine analogen zijn 
effectief in het verlagen van de bloedtransfusiebehoefte en zouden overwogen kunnen worden in 
patiënten met chronische transfusiebehoefte door angiodysplasie bloedingen. 
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DANKWOORD
Dit was zacht gezegd tot op heden de grootste uitdaging in mijn leven, want hoe kan iemand zonder 
discipline een promotietraject volbrengen? Er is maar een correct antwoord: dankzij jullie!
Allereerst wil ik alle patiënten bedanken die hebben meegewerkt aan het onderzoek. Zonder 
jullie was er überhaupt geen medisch wetenschappelijk onderzoek mogelijk en daarmee geen 
ontwikkeling in de dagelijks praktijk van medische zorg.
Dr. E.J.M. van Geenen, beste Erwin, wat kan ik mij gelukkig prijzen met jou als mijn co-promotor. 
Je hebt een gave om kansen en mogelijkheden te zien, waar ik soms alleen maar obstakels zag. Je 
inzicht in organisatie en aanpak van een multicenterstudie waren onmisbaar, maar vooral de politieke 
finesses inzien waar ik geen gevoel voor heb. Hier heb ik enorm veel van geleerd! Helaas moeten we 
wel bekennen dat ik nog steeds niets van auto’s weet, maar gelukkig heb ik jou zover gekregen om 
ook eens thee te drinken. 
Prof. dr. J.P.H. Drenth, beste Joost, dank voor alle kansen en vrijheid die je mij hebt gegeven in mijn 
promotietraject. Met je enthousiasme en gedrevenheid voor onderzoek en de junior onderzoekers 
(zoals jij ze noemt) in het bijzonder, wist je mij gemotiveerd te houden ondanks de tegenslagen. 
Het is bijzonder hoe je mij en de anderen de ruimte geeft om ons persoonlijk te ontwikkelen. Ik heb 
het zeer gewaardeerd dat je niet alleen onze promotor bent, maar ook gewoon Joost die altijd mee 
gaat voetballen en tijdens de UEGW een avond vrijhoudt om met de junior onderzoekers een biertje 
(of 2, 3, 4…) te drinken. Vele malen dank voor je eerlijkheid en de prettige samenwerking!
Zonder manuscriptcommissie en corona geen proefschrift en verdediging. Dank aan professor 
de Wildt, professor Maas en professor Bouma dat ze deze taak op zich hebben genomen en bij 
de verdediging aanwezig zijn. 
Prof. H. van der Hoeven, beste Hans, ook al hebben we elkaar niet vaak gesproken, 
de mentorgesprekken waren toch zeer waardevol en hebben mij op knelpunten verder gebracht. 
Dank voor het andere perspectief wat u mij kon geven door net even iets verder van mij en mijn 
onderzoek af te staan. 
Alle principal investigators, research nurses en secretaresses van de deelnemende centra van 
de OCEAN studie wil ik bedanken. Ik weet dat jullie voor andere projecten waarschijnlijk meer 
incentives konden krijgen, maar toch zagen jullie het belang van de studie en hebben jullie je 
kostbare tijd erin geïnvesteerd. Dank daarvoor! Prof. McNamara and Grainne, thanks for having 
me in Tallaght Hospital and collaborating with our cohort study to increase the value of research 
in the field of angiodysplasias. Prof. Jackson, thank you for thinking with us about new research 
proposals and giving input on our manuscripts. Dr. Baron, thank you for being the first to show me 
how much fun research can be and thereby making to make me want to do a PhD in the first place. 
Moreover, thanks for showing me you can still be yourself and not play political games in a highly 
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competitive world. You are extraordinary! Last but not least van de samenwerkingsverbanden, 
de ROW onderzoeksgroep uit het St. Antonius: Steven, Jacco, Repke en Hans-Jurgen, dank voor 
het enthousiasme waarmee jullie mijn ideeën ontvingen. Uiteindelijk heeft dit tot een mooie pilot 
studie geleid met als klap op de vuurpijl de grant honorering van ZonMW. Ik hoop dat dit het begin 
was van een mooie samenwerking tussen het Radboudumc en St. Antonius op ROW gebied. 
Dan, de MDL onderzoeksgroep: een ding is zeker jullie hebben mijn promotie gemaakt! In mijn 
promotietraject heb ik voor mijn gevoel 2 hele onderzoeksgroepen voorbij zien komen met ieder 
zijn eigen charmes. Een aantal dingen zullen echter nooit veranderen: te weinig plek tijdens de lunch 
op de rode bankjes, het eeuwige geëvalueer van alles wat we doen en de ‘is het al tijd voor bier?’ om 
vrijdagmiddag 16:00 (of was het nu 15:30?). Het begon met een gezellige en relaxte opstartperiode. 
Dank hiervoor Mark L., Mark B., Jos, Hedwig en Loes. Edgar, dank voor laten zien wat hard werken 
is, want als iemand dat kan ben jij het wel! Marten, onze roadtrip naar de eerste wintersport zal 
ik niet vergeten (en nog sorry voor de inhaalactie). Titus, levensgenieter met hoofdletters, dank 
voor de mooie ritjes langs de uiterwaarden en La Folie Douche. Daarna de ‘tussen-garde’: Dorian, 
Govert, Anna, René alias RILMS / rimmie, Yannick, Angelique. Dank voor de Nederlandse hitjes en 
het vooral over wielrennen hebben. Dan de nieuwe garde die al lang niet meer nieuw is: Judith, Lisa 
& Yonne (geen foto’s van Chicago aub!), Ali, Bram (nee ik ben geen kenau), Kelly, Vince (pas op voor 
mijn rechter), Michelle, Vera, Michiel, Liyanne. Jullie zijn een super gezellige groep samen en ik heb 
genoten van jullie in de laatste periode. Lucas, dank voor al je hulp met de OCEAN en natuurlijk je 
eeuwige aanwezigheid bij de borrels. Tim, veel succes met de start van SAIPAN. Xavier, dank voor 
het soms sparren over Erwin. Dan mijn zeer gewaardeerde collega Floor, wat ben jij een mooi mens! 
Bijzonder hoe jij pas op plaats 10 aan jezelf denkt. Simon, HELD! Ik heb veel respect voor je principes 
en taalgevoeligheid (al had ik er meer last van dan (of was het als?) plezier), maar vooral hoe je je 
presentatie gaf op de PhD retraite. Wagentje 1! Als laatste het pottenbakkers squad,: Myrte, Yasmijn, 
Lauranne en Isabelle. Dank voor de vriendschap die is ontstaan en dat alle deuren en bedden in 
Nijmgen altijd voor mijn open staan! Ik mis jullie sinds ik de opleiding in Amsterdam doe, maar 
gelukkig houden we onze activiteiten incl bier drinken erin!
De dames van de Research Unit, Sonja, Chantal en Cynthia, wat is het vooral gezellig dat de deur 
altijd openstaat en daarmee de snoeppot. Maar natuurlijk ook bedankt voor het meedenken in 
de uitvoer van studies en grant aanvragen. Jullie hebben je binnen no-time ontpopt tot een 
zelfstandig expertisecentrum binnen de onderzoeksgroep, daarmee zijn jullie van grote waarde 
voor ons. Minstens zoveel dank verdient de lab groep ‘boven’: Jody, Hennie, Rene en Daisy wat 
maakten jullie mijn 1e promotiejaar iets te gezellig. Helaas, maar misschien maar goed ook, moest ik 
terug naar beneden. Geen rikken meer, maar wel een significant hogere effectiviteit was het gevolg. 
Helaas geen lab stuk in mijn proefschrift, maar hopelijk pakt Tim dat anders aan! Daarnaast wil ik 
Wietske bedanken voor alle methodologische en statistische input in nagenoeg al mijn stukken. Je 
kritische houding brengt menig onderzoek verder en zeker die van mij. Ik wens je veel succes bij je 
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nieuwe afdeling, gelukkig hebben we altijd nog de wintersportherinneringen en zullen we je niet 
snel vergeten. 
Ik wil ‘mijn studenten’ Marjon, Shelley, Iris en Mijntje bedanken voor de bijdrage aan dit 
proefschrift. Jullie hebben mij enorm geholpen en tegelijkertijd veel plezier gegeven. Dank voor 
jullie 200% inzet. Al heb ik jullie niet allemaal kunnen overtuigen voor het prachtige MDL vak, ik 
wens jullie een mooie toekomst.
Alle stafleden, AIOS, verpleegkundigen en secretaresses van de afdeling MDL in het Radboudumc, 
dank voor jullie hulp bij de uitvoer van mijn klinisch onderzoek en de prettige werksfeer. Tanya, 
dank voor de mogelijkheid om ook onderwijs te geven tijdens mijn promotietraject. Dit was een 
zeer leuke en leerzame toevoeging. Sietske, Irma en Thy, wat moeten promovendi zonder jullie? 
Jullie regelen alles wat er te regelen valt, en snel. Daarmee zijn jullie van ongekende waarde 
voor ons! 
Collega’s van de Interne in het OLVG West, met jullie ben ik aan een nieuw hoofdstuk begonnen in 
Amsterdam. Dank voor de gezelligheid, de vele vrimibo’s in de Frits, de onvergetelijke wintersporten, 
maar vooral voor het samen beleven van de vele up’s en soms down’s van het AIOS bestaan. Het was 
een top tijd! Ik kan niet wachten om bij de MDL te starten!
Lieve vrienden en vriendinnen, waar moet ik beginnen… Ik ga jullie niet allemaal bij naam noemen, 
maar gelukkig weten jullie dat dit voor jullie allen geldt: dank dat jullie er altijd voor mij zijn! Qua 
promotie hebben jullie af en toe mijn frustraties moeten aanhoren, maar vooral dank voor het er 
niet over hebben en mij afleiding te geven (en bij tijden iets te veel afleiding). Één voor één waardeer 
ik jullie om wie jullie zijn en ik hoop nog heel lang met jullie te kunnen proosten op het leven! 
Paranimfen. Seng, wat ben ik je dankbaar! Nog het minste om dat je mijn paranimf wil zijn, maar 
vooral dat je mij als goede vriend altijd door dik en dun hebt gesteund. Al geloofde ik het zelf niet, jij 
wist dat ik MDL-arts ging worden en had hier het volste vertrouwen in. Ik hoop over een aantal jaar 
samen deel uit te maken van dezelfde vakgroep. Maar nog veel belangrijker, laten we leuke actieve 
dingen blijven doen, goede discussies voeren en mij mango’s met schillen laten blijven geven. Kikker 
(of moet ik je nu Esther noemen?), ik heb geen idee waar ik moet beginnen. Aangezien we niet aan 
woorden doen, maar aan daden dan toch een paar highlights: verstoppen voor Jan bij de geiten, van 
de dijk af rollen, pas naar de kroeg na Baantjer, kauwgom in Koudum, de zonsopkomst missen in de 
woestijn, de hammam in Marrakech, de draid-freak in Nice etc etc. De veeeeele veeeele feestjes en 
festivals! Dank bestie dat ik ondanks mijn gesnurk bij jou en Ivo in de caravan mag en dat we vooral 
geen politieke discussies voeren. Laten we nog heel veel langer verder gaan op mambo number 5 
in plaats van…..
Arjan & Remee en Jorian & Evelyn, al spreken wij het niet vaak uit, bij deze: ik ben ontzettend 
gelukkig met jullie als mijn grote broers en schoonzussen. Mams en paps maken grapjes over hun 
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‘goede’ opvoeding, maar ik vrees dat ik ook voor een groot deel gevormd ben door de wereld 
door de ogen van jullie en jullie puberende vrienden te zien toen ik nog een klein en onschuldig 
Kaatje was. Ik weet dat de deur altijd open staat en dat jullie er voor mij zijn. De kleintjes, Tibbe, 
Lauren, Jorrit en Dylan, waren een vrolijke afleiding en work-out als de promotie even wat stroever 
liep. Dank!
Ten slot, bedankt lieve paps en mams! Al begrepen jullie niet altijd even veel van de wetenschapswereld 
en daarmee mijn hoogte- en dieptepunten van mijn promotietraject, jullie snappen wel jullie 
dochter en bieden altijd een luisterend oor met daarbij op de juiste momenten een kritische noot. 
Al bestond die kritische noot meestal uit dat ik toch iets rustiger aan moest doen. Blijf het vooral 
zeggen mam, wie weet zal ik ooit luisteren. Pap, ook al vindt iedereen me op mams lijken, wij weten 
wel beter. Dank voor het meegeven dat ik niet te snel moet oordelen en daarnaast dat ik vooral 
mijzelf mag zijn. Ik zal jullie nooit afdoende kunnen bedanken voor de steun, het vertrouwen maar 
vooral de onvoorwaardelijke liefde die jullie mij geven. Gelukkig hoeft dat ook niet, laten we vooral 
blijven genieten van het samen zijn en de Skip-Bo avondjes. 
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